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PENILAIAN FITOKIMIA DAN KESAN IMUNOMODULASI SEL 
PEMBUNUH SEMULA JADI OLEH EKSTRAK DAUN PERESKIA BLEO KE 
ATAS SEL KANSER SERVIKS 
ABSTRAK 
Pereskia bleo merupakan tumbuhan berdaun dan boleh dimakan. Ia dikenali 
sebagai Pokok Jarum Tujuh Bilah di kalangan penduduk setempat dan mempunyai 
sifat anti-kanser. Kajian ini bertujuan untuk menjelaskan mekanisme tindakan 
tumbuhan ini sebagai anti-kanser untuk mendorong kematian sel dan menilai kesan 
imunostimulasi ke atas sel pembunuh semulajadi (sel NK) sebagai potensi tambahan 
ke atas kesan anti-cancer. Dalam kajian ini, daun P. bleo diekstrak dengan 
menggunakan beberapa teknik dan pelarut organik dengan polariti yang berlainan 
yang kemudiannya dianalisis menggunakan GC-MS. Ekstrak tersebut juga diuji untuk 
kesan sitotoksiknya terhadap sel-sel HeLa, MDA-MB-231, SW480 dan NIH/3T3 
menggunakan asai MTT.  Ekstrak yang mempunyai kesan sitotoksik paling kuat dan 
sel kanser yang berkaitan seterusnya diuji sama ada mampu mengaruh kematian sel 
melalui perencatan kitaran sel, asai Annexin V / PI dan pengukuran protein apoptotik 
menggunakan sitometri aliran. Selain daripada itu, sel-sel NK didedahkan dengan 
pelbagai kepekatan ekstrak etil asetat daun P. bleo (PBEA) dan kadar 
perkembangannyaa ditentukan melalui asai MTT. Sel NK dari individu sihat dan 
pesakit kanser serviks kemudiannya dirawat dengan PBEA berkepekatan 14.4 µg/ml 
selama 24 jam untuk dinilai aktiviti sitotoksinya. Kematian sel-sel sasaran dikenalpasti 
melalui sitometri aliran sementara itu asai ELISA dilakukan untuk menentukan 
penghasilan perforin, granzim B, IFN-  dan IL-2. Keputusan kajian menunjukkan 
kehadiran terpenoid, sterol, alkaloid, flavonoid, fenol, asid lemak dan vitamin E di 
xx 
dalam daun P. bleo bersama-sama sebatian baru iaitu (-)-Loliolide, neoph adiene, -
okoferol, -tokoferol, squalene, 4H-Pyran-4-one,2,3-dihydro-3,5-dihydroxy-6-
methyl, 4-vinyl-syringol, phenol,2-methoxy-4-(1-propenyl) and asid heksadekanoik. 
PBEA memperlihatkan nilai IC50 terendah (14.37 ± 8.40 µg/ml) menunjukkan kesan 
sitotoksik terkuat secara selektif ke atas sel HeLa. Analisis kitaran sel menunjukkan 
perencatan perkembangan sel HeLa yang dirawat dengan PBEA pada fasa G0/G1 
dibuktikan dengan pengumpulan sel yang signifikan pada fasa ini (P<0.05). 
Pemeriksaan morfologi terhadap kematian sel HeLa menunjukkan kehadiran cebisan 
nukleus, kondensasi kromatin sementara kejadian apoptosis juga telah dikesan di 
dalam asai Annexin V/PI. Analisis protein apoptotik menunjukkan pertambahan 
protein pro-apoptotik (Bax, p53 dan caspase-3) dan perencatan protein anti-apoptotik 
Bcl-2 (P<0.05). Sementara itu, perkembangan sel NK selepas 24 jam dirawat dengan 
PBEA didapati meningkat secara signifikan berbanding 48 dan 72 jam (P<0.05). Sel 
HeLa mengalami peningkatan apoptosis yang ketara dan meningkatkan ekspresi 
granzim B serta IFN-  selepas diink basi dengan sel NK pesaki  kanser ang dira a  
dengan PBEA. Oleh itu, penemuan kami menunjukkan PBEA menyebabkan kematian 
sel kanser serviks HeLA dan merangsang pengaktifan sel NK dari pesakit kanser yang 
meningkatkan kesan sitotoksiknya terhadap sel HeLa. Hasil kajian ini memberikan 
kefahaman tentang keberkesanan P. bleo sebagai ejen pencegahan kimoterapi dan 
seterusnya membuka ruang bagi kajian selanjutnya.   




PHYTOCHEMICAL SCREENING AND NATURAL KILLER CELLS 
IMMUNOMODULATION EFFECTS OF PERESKIA BLEO LEAVES 
EXTRACT ON CERVICAL CANCER CELLS  
ABSTRACT 
Pereskia bleo is a leaf  and edible plan , locall  kno n as Pokok Jar m T j h 
Bilah  hich has anti-cancer properties. This study purposed to elucidate the 
underlying mechanism of this plant as anti-cancer in inducing cell death as well as to 
evaluate its immunostimulatory effects on Natural Killer cells (NK cells) as a potential 
additional anti-cancer effect. In this study, the leaves of P. bleo were extracted using 
different techniques and solvent polarities, and subsequently subjected to GC-MS 
analysis. The extracts were tested for its cytotoxic effects on HeLa, MDA-MB-231, 
SW480 and NIH/3T3 cell lines using MTT assay. The most cytotoxic extract and its 
corresponding cancer cell lines were investigated for their cell death induction through 
cell cycle arrest, Annexin V/PI assay and measurement of apoptotic proteins using 
flow cytometry. NK cells were exposed to different concentrations of ethyl acetate 
extract of P. bleo leaves (PBEA) and its proliferation rate was determined via MTT 
assay. NK cells from healthy individuals and cervical cancer patients were treated with 
14.4 µg/ml of PBEA and co-cultured with target cells for 24 h to evaluate its cytotoxic 
activity. Target cells death was identified by flow cytometry while ELISA assay was 
performed to determine the production of perforin, granzyme B, IFN-  and IL-2. 
Results showed the presence of terpenoids, sterols, alkaloids, flavonoids, phenols, fatty 
acids and vitamin E in the extracts of P. bleo leaves together with new compounds 
namely (-)-Loliolide, neophytadiene, - ocopherol, -tocopherol, squalene, 4H-Pyran-
4-one,2,3-dihydro-3,5-dihydroxy-6-methyl, 4-vinyl-syringol, phenol,2-methoxy-4-(1-
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propenyl) and hexadecanoic acid. PBEA exhibited the lowest IC50 value (14.37 ± 8.40 
µg/ml) indicated the strongest cytotoxic effect selectively on cervical cancer cells 
(HeLa). The cell cycle analysis showed inhibition of cell proliferation at G0/G1 phase 
in PBEA treated HeLa cells as evidenced by a significant accumulation of the cells at 
this phase (P<0.05). Morphological examination on PBEA treated HeLa cell showed 
the presence of fragmented nuclei and condensation of chromatin while apoptosis was 
detected in the Annexin V/PI assay. Analysis of apoptotic proteins revealed a 
significant upregulation of pro-apoptotic proteins (Bax, p53 and caspase-3) while 
downregulation of anti-apoptotic protein Bcl-2 (P<0.05) in PBEA treated HeLa cells. 
Meanwhile, NK cells proliferation at 24 h was found significantly increased compared 
to 48 h and 72 h of PBEA treatment (P<0.05). Apoptosis of HeLa cells was markedly 
increased in PBEA treated NK cells from cancer patients. This extract also enhanced 
granzyme B and IFN-  e pression in NK cells from cancer pa ien s. Thus our findings 
demonstrated that PBEA induced cell death in the cervical cancer cells (HeLa) and 
stimulate activation of NK cells from cervical cancer patients which enhanced 
cytotoxic effect against HeLa cells. These results provide some insight into the 
effectiveness of P. bleo as a potential chemopreventive agent which open up for further 








CHAPTER 1  
 
INTRODUCTION 
1.1 Background of study 
Cancer is a leading cause of death worldwide thus making it a public health 
concern (Kooti et al., 2017). It is known to cause alteration of cells  genes, disturbance 
of growth signaling receptor for activation of cancer cells, evasion from apoptosis and 
immune surveillance escape which make them resistant to cell death and sustain 
prolifera ion in he hos s bod  (Hanahan and Weinberg, 2016).  
Nowadays, chemotherapy remains the treatment option for various types of 
cancer coupled with either radiotherapy or surgery (Chen et al., 2018). 
Chemotherapeutic drugs aim to eliminate proliferating cancer cells through the 
mechanism of apoptosis (Chen et al., 2018; Liu et al., 2015). However, the killing 
action of these drugs is non-specific which kill not only the malignant cells but also 
the normal cells thus prompting several adverse side effects such as cardiac 
dysfunction, bone marrow suppression and cognitive impairment (Demaria et al., 
2017; Dietrich and Kaiser, 2016; Norwood Toro et al., 2019). Apart from targeting 
cancer cell death, enhancement of immune response is another approach to eliminate 
cancer cells as offer by modern modalities for instance hormonal therapy, 
immunotherapy and cell based therapy (Koury et al., 2018). Nonetheless, these 
modalities also exhibit adverse side effects such as neurotoxicity (Naran et al., 2018). 
Furthermore, the emerging of drug resistance to chemotherapeutic agents has become 
a major challenge in cancer treatment (Chen et al., 2018). All these limitations have 
reduced the response rates of the patients leading to ineffectiveness of the treatment 
and diminishing their quality of life.  
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Nowadays, medicinal plants provide new approach in the development of 
therapeutic agents for cancer treatment with promising results without harming the 
normal cells (Zaid et al., 2017). These plants consist of flavonoids, phenolic 
compounds and alkaloids that work synergistically thus responsible for their anti-
cancer property as well as other pharmacological properties (Yuan et al., 2017). 
Therefore, availability of plant-based compounds with minimal side effects and less 
toxic effects to the healthy cells is desired for prevention and treatment of cancer 
(Greenwell and Rahman, 2015). Several medicinal plants that have been reported 
useful in the prevention and cancer treatment such as Annona muricata for colon and 
breast cancer, Abrus precatorius for breast cancer and Clinacanthus nutans for cervical 
cancer (Kim et al., 2018; Moghadamtousi et al., 2015; Sofi et al., 2018; Zakaria et al., 
2017). In addition, medicinal plants can modulate the immune response against cancer 
cells.  
Pereskia bleo (P. bleo) is a well-known medicinal plant in Malaysia that 
possess various health benefits for instance muscle ache relieve, detoxification, 
hemorrhoid, hypertension as well as in cancer prevention and treatment (Malek et al., 
2009; Yen et al., 2013). The leaves of this plant have been reported to show several 
biological activities including anti-cancer effects (Abdul-Wahab et al., 2012; Sim et 
al., 2010a; Sri Nurestri et al., 2008; Wahab et al., 2009). 
Cytotoxic activity of this plant leaves has been demonstrated on several cancer 
cell lines: human colon carcinoma (HCT 116), nasopharyngeal epidermoid carcinoma 
(KB), human hormonal-dependent breast cancer (MCF-7) and human cervical cancer 
(CasKi) (Sri Nurestri et al., 2008).  P. bleo leaves methanol extract and ethyl acetate 
fraction along with -tocopherol compound isolated from this plant were found highly 
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cytotoxic against KB cell line while no cytotoxic effects observed in normal human 
fibroblast cell line (MRC-5) (Malek et al., 2009; Sri Nurestri et al., 2008). 
Furthermore, P. bleo leaves methanol extract promoted cell death in T47-D cell line 
(breast carcinoma) by apoptosis via c-myc pathway and caspase-3 activation (Tan et 
al., 2005).  Therefore, P. bleo serves a promising plant candidate for cancer therapy. 
However, deeper understanding and fundamental information needed to be gathered 
about this plant.  
1.2 Rationale of study 
Chemotherapy has been a mainstay of cancer treatment for decades. However, 
it causes cytotoxic effects to the normal cells which induce adverse effects in the 
patients due to the non-specific action of the chemotherapeutic agents. Apart from that, 
the emerging of chemotherapy resistance has become one of the obstacles to the 
effectiveness of cancer treatment.  
Nowadays, many people are seeking for complementary alternative medicine 
that harmless to the normal cells and effective to eliminate cancer cells. Medicinal 
plants can serve as an alternative for the treatment of cancer with natural 
immunoadjuvant, negligible side effects and effective in killing cancer cells. Previous 
studies of P. bleo have shown the leaves of this plant comprised anti-cancer effects. 
However, this effect was only reported in studies where fraction extracts and single 
compound were used (Malek et al., 2009; Sri Nurestri et al., 2008).  In traditional 
practice, the plants usually taken in crude or raw form and often claimed more effective 
compared to purified single compounds due to benefit of synergistic action from the 
compounds mixture in the crude extract (Caesar and Cech, 2019). Besides, up until 
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now, there is no report on immunomodulatory effects of P. bleo leaves in eliminating 
cancer cells.  
Thus, it is essential to explore the anti-cancer activity and immunostimulatory 
effects of P. bleo leaves crude extracts against cancer cell lines in order to provide 
better understanding on its ability as anti-cancer and stimulatory agents for cancer 
treatment.                
1.3 Objectives of study 
1.3.1 General objective 
To study apoptosis induction and immunomodulatory activity of P. bleo leaves 
extracts on cancer cell line.  
1.3.2 Specific objectives 
1. To analyze phytochemical compounds of P. bleo leaves extracts via gas 
chromatography-mass spectrometry (GC-MS).  
2. To determine the cytotoxic effects of P. bleo leaves extracts on selected 
cancer and normal cell lines for their potential as anti-cancer agents.  
3. To investigate the mechanism of cell death induced by the selected P. bleo 
leaves extract that exert the most potent cytotoxic effects on its 
corresponding cancer cells.  
4. To evaluate immunostimulatory effects induced by the selected P. bleo 
leaves extract on activation of Natural Killer (NK) cells against cervical 
cancer HeLa cells.   
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CHAPTER 2  
 
LITERATURE REVIEW 
2.1 Cancer  
When abnormal cells in the body begin to proliferate uncontrollably, this 
condition leads to the formation of a malignant tumor known as cancer (Abbas and 
Rehman, 2018). These cancer cells undergo mutation leading to metabolic 
transformations that inhibits tumor suppressor genes and activate oncogenes. As a 
result, this condition promotes cancer progression when glucose consumption is 
increased, mitochondrial respiration is reduced, reactive oxygen species generation 
rises and cell death is resisted (Ribas et al., 2016).  
In 2018, approximately 18.1 million of new cancer incidences worldwide were 
reported while 9.6 million of deaths were caused by this disease (Bray et al., 2018). The 
most common cancer among men were lung, prostate and colorectal cancer while in 
female, breast cancer recorded the highest incidence followed by colorectal and lung 
cancer (Bray et al., 2018). Overall, mortality according to cancer types are as follows: 
lung cancer (18.4 %) followed by breast cancer (11.6 %), prostate cancer (7.1 %) and 
colorectal cancer (6.1 %) (Bray et al., 2018).  
In Malaysia, the largest incidence of cancer among males was prostate, 
colorectal and bladder  (Azizah et al., 2019). Meanwhile, breast cancer, corpus uteri 
and thyroid were the most common cancer identified among females (Azizah et al., 
2019).  
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2.1.1 Hallmark of cancer 
Tumorigenesis is a complex and multistep process. The mutation of oncogenes 
and tumor-suppressor genes take place in normal cells resulting in fast proliferation and 
resistance to cell death (Yuan et al., 2016). Normal cells evolve into a malignant state 
when they acquire several biological capabilities during tumorigenesis. Once the 
biological capabilities are obtained, they become the hallmark of cancer which 
describes the concept of tumor development. Eight biological capabilities have been 
highlighted by Hanahan and Weinberg (2016) as the hallmark of cancer, each with their 
own functional role, as summarize below:  
 
Hallmark 1: Sustaining proliferative signaling  
Normal cells maintain their proliferation and tissue homeostasis through a 
growth signaling pathway in a cell cycle that are tightly regulated (Matson and Cook, 
2017). In the context of cancer, sustaining proliferative signaling involves the mutation 
of genes in cancer cells known as oncogenes which eventually promotes the 
uncontrolled proliferation of daughter cells (Martincorena and Campbell, 2015). Cancer 
cells can sustain proliferative signaling via several mechanisms such as the production 
of their own growth factor ligands that stimulate proliferation or altering receptor 
signaling by producing more receptor proteins on cancer cells for their activation 
(Hanahan and Weinberg, 2016). 
 
Hallmark 2: Evading growth suppressors 
Cancer cells have the ability to escape the negative regulation process that is 
mostly governed by tumor suppressor genes. Tumor suppressors are essential to limit 
the growth and proliferation of the cell. Examples of genes that codes for tumor 
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suppressors include retinoblastoma-associated (RT) and TP53 that play a crucial role in 
cellular regulation whether to proliferate or undergo senescence or apoptosis.  
 
Hallmark 3: Resisting cell death 
The mechanism of triggering cell death includes apoptosis, necrosis and 
autophagy. Cancer cells have to evade these processes in order to continue their 
proliferation, expansion and progression to a higher state of malignancy. Apoptosis is 
the most prominent programmed cell death, where the cells are genetically programmed 
to die. The apoptotic program can be triggered via two mechanisms which are intrinsic 
and extrinsic pathways (Hanahan and Weinberg, 2016). Furthermore, apoptosis 
deregulation in cancer cells has led to the development of cancer treatment that uses 
apoptosis as a tool to inhibit their proliferation (Abraha and Ketema, 2016).  
 
Hallmark 4: Enabling replicative immortality 
There are two proliferation barriers in the cell growth and division cycle which 
are senescence (viable state) and crisis (leading to cell death) that normal cells can 
bypass. The telomerase functions as a protector in the cell that restricts them from 
unlimited replication (immortalization) (Hanahan and Weinberg, 2016). The presence 
of telomerase activity is almost absent in normal cells indicated by short telomeres 
which leads to the activation of either one of the proliferation barriers (Hanahan and 
Weinberg, 2016). In contrast, cancer cells exhibited high telomerase activity 
characterized by the increased telomere size which prevents them from triggering 
senescence or apoptosis and eventually lead to unlimited replication (Hanahan and 






Hallmark 5: Inducing angiogenesis 
Nourishment (nutrients and oxygen) and waste elimination (metabolic waste 
and carbon dioxide)  are essential in both normal cells as well as cancerous ones  
(Fadaka et al., 2017). This is made possible via angiogenesis, the formation 
neovasculature in tumours (Hanahan and Weinberg, 2016). It is a process where new 
blood vessel forms and activated by the cancer cells in order to sustain and expand 
neoplastic growth (Liao and Johnson, 2007). 
 
Hallmark 6: Activating invasion and metastasis 
Due to the aggressive nature of cancer cells, they attack neighbouring tissue and 
the circulatory systems including blood and lymphatic vessels. These vessels are used 
as pathways for the spread of cancer cells to nearby or distant organs. The tissue-
draining of the lymphatic vessel enables the invasion of cancer cells to lymph nodes 
leading to metastasis. Invasion and migration are often associated with an advanced 
stage of cancer progression (Su et al., 2017). 
 
 
Hallmark 7: Deregulating cellular energetics and metabolism  
The uptake of glucose as an energy source in the presence of oxygen are 
markedly higher for cancer cells in order to support their proliferation and sustainability 
in the tumor microenvironment (Warburg et al., 1927). In addition, lactate, is a toxic 
waste from the cells that undergoing anaerobic and aerobic glycolysis has been 
recognized as tumor-promoters, serving as metabolic fueling for the cancer cells (Dhup 







Hallmark 8: Avoiding immune destruction 
Cancer cells con in e gro  in he bod  and e hibi ed cancer imm noedi ing  
which enable them to escape from immune surveillance (Lussier and Schreiber, 2016). 
During this phase, cancer cells manage to evade from immune surveillance and control 
through several mechanisms including the absence of tumor-antigen recognition due to 
the tumor or effector cells modification, cell death resistance and immunological 
proofing via immunosuppressive factors secretion (Malmberg, 2004).   
2.1.2 Treatment modalities for cancer 
Cancer treatments consist of several common methods namely chemotherapy,  
surgery, radiotherapy, immunotherapy, targeted therapy and hormonal therapy (Chen et 
al., 2018). In Malaysia, surgery, radiotherapy, chemotherapy as well as hormonal 
therapy are presently available for cancer treatment (Taib et al., 2017; Tamin, 2017; 
Wong, 2014). The success of the treatment depends on the cancer type, tumour area and 
stage (Abbas and Rehman, 2018).  
Surgery is a conventional treatment for benign and malignant solid tumors 
(Abbas and Rehman, 2018; Tohme et al., 2017). This treatment involves the removal 
of solid tumors and becomes a preferred treatment option compare to radiotherapy and 
chemotherapy due to its minimal risk of surrounding tissues damage during the tumor 
removal (Abbas and Rehman, 2018). Radiotherapy utilizes electron beams, x-rays, or 
gamma rays to kill tumor cells (Terasawa et al., 2009). This therapy often used in 
combination with chemotherapy, immunotherapy or surgery (Baskar et al., 2012). 
Radiation therapy alone can be used in treatment of cancers such as  lung carcinomas 
(non-small cell), prostate carcinomas, and cervix carcinomas (Baskar et al., 2012). In 
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addition, radiotherapy in combination with other treatments are used to treat breast 
carcinoma, local advanced cervix carcinoma and local advanced lung carcinomas 
(Baskar et al., 2012)  
Chemotherapy uses cytotoxic mediators targeting cells that are rapidly dividing, 
interfere with the cell division process, stimulate the expression of pro-apoptotic 
proteins and suppression of anti-apoptotic proteins which ultimately leads to apoptosis 
in cancer cells (Hassan et al., 2014; Jones and Ocen, 2020). This mechanism is shown 
in several chemotherapeutic agents such as taxane (e.g., paclitaxel and docetaxel) that 
slow down the mitosis of the cancer cells when they intervene with microtubule 
polymerization and prompt the cell death via apoptosis (Jordan et al., 1996). 5-5-
Fluorouracil (5-FU) is an FDA-approved breast and colorectal cancer treatment (Ajani, 
2006; Ershler, 2006). This drug causes the disruption of nucleoside metabolism and 
alteration of the DNA and RNA thus causing cancer cell death (Longley et al., 2003). 
Apart from the conventional treatment methods, there are some of modern 
cancer treatments option such as immunotherapy and hormonal therapy. Cancer 
immunotherapy is designed to enhance immune response towards combating cancer 
cells (Sambi et al., 2019). Example of immunotherapy including the administration of 
exogenous cytokines, therapeutic vaccines, cancer vaccines and cell-based therapies 
(Ventola, 2017b). Mechanism of the action exerted by immunotherapy is specific 
towards target cancer cells while sparing the normal cells (Imai and Takaoka, 2006). 
Treatment strategies involved the using of monoclonal antibodies, small molecule 
inhibitors and nano-particulate antibody conjugates (Lord and Ashworth, 2008; Padma, 
2015; Sanna et al., 2014). For instance, epidermal growth factor receptor (EGFR) 
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tyrosine kinase inhibitors (TKIs) is used in targeted treatment for EGFR-mutation-
positive non-small cell lung cancer (Skinner et al., 2018). 
Hormonal therapy involves the administration of exogenous hormones in 
hormone-dependent cancer which modulate the endocrine system by reducing the 
production of the hormone or interfering with the activity of receptor (Fairchild et al., 
2015). This therapy is used for treatment in breast and prostate cancer (Awan and 
Esfahani, 2018; Brawer, 2006). For example, anti-hormonal agents that selectively 
regulate estrogen receptor (e.g., tamoxifen) and  aromatase inhibitors are used for breast 
cancer treatment (Awan and Esfahani, 2018). In addition, certain hormones such as 
exogenous corticosteroids have general antineoplastic effects on cancer cells by causing 
apoptosis thus included in almost all chemotherapy protocols for lymphoid malignancy 
(Roth et al., 2010; Schmidt et al., 2004).  
2.1.3 Limitations of current cancer drugs 
Chemotherapy remains a mainstay for current cancer treatment which usually 
offer alongside other conventional treatment options like surgical intervention and 
radiotherapy  (Senapati et al., 2018; Singh et al., 2019). In general, chemotherapeutic 
drugs work via different mechanisms that cause oxidative stress, DNA damage, cell 
cycle arrest or cytoskeleton damage, targeting both dividing cancer and dividing healthy 
cells (Basu and Krishnamurthy, 2010; Qi et al., 2018; Trendowski, 2014; Yokoyama et 
al., 2017).  
Although the aim of chemotherapy is the eradication of cancer cells, it also 
attacks normal cells causing adverse effects in multiple organ systems (Mittra et al., 
2017). Such debilitating effects have cause a major clinical problem, leading to a low 
12 
survival rate in the majority of cancer patients (Nurgali et al., 2018). In addition, 
chemotherapeutic drugs toxicity observed in patients contribute to inefficacy of these 
anticancer agents (Gewirtz et al., 2010).  
Chemotherapy-induced nausea and vomiting (CINV) are among the major 
concern in cancer patients during chemotherapy regimens. This symptom can be acute 
(occur less than 24 hours after treatment) or delay (occur after 24 hours and up to 8 days 
of treatment) (Roscoe et al., 2004). CINV will become an anticipated response in the 
following chemotherapy cycles which involves nausea and vomiting (Roscoe et al., 
2011). Vomiting is an action that is prompted once the body recognizes the presence of 
harmful elements in the body. This reflex can damage cells of the stomach and intestines 
(Mustian et al., 2011). When foreign substances are detected by the mucosa of the 
gastric or small intestine, it stimulates he agal afferen s  in erac ion i h he 
hindbrain, a component of the central nervous system (CNS), contributing to an emetic 
response as an efferent vagal action (Mustian et al., 2011). Once acute, delayed and 
anticipatory CINV turns severe, patients are less likely to comply with their 
chemotherapy regiment, while those who do will be susceptible to a compromised 
bodily function, anxiety, depression leading to a poorer quality of life (Rodríguez, 2013; 
Roscoe et al., 2011).  
Apart from CINV, most cancer patients undergoing cytotoxic therapy 
experienced fatigue. Fatigue is related to the activation of pro-inflammatory cytokines 
induced by chemotherapeutic agents or by the tumor itself (Bower and Lamkin, 2013). 
About 30% to 60% of cancer patients reported experience moderate to severe fatigue 
during chemotherapy, leading to discontinuation of treatment in some patients and 
ca se  significan  impairmen  in he pa ien s  q ali  of life  (Bower, 2014). 
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Mucositis is another common side effects due to cancer chemotherapy. 
Mucositis-related chemotherapy causes mucosal injury in gastrointestinal (GI) tract 
which damage normal cells that are rapidly dividing (Cinausero et al., 2017). 
Gastrointestinal mucositis may lead to local ulceration and pain, which in turn results 
in susceptibility to sepsis, anaemia, fatigue, anorexia, malabsorption and weight loss 
(Nurgali et al., 2018). Due to this gastrointestinal side effects, susceptible patients 
become reluctant to adhere to their chemotherapy regiment followed by the 
discontinuation of the treatment altogether. This will subsequently reduce their quality 
of life and survival rate (Cinausero et al., 2017). 
 Meanwhile, a lot of anti-cancer drugs such as angiogenesis inhibitors, platinum-
based agents, taxanes, proteasome and vinca alkaloids causes chemotherapy-induced 
peripheral neuropathy (CIPN) (Nurgali et al., 2018). The side effects of long-term CIPN 
results in ataxia, insomnia and depression, thus diminishing the ability to function and 
living quality in cancer survivors (Nurgali et al., 2018). 
Most cytotoxic drugs have immune suppressive side effects. They act by 
eliminating dividing haematopoietic cells that will be manifested as severe neutropenia 
and cytopenia (Hashiguchi et al., 2015). Treatment-associated neutropenia remains 
dose-limiting toxicity of cancer chemotherapy due to adverse effects including 
susceptibility to life-threatening infection, elevated risk of bleeding, decreased 
immunity and fever (Dinan et al., 2015; Fontanella et al., 2014). Besides, neutropenia 
and its complications make it necessary for early termination of treatment, delays or 
dose reductions (Dinan et al., 2015).  
In addition, multidrug resistance (MDR) poses a challenge to the potency of 
cancer chemotherapy. Drug resistance in cancer occur during the invasion and 
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metastasis of cancers (Mansoori et al., 2017). It is manifested in the form of reduced 
sensitivity towards drugs that are supposed to inhibit tumor growth by interfering with 
the membrane transport involving the P-glycoprotein product, modification of target 
enzyme, impairment in drug activation, suppression of apoptosis, promoting DNA 
repair and mutation in cell cycle proteins such as p53 (Krishna Vadlapatla et al., 2013; 
Luqmani, 2005; Mansoori et al., 2017). Nowadays, MDR has emerged as a major 
challenge in cancer chemotherapy leading to many treatment failures and severe adverse 
effects in patients (Ye et al., 2019). 
2.2 Apoptosis and cancer 
2.2.1 Mechanism of apoptosis 
Apoptosis is essential in the case of normal development and homeostasis. The 
normal cells usually undergoing apoptosis when they are damaged in various ways, 
mislocalized or inappropriately proliferating (Hanahan and Weinberg, 2016).  
 
Apoptosis can be activated by two pathways which are extrinsic and intrinsic 
pathway. Extracellular ligands such as tumor necrosis factor (TNF), Fas Ligand (Fas-
L) and TNF-related apoptosis-inducing ligand (TRAIL) affects apoptotic signaling 
through the extrinsic pathway. Apoptosis occurs when these receptors are activated 
through the formation of a death-inducing signal complex (DISC) after the caspases 
cascade is activated (Jan and Chaudhry, 2019). Apoptosis is triggered through the 
intrinsic pathway is controlled by the Bcl-2 family consisting of pro-apoptotic (Bax, 
Bak) and anti-apoptotic (Bcl-2, Bcl-xL and Mcl1) proteins (Elmore, 2007; Llambi et 
al., 2011). Upon activation by stimuli such as DNA damage, deprivation of cytokines 
and growth factors, cytochrome c is released into the cytosol and converge the 
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activation of caspase cascade of pro-apoptotic proteins leading to the mitochondrial 
outer membrane permeabilization (MOMP) causing cell death (Green and Llambi, 
2015; Zaman et al., 2014).  
Caspase cascade signaling system is important in apoptosis as it is controlled by 
various proteins that either promote or inhibit apoptosis (Green and Llambi, 2015; Ng 
et al., 2013). There are two types of caspases: the initiator (caspase-2, -8, -9, and -10) 
and the effector caspases (caspase-3, -6, and -7) (Parrish et al., 2013). In the intrinsic 
pathway, the cell death is initiated by the release of cytochrome c which forms an 
apoptosome complex with Apaf-1 proteins and activates caspase-9 (initiator caspases). 
Meanwhile, the stimulation of death receptor (e.g. FasL) that binds to the intracellular 
domain receptor (e.g. FADD) which induces cell death through the extrinsic pathway 
is triggered by the activation of caspase-8 or -9 (initiator caspases) (Baliga and Kumar, 
2003; Parrish et al., 2013). The activation of initiator caspases either by extrinsic or 
intrinsic pathways eventually causes cell death via the activation of downstream effector 
caspases such as caspase-3  (Porter and Janicke, 1999). Figure 2.1 shows overview of 







           Figure 2.1   Mechanism of apoptosis via extrinsic and intrinsic pathway 
          (Source: Google image free to use license) 
 
2.2.2 Targeting apoptosis in cancer treatment 
One way of treating cancer is to eliminate the uncontrolled proliferate cancer 
cells. Targeting apoptosis is an effective method in cancer treatment by modulating the 
cells  o n mechanism of dea h in order to terminate them (Pfeffer and Singh, 2018). 
Common strategies of chemotherapeutic drugs target various stages of apoptosis 
pathways such as pro-apoptotic proteins stimulation and suppression of anti-apoptotic 
molecules (Hassan et al., 2014).  
Several agents act as apoptotic signals that have been discovered include 
inhibitors for Bcl-2, ligands for death-receptors, inhibition of X-linked inhibitor of 
apoptosis (XIAP) proteins and alkylphospholipid analogs (APL). Venetoclax is an 
example of Bcl-2 inhibitor that is used in leukemia treatment (Sharma and Pollyea, 
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2018). XIAP inhibitor such as antisense oligonucleotide AEG35156 was clinically 
tested to reduce the expression of XIAP and increase cytotoxic activity against solid 
tumors (Miura et al., 2011). 
2.3 Immune modulation for treatment of cancer 
What begins as a mutation in the genetic material in normal cells and 
physiological alteration in cancer cells and defence mechanisms in the body, soon 
develops into a malignant form known as cancer (Furuta et al., 2010). These cellular 
alterations lead to other problems such as the loss of function in tumor suppressor genes 
resulting in cellular immortality, proliferation and carcinogenesis (Wang et al., 2018). 
This is where the role of the immune system comes in by preventing the spread of tumor 
and carcinogenesis (Koury et al., 2018).  
Imm ne mod la ion in cancer refers o rea men s ha  mod la e pa ien s  
immune response to control the growth and eliminate the tumor cells (Naidoo et al., 
2014). Immunotherapy is a modern strategy for cancer treatment which modulates the 
immune system of the patients to selectively kill target cancer cells (Koury et al., 2018). 
This technique makes use of a process called immunoediting, also known as immune 
surveillance, where cells within the immune system suppress tumor growth and 
progression by identifying and dismissing malignant cells (Ribatti, 2017). 
Cancer cells use several mechanisms to evade from host immune surveillance 
to reestablish their growth and continue to progress such as upregulation of checkpoint 
receptor ligands that essentially prevent tumor-infiltrating lymphocytes (TILs) from 
entering the tumor mass, upregulation of immune-suppressing cells including 
regulatory T-cells (Tregs), downregulating the antigen presentation system or induction 
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of the production of suppressive cytokines such as IL-10 and TGF-  (Park et al., 2018; 
Reeves and James, 2017; Thepmalee et al., 2018; Wan, 2010).  
This section will provide the details regarding the roles of major immune cells 
involved in cancer progression and targeted therapy including macrophages, 
neutrophils, natural killer (NK) cells, T cells and B cells. Apart from that, strategies that 
have been developed to manipulate anti-tumor response and targets in modern 
immunotherapy will also be highlighted.  
2.3.1 Immune cells in cancer 
Various immune cell types infiltrate the tumor environment and interaction 
between tumor and immune cells give rise to production of cytokines and growth factors 
that facilitate tumor cells in sustaining survival and metastasis (Gun et al., 2019). 
Interestingly, apart from pro-humoral role, these cells have potential as anti-cancer (Gun 
et al., 2019). Despites multifunctional roles of these immune cells (such as 
macrophages, neutrophils, NK cells, T cells and B cells), understanding their roles 
contributes toward development of innovative anti-cancer strategies (Gun et al., 2019).  
Macrophages are immune cells that are essential for normal physiological 
processes such as fighting infections, wound healing as well as promoting diseases such 
as autoimmune disorders and tumorigenesis (Wynn et al., 2013). Generally, 
macrophages can be activated by interferon gamma (IFN- ) IL-4, IL-10 which in return 
they produce pro-inflammatory cytokines and nitric oxide against bacterial, virus 
infections as well as involved in wound healing (Wynn et al., 2013). However, tumor 
associated macrophages (TAMs) induce cancer metastasis by promoting angiogenesis, 
inducing tumor growth and enhancing tumor-cell migration and invasion (Dandekar et 
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al., 2011). The presence of TAMs in the tumor microenvironment has been associated 
with poor prognosis for breast, prostate, ovarian, cervical, endometrial, esophageal and 
bladder cancers (Dandekar et al., 2011).  
NK cells are innate cells with cytotoxic ability to eliminate tumor cells. These 
cells have lytic potential by releasing lytic granules or expressing death signals (Gun et 
al., 2019). The mechanism of NK cells begins with the probing of other cells via 
activating or inhibitory receptors that will either allow or prevent the action of NK cells. 
Activating receptors recognizes foreign or stress-induced ligands while inhibitory 
receptors identify self-MHC-I molecules respectively (Gun et al., 2019). For example, 
in an in vitro study, NK-mediated tumor lysis was activated when the NK cells 
recognized tumor antigen UL16-binding protein 2/5/6 on anaplastic thyroid carcinoma 
cells via natural killer group 2, member D receptor (NKG2D) (Wennerberg et al., 2014). 
In a different study, it was reported that FasL-mediated malignant melanoma cells were 
eliminated upon the activation of NK cells once IL-18 was secreted as a response to the 
in vivo CXCR4 blockade on neutrophils or up-regulated NLRP3 inflammasome 
signalling in kupffer cells (Yang et al., 2018).  
In contrast, the adaptive immune system is slower in response to threats 
compared to cells of the innate immune system due to their antigen-specific action (Gun 
et al., 2019). In the context of cancer, cytotoxic CD8+ T cells from the T cells family 
have a significant role to play (Gun et al., 2019). These cells are activated when the 
receptor on naïve T cells surface (TCR) engage with its specific antigenic peptide MHC-
I on the tumor cells initiating target cell lysis upon the release of perforin and granzyme 
B which are cytotoxic molecules (Gálvez et al., 2019; Gun et al., 2019). The results of 
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this study highlight the potential of CD8+ T cells in modulating antitumor immunity 
(Tsukumo and Yasutomo, 2018).  
2.3.2 Types of immunotherapy 
In recent years, a breakthrough in cancer treatment was achieved with the 
clinically approved immunotherapy modalities in patients (Ventola, 2017a). This new 
approach enhances the immune response in killing cancer cells including monoclonal 
antibodies, immune checkpoint inhibitors, cytokines, cancer vaccines and cell-based 
immunotherapy (Sambi et al., 2019). 
Where monoclonal antibodies are applied, they can either be conjugated or 
unconjugated with particular drugs to produce cytotoxic effects on cancer cells (Kimiz-
Gebologlu et al., 2018). These antibodies aim to block cell proliferation and some 
signaling pathways besides targeting a particular antigen on cancer cells (Papaioannou 
et al., 2016). Rituxumab is an example of unconjugated monoclonal antibodies used to 
treat B-cell non-Hodgkin s l mphomas and i  is he firs  monoclonal an ibodies 
approved by FDA to be used in cancer treatment (Kimiz-Gebologlu et al., 2018). Other 
example of monoclonal antibodies include Transtuzumab used in breast cancer 
treatment, Alemtuzumab for chronic lymphocytic leukemia and Panitumumab for 
metastatic colorectal cancer (van Krieken et al., 2017; von Minckwitz et al., 2017; 
Winqvist et al., 2017).  
Meanwhile, a different type of monoclonal antibody known as the immune 
checkpoint inhibitors enable T cells activation and tumor cells eradication by blocking 
immune checkpoint receptors (Sambi et al., 2019). Two checkpoint inhibitors have been 
approved by FDA which are anti-programmed death ligand -1 (anti-PD-L1) and anti-
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cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) (Ventola, 2017a). They have 
been successfully used in treating metastatic melanoma (Hugo et al., 2016; Reddy et 
al., 2017).  
Infusion of specific cytokines is another approach of immunotherapy that can 
boost immune response to eliminate cancer cells (Klener et al., 2015). Two cytokines 
have received FDA approval which are Interleukin -2 (IL-2) for hairy cell leukemia 
treatment and interferon-alpha (IFN- ) for advanced melanoma and metastatic renal 
cancer treatment (Berraondo et al., 2019; Waldmann, 2018). Where IL-2 is used, it 
promotes T cells activity, especially tumor-infiltrating cells as well as increasing NK 
cells activity (Klener et al., 2015). On the other hand, IFN-  enhances immune response 
by activating dendritic cells and promoting antigen presentation as well as enhances the 
T helper type 1 (Th1) cells response, cytotoxic T cells (CD8+ T cells) activity and 
cytotoxic effects of NK cells (Alatrash et al., 2013).  
  Vaccination for cancer is available for immunotherapeutic treatment that can 
induce immune response. Similar to the conventional vaccines, cancer vaccines consist 
of total or a portion of cancer cells or antigens (Sambi et al., 2019). For instance, gp100 
is used in the treatment of melanoma while E75 is useful for breast cancer treatment 
where these peptide-based vaccines respond to one tumor antigen in complex with its 
human leukocytes antigens (HLA) (Bianchi et al., 2016; Clifton et al., 2016). Apart 
from that, immune- or dendritic cell-based vaccines are produced by specifically 
extracting dendritic cells (DCs) and activating them with specific tumor antigen of 
interest and reintroduced into the patients to eliminate cancer cells of interest as 
illustrated in Figure 2.2 (Sambi et al., 2019). Example of available cancer vaccines such 







Figure 2.2 Mechanism of action of cancer vaccines. Cancer vaccines are 
administrated through intradermal injection (1) with adjuvants that 
activate dendritic cells (2). Immature dendritic cells take up the antigens; 
typically this antigen is uniquely expressed on tumor cells (3) and 
presents the antigen to CD4 cells (4) and CD8 cells (5). CD8 cells are 
then activated to seek out the antigen on the surface of tumor cells (6). 
Abbreviations: CD is cluster of differentiation and MHC is major 




In cell-based immunotherapy, ex vivo cultured natural or genetically modified T 
cells are transferred into patients to eliminate cancer cells (Feng, 2013). Then, cytokines 
such as IL-2 are introduced along with the T cells for better efficacy (Alatrash et al., 
2013). Example of cell-based immunotherapies includes the infusion of autologous 
tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR)-transduced T cells and 
chimeric antigen receptor T cells (CAR T cells) (Koury et al., 2018). It has been 
reported that the application of CAR T cells has been successful against acute and 
chronic B cell leukemia (Koury et al., 2018). Table 2.1 presents some example of 
immunotherapy that is used in cancer treatment.  
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  Table 2.1   Example of cancer immunotherapies with demonstrated efficacy in  
cancer treatment (Alatrash et al., 2013; Weiner, 2015). 
 




Lymphomas, human epidermal growth 
factor receptor2-positive (HER-2+) breast 
cancer, colorectal cancer 
Immune checkpoint blockers Metastatic melanoma, renal cell carcinoma, 













Allogenic hematopietic stem cell 
transplant 
Acute myeloid leukemia, hematologic 
malignancies 
Autologous cell transfer Metastatic melanoma 
Genetically modified T-cell 
infusions 
Leukemia, lymphomas  
 
2.4 Natural Killer cells potential in cancer therapy  
2.4.1 Natural Killer cells 
NK cells are characterized by the expression of CD16 and CD56 and lacking of 
CD3 surface molecule (Chieregato et al., 2017). These cells can be classified into 
CD56bright and CD56dim. CD56bright NK cells is immature, present majority in lymph 
nodes and tonsils and have poor cytotoxic activity (de Jonge et al., 2019). In contrast, 
CD56dim NK cells are mature and exert potent cytotoxic effects when attached to Fc 
receptors (CD16) on target cells which activates antibody-dependent cell-mediated 
24 
cytotoxicity (ADCC) (de Jonge et al., 2019). They make up around 5  15 % of NK 
population in the peripheral blood (Mahapatra et al., 2017).  
Cytokines are not only responsible for the regulation of innate and adaptive 
immunity but also other biological processes in various cells such as growth, survival 
and proliferation of NK cells (Abel et al., 2018). Interleukins (ILs) such as IL-2, IL-15, 
IL-21 are the keys to activate NK cells (Gasteiger et al., 2013).  
NK cells responses to transformed or virally-infected cells depend on interaction 
of signals received through their inhibitory and activating receptors (Tremblay-McLean 
et al., 2019). Some of the activating receptors on NK cells include the natural 
cytotoxicity receptors (NKp30, NKp44, NKp46, NKp80), NKG2D, DNAX accessory 
molecule-1 (DNAM1), activating killer cell-immunoglobulin-like receptors (KARs) 
and others (Konje i  et al., 2017; López-Larrea et al., 2008). Meanwhile, inhibitory 
receptors can identify MHC-I molecule. Examples of inhibitory receptors are 
NKG2A/CD94 (the c-type lectin), killer immunoglobulin-like receptors (KIRs) and 
leukocyte immunoglobulin-like receptors (LILRs) (Canossi et al., 2016; Hatton et al., 
2016; Li et al., 2011). The ligands for inhibitory receptors are mostly MHC-I molecules. 
NK cells do not attack healthy cells since they express MHC-I molecules (Isvoranu, 
2017).  
2.4.2 Natural Killer cells killing mechanism 
NK cell-mediated cytotoxicity is controlled by inhibitory and activating 
receptors expressed on its surface. Ligation of these receptors with their corresponding 
ligands on target cells stimulates downstream signalling events and balance between 
inhibitory and activating signals subsequently leading to apoptosis (Ogbomo and Mody, 
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2016). NK cells cytotoxic activity can be mediated by lytic granules release pathway. 
In this pathway, a pore-forming molecules called perforin is released into the target cell 
membrane which allows delivery of granzyme B, thereby stimulate activation of 
caspases and induce target cell death (Leischner et al., 2015).  
Besides, the lytic granules pathway can be triggered in absent of caspases 
activation (Smyth et al., 2005). Apart from lytic granules release pathway, NK cells 
cytotoxicity is modulated via activation of death receptor which involves ligation of NK 
cells death receptors such as Fas Ligand (FasL), tumor necrosis factor (TNF) and TNF-
related apoptosis-inducing ligand (TRAIL) to their related ligands on target cells 
(Smyth et al., 2005). The activated receptor complex recruits the adaptor protein FADD 
and initiator caspases (caspase -8 or -10) leading to the formation of death-inducing 
signalling complex (DISC) which activate effector caspases and triggers cell death 
(Bratton and Cohen, 2001).  
Antibody-dependent cell-mediated cytotoxicity (ADCC) is another mechanism 
of NK cells cytotoxicity induce by binding of their CD16 receptor with Fc region of 
antibodies which together attach to the specific antigens present on the target cells 
(Wang et al., 2015a).  Activation of ADCC triggers the release of perforin, granzymes 
and cytokines finally induce target cells death (van der Haar Àvila et al., 2019)      
2.4.3 Natural Killer cells immunotherapy for cancer 
As part of the innate immune system, NK cells possess the ability to eliminate 
tumours or infected cells in them without first being sensitized (Marcus et al., 2014). 
They express inhibitory receptors (such as KIRs, NKG2A/CD94) that ligand with 
MHC-I molecules which are ubiquitously on normal cells and this activity block the 
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production of cytolytic granules and cytokine from NK cells thus preventing them from 
killing normal cells (Davis et al., 2015).  In contrast, abnormal cells such as cancer cells 
are lacking MHC-I molecules allowing NK cells to identify and eliminate them (Hu et 
al., 2019). Therefore, NK cells have been targeted as a therapeutic option in treating 
cancer especially in adoptive immunotherapy (Ghaemdoust et al., 2019).  
In adoptive immunotherapy, NK cells are extracted from various sources and 
are cultured in vitro. Af er a special process, he  ill be injec ed o he pa ien s bod  
and this therapy can be done via using autologous or allogenic NK cells (Ghaemdoust 
et al., 2019). Autologous NK cells originate from he pa ien s o n bod  hereas 
allogenic NK cells are obtained from various sources including hematopoietic stem cell 
transplantation or adoptive cell transfer models, NK cell lines and genetically modified 
NK cells (Geller and Miller, 2011; Ghaemdoust et al., 2019). 
Clinical trials have been carried out by using adoptive transfer of autologous 
NK and applied as a cancer treatment involving solid tumours including lymphoma, 
breast cancer, colon cancer, and lung cancer (Hu et al., 2019). However, its efficacy is 
limited to only certain cancers (Burns et al., 2003; Krause et al., 2004). Allogenic NK 
cells products are used for the treatment of leukaemia, renal cell carcinoma, colorectal 
cancer and lymphoma (Harada et al., 2017). A major concern with the application of 
allogenic NK cells is the start of graft versus host disease (GvHD) observed along with 
the use of immunosuppressive agents, injection of high-purity NK cells by CD3 
depletion and selection of donors that is compatible with the host HLA (Iliopoulou et 
al., 2010; Yoon et al., 2010). 
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2.5 Medicinal plants as anti-cancer and immunostimulatory  
Cancer is often a result of DNA aberrations in affected cells (Zaid et al., 2017). 
Besides conventional cancer treatments like surgery, new approaches like cytotoxic 
regimes of compounds and radiation are gaining popularity which hinders the cellular 
replication system by primarily targeting rapidly dividing cells (Jones and Ocen, 2020). 
Nevertheless, these treatments are accompanied by side effects due to their low 
selectivity and rendered ineffective due to their increasing resistance (Zaid et al., 2017).  
The search for new modalities in the battle against cancer should focus on 
treatments that can overcome the resistance capability of cancer cells with almost 
insignificant side effects. Plant-derived drugs (particularly from medicinal plants) are 
desireable anti-cancer agents because they are natural, readily available and offer 
minimal side effects (Kooti et al., 2017; Zaid et al., 2017). Interestingly, almost 60% of 
drugs used in cancer treatment are derived from plant-based products (Kooti et al., 
2017). Examples of plant-based anti-cancer agents that have been clinically used are 



















Table 2.2    Plant-derived anti-cancer agents in clinical use 
 









Hodgkin s l mphoma, 
leukaemia, testicular 






Paclitaxel  Taxus brevifolia Breast, ovarian, lung, 
head and neck, 
oesophageal, prostate 
and bladder cancers 
(Kuruppu et al., 
2019) 
Docetaxel  Taxus baccata Breast, ovarian, head 
and neck, lung, gastric 
and bladder cancers 
(Fu et al., 2009) 
Etoposide  Podophyllum 
peltatum 
Hodgkin s and non-
Hodgkin s l mphoma, 
















2.5.1 Medicinal plants with anti-cancer effects 
Plants produce a wide range of chemical compounds known as secondary 
metabolites such as alkaloids, flavonoids, terpenoids, steroids, phenolic compounds and 
others that responsible for their anticancer effects (Kooti et al., 2017). These metabolites 
act b  s ppressing cancer s s im la ing en mes, repairing DNA, s imulating 
production of antitumor enzymes (caspase-3, -7, -8, -9, -10, -12) in cell and inducing 
antioxidant effects (Sakarkar and Deshmukh, 2011). Table 2.3 shows example of 
medicinal plants that effective in cancer treatment.
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Table 2.3    Medicinal plants that possess anti-cancer effects 
 
Plant name Extracts used Mechanism of action References 
Achillea wilhelmsii Methanol extract of leaves Induce apoptosis in colon, stomach, breast 
and human melanoma cells 
(Azadbakht et al., 2003; 
Dokhani et al., 2005; Uddin et 
al., 2011) 
Ammi majus Ethanol extract Cytotoxic effects on human non-small cell 
lung carcinoma (H1299) cells line induced 
by apoptosis via inhibition of cytochrome 
p450 activity 
(Shokoohinia et al., 2014) 
Annona muricata Ethyl acetate extract of leaves Induce G1 cell cycle arrest and apoptosis via 
mitochondria-mediate pathway in human 
HCT-116 and HT-29 colon cells 
(Moghadamtousi et al., 2014) 
Astrodaucus orientalis Extract of root and above-ground 
part of plant 
Anti-proliferative effects on breast cancer 
cells (T47D) via inhibition of cell cycle and 
induction of apoptosis 
(Abdolmohammadi et al., 2009) 
Clinacanthus nutans Methanol extract of leaves Anti-tumor effects against 4 T1 tumor-
bearing mice 
(Rahman et al., 2019) 
Goniothalamus 
umbrosus 
Ethyl acetate extract of leaves Induce apoptosis in human breast cancer 
cells (MCF-7) 




2.5.2 Medicinal plants with immunostimulatory effects against cancer  
Medicinal plants with immunomodulatory properties are a moderately concept 
in the phytomedicine (Hasson et al., 2019). In addition to the enhancement of the 
humoral and cell-mediated immunity, immunomodulatory agents initiates the activation 
of he non-specific  responses hich he ac i a ion of he complemen  s s em, 
granulocytes, macrophages and natural killer cells (Hasson et al., 2019). The activation 
of these essential immune cells initiates production of molecules such as cytokines that 
take part in the modulation and enhancement of the immune responses (Gummert et al., 
1999; Vigila and Baskaran, 2008). All these events produce alternatives to the current 
cancer chemotherapy. Immunomodulatory agents are non-specific compounds that 
work without antigenic specificity similar to the adjuvants that are associated with some 
vaccines (Gupta et al., 2010; Liu et al., 2016). 
Several example of medicinal plants that demonstrated immunostimulatory 
effects in cancer such as Tinospora cordifolia, Nitraria retusa and Solanum nigrum. 
Tinospora cordifolia has showed immunomodulatory and anti-tumor activity when 
administered mice. Administration of methanol extract of this plant in mice has 
increased white blood cell count significantly, enhance macrophage activation and 
reduced solid tumor growth (Mathew and Kuttan, 1999). The chloroform extract of 
Nitraria retusa leaves that contain -sitosterol and palmitic acid was reported for its 
anti-tumoral and immunostimulatory effects in mice bearing induced lung tumor by 
enhancing proliferation of cytotoxic T lymphocytes (CTLs) and splenocytes as well as 
reduction in metastatic tumor due to compound (Boubaker et al., 2018). The enhance 
of immune response observed in breast tumor bearing-mice after treatment with 
polysaccharide fraction from Solanum nigrum (SN-ppF3) was indicated by increasing 
31 
of infiltrating-T cells, NK cells and macrophage in tumor tissues, higher apoptosis 
tumor cells and elevation of TNF- , IFN-  and IL-4 in treated mice (Razali et al., 2016).      
2.6 Pereskia bleo 
Pereskia bleo (P. bleo) is an edible medicinal plant from the family of Cactaceae 
(Zareisedehizadeh et al., 2014). It is originated from the western region of South 
America and commonly found in subtropical and tropical countries such as Malaysia, 
Indonesia, Singapore and India (Christophe, 2006). The scientific name of this plant is 
Pereskia bleo (Kunth) DC (Zareisedehizadeh et al., 2014). This plant is famous among 
locals by the name of Pokok Jar m T j h Bilah  among Malay hile Cak Sing Cam  
for the Chinese (Tan et al., 2005; Wahab et al., 2009).    
P. bleo is a leafy and shrubby plant with a height between 0.8 to 8 m. The trunk 
of this plant is about 10 cm in diameter and comprises leafy branches bearing 5 to 7 
black spines of 1 cm in length (Zareisedehizadeh et al., 2014). This plant produces an 
orange-red rose-like flowers (Figure 2.3(i)) while the fruits are yellow in color, glossy, 
fleshy, thick walled and containing the brown or black seeds (Christophe, 2006; Sim et 
al., 2010b). The leaves are glossy, thin, succulent and oblong in shape about 6 to 21 cm 





















Figure 2.3 Pereskia bleo used in this study produces an orange-red flower (i). The 




P. bleo is usually utilized for health and dietary purposes and in some places, it 
is popular as a food spice (Christophe, 2006; Malek et al., 2009; Nugent, 1999). In 
Malaysia, the leaves of this plant are consumed raw as a salad or a drink in the form of 
tea from decoction of fresh leaves (Er et al., 2007; Sri Nurestri et al., 2008). In 
traditional medicine, this plant is useful in the treatment of ailments including 
hemorrhoid, diabetes, hypertension, headache, ulcer, infections, gastric pain, asthma 
and rheumatism (Er et al., 2007; Malek et al., 2009; Sim et al., 2010b; Tan et al., 2005). 
In addition, locals have claimed that the leaves of this plant are useful in the prevention 
and treatment of cancer (Yen et al., 2013).  
P. bleo leaves have been extensively studied as they are commonly utilized for 
the medical purposes in the traditional practice compared to the other parts. The earliest 
phytochemical study involving the leaves of P. bleo was done by Doetsch et al. (1980) 
that identified alkaloids like 3-methoxytyramine, tyramine and 3,4-dimethoxy- -
phenethylamine. In addition, the presence of -sitosterol, phytol, vitamin E, 2,4-di-tert-
butylphenol and -tocopherol were reported in his plan s lea es (Malek et al., 2009; 
Sri Nurestri et al., 2008). The leaves were also reported to contain high amount of 
phenolic compounds and phytochemicals including lactone, glycosides, fatty acids, 
alkaloids, sterols and terpenoids (Sim et al., 2010a; Zareisedehizadeh et al., 2014).  
The leaves of P. bleo have shown various biological activities such as 
antioxidant, anti-microbial, anti-proliferative and cytotoxic effects. Its cytotoxic effects 
have been reported on several cancer cell lines. Crude, fraction and pure compounds 
have isolated from the leaves of this plant and evaluated for its cytotoxic effects on 
several cancer cell lines. For instance, methanol extract of P. bleo leaves was found to 
be cytotoxic against T-47D breast cancer cell line (EC50 value = 2.0 µg/ml) and induced 
apoptosis in this cells through c-myc pathway and caspase-3 activation (Tan et al., 
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2005). Ethyl acetate fraction and crude methanol extract of this plant were demonstrated 
high cytotoxic effects against KB cancer cell line (human nasopharyngeal epidermoid 
carcinoma) at IC50 value of 4.5 and 6.5 µg/ml respectively (Sri Nurestri et al., 2008). 
Several pure compounds isolated from this plant also showed significant cytotoxic 
effects against several cancer cell lines. For example, 2,4-di tert butylphenol exerted 
high cytotoxic effects on KB, MCF7 (human hormonal dependent breast cancer cells), 
CasKi (human cervical carcinoma) and A549 (human lung carcinoma) cell lines with 
IC50 value of 0.81, 5.75, 4.5 and 6.0 µg/ml respectively (Malek et al., 2009). Apart from 
that, -tocopherol was found highly cytotoxic against KB (IC50 value = 8.0 µg/ml), 
MCF7 (IC50 value = 7.5 µg/ml), CasKi (IC50 value = 6.0 µg/ml) and A549 (IC50 value 
= 6.0 µg/ml) (Malek et al., 2009) cell lines. 
As for its antioxidant activity, ethyl acetate and hexane extracts of P. bleo 
showed high antioxidant activity determined through assay such as -carotene 
bleaching and scavenging effect on DPPH radicals (Hassanbaglou et al., 2012; Sim et 
al., 2010a; Wahab et al., 2009). In antimicrobial activity, dichloromethane extract of P. 
bleo showed the strongest antimicrobial activity against Methicillin Resistant 
Staphylococcus aureus (MRSA) bacteria while hexane extract exhibited high 
antimicrobial activity and methanol extract showed moderate antimicrobial activity 
against both gram negative bacteria Pseudomonas aeruginosa and Salmonella 
choleraesuis (Wahab et al., 2009). 
Nowadays, modulation of the immune system to improve health status 
especially in the treatment of cancer has gained attention in the research field and 
continue to increase in demand due to limitations of the current cancer treatment. 
Therefore, numerous research involving medicinal plants are ongoing to explore for 
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their immunomodulatory effects on cancer cells. However, to our knowledge, study on 






































CHAPTER 3  
 
PHYTOCHEMICAL SCREENING OF Pereskia bleo LEAVES EXTRACT via 
GC-MS 
3.1 Introduction 
Advancement and breakthroughs in the pharmaceutical industry are reliant upon 
traditional medicinal plants (Wright, 2005). This is mainly due to the fact that these 
plants contain metabolites be it in the form of crude or pure material that is used as a 
remedy that was passed down through generations for various ailments (Dekebo, 2019). 
Several example of modern drugs that are developed from plants such as Artemisinin 
isolated from Artemisia annua used for malaria treatment (Mander and Liu, 2010), 
Galantamine (Reminyl®) is sed in rea men  of Al heimer s disease derived from 
Galanthus woronowii Losinsk. (Anand et al., 2019; Kurz, 2002) and Vinblastine 
produced from Catharanthus roseus sed as chemo herap  for Hodgkin s lymphoma 
(Kuruvilla, 2009; Seneca, 2007). 
The bioactive compounds in plants can be classified into primary and secondary 
metabolites. Primary metabolites play a role in growth, development or reproduction 
via molecules like amino acids, carbohydrates and lipids (Dekebo, 2019). Meanwhile, 
secondary metabolites are divided into several classes such as terpenoids, phenolics, 
alkaloids, tannins and others that are used by plants in their defense mechanism against 
predators (Harborne, 1998). In addition, these compounds provide plants with their 
therapeutic properties such as antibiotic, anti-cancer, antifungal and antiviral that are 
beneficial to human health (Hussein and El-Anssary, 2018).  
One of the commonly used medicinal plants is Pereskia bleo (P. bleo). The 
leaves of this plant are claimed to be effective in traditional cancer treatment when 
consumed raw or as tea (Abdul-Wahab et al., 2012; Malek et al., 2009; Yen et al., 
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2013). Phytochemical studies on the leaves of P. bleo often uses fractions or pure 
compounds instead of crude extracts. In traditional medicine, a crude extract is preferred 
instead of an isolated single compound because the synergistic of all the compounds 
that are present in the plant offers greater effectiveness (Rasoanaivo et al., 2011).  
The first and crucial step in the isolation of bioactive compounds from medicinal 
plants is the extraction process. There are various extraction methods available to obtain 
the desired bioactive compounds from plants. The maceration, Soxhlet and decoction 
extraction techniques are some of the most used methods in medicinal plant studies. 
Maceration is a simple procedure that involves the soaking of plant materials in a 
solvent for a minimum of 3 days with frequent shaking at room temperature (Handa et 
al., 2008). The low extraction temperature in this method can preserve some of the 
compounds from degradation (Wu et al., 2015). Soxhlet extraction is a common practice 
for plant leaves extraction which result in good recovery of plant secondary metabolites 
(Dekebo, 2019) . This method usually requires the heating of plant samples at a high 
temperature which can increase the possibilities of losing thermolabile compounds 
(Zhang et al., 2018). Decoction also involves soaking of the plant materials in boiled 
water. This method is suitable for extracting heat-stable compounds and hard plant 
structures such as barks and roots (Azwanida, 2015). Thus, different preparation 
methods will result in the isolation of different compounds since the heating process 
will cause some compounds to be degraded. This further emphasizes the importance of 
selecting the best extraction method in research.  
Besides the methods of extraction, type of solvent for extraction also has a 
significant impact on the extraction of target compounds from medicinal plants that vary 
in terms of polarity. In the current study, four types of solvents were used for polarity 
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screening of P. bleo leaves. Hexane is used to extract nonpolar compounds, ethyl acetate 
for medium-polarity compounds, while methanol and aqueous solution for polar 
compounds. In addition to methanol and aqueous solution, ethanol is also useful for 
extracting compounds that are hydrophilic in nature (Bergs et al., 2013; Sasidharan et 
al., 2011). On the other hand, lipophilic extraction requires medium-polarity solvents 
such as ethyl acetate and dichloromethane (Bergs et al., 2013; Sasidharan et al., 2011). 
Meanwhile, solvents that are suitable for the extraction of non-polar compounds include 
petrol ether, chloroform and hexane (Bergs et al., 2013).  
Until now, gas chromatography-mass spectrometry (GC-MS) analysis remains 
a valuable method for the analysis of crude extracts of medicinal plants that contains 
volatile compounds. It is a rapid process with high sensitivity and selectivity, better 
resolution, high throughput and broad coverage (Deslauriers, 2002; Wang et al., 2015b). 
Previous studies involving GC-MS on crude methanol extract of P. bleo leaves revealed 
the presence of -sitosterol and stigmasterol while high amount of sugar and fatty acids 
were found in the aqueous extract (Sharif et al., 2015). Despite the numerous studies 
involving this plant, the phytochemical investigation on its crude extract remains 
unexplored. In this study, we opted for the maceration, Soxhlet and aqueous decoction 
to determine the therapeutic potential of P. bleo leaves crude extracts while mimicking 
the traditional crude preparation at the same time. Thus, the present research was carried 
out to identify the phytochemicals present in the crude extracts of P. bleo leaves by 




3.2 Materials and methods 
3.2.1 Plant leaves collection and preparation 
The leaves of P. bleo were collected from Kampung Cherang, Kota Bharu, 
Kelantan and verified by our botanist Dr. Rahmad Zakaria. A voucher specimen 
(Voucher No: 11575) was submitted to the herbarium at the School of Biology, 
Universiti Sains Malaysia (USM), Penang. The leaves were rinsed thoroughly with 
water before being subjected to oven-drying at 50°C and processed into powder form 
by grinding. 
3.2.2 Maceration extraction of P. bleo leaves 
A total of 10 g of P. bleo leaves powder were soaked in 500 ml of hexane, ethyl 
acetate and methanol successively for approximately 30 days at room temperature. 
Then, the extracts were filtered (Whatman paper no. 1) and concentrated by using a 
rotary evaporator. 
3.2.3 Soxhlet extraction of P. bleo leaves 
A total of 20 g of powdered leaves were extracted successively using hexane, 
ethyl acetate, and methanol solvent via Soxhlet apparatus. The leaves powder was 
loaded into ¾ of the thimble and placed in the chamber of the Soxhlet. Then, the Soxhlet 
extractor was placed in the flask containing hexane solvent and subjected to reflux 
heating. The solvent vapors travelled through the extractor and reached the thimble and 
returned to the flask. This process continued for 24 h until the solvent became clear. 
The thimble containing the plant leaves was dried under a fume hood for overnight and 
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this process was repeated for ethyl acetate and methanol. The extracts were then 
concentrated using the evaporator and stored at  20 °C until use.  
3.2.4 Aqueous decoction of P. bleo leaves 
The aqueous extract was prepared by decoction method where 10 g of the P. 
bleo leaves sample were boiled in 450 ml water at 50°C until the water was reduced to 
one-third of its initial volume. Then, the sample was filtered with Whatman filter paper. 
Subsequently, the aqueous extract was frozen (-20 C) o ernigh  and dried sing free e 
dryer. The extract was stored at -20°C until further use.   
3.2.5 Determination of extraction yield from P. bleo leaves 
The extraction yield (%) for each solvent extract from the leaves of P. bleo 
obtained through maceration, decoction and Soxhlet extractions was calculated as 
follows: 
                                Weight of the crude extract after  
The yield of extract (%) =  evaporating process or freeze-drying    x  100 % 
                                 Weight of dried leaves 
3.2.6 Gas Chromatography  Mass Spectrometry (GC-MS) Analysis 
The GC-MS analysis of P. bleo leaves extracts were carried out by using 
Hewlett Packard 6890 Gas Chromatograph with 5973N Mass Selective Detector. The 
column was fused silica capillary, HP-5 column (30 m x 0.25 mm i.d x 0.25 µm film 
thickness) (Agilent Technologies, USA). The carrier gas was helium with a flow rate of 
1.0 ml/min with the oven temperature programmed from 50°C (5 min) to 300°C (10 
41 
min) at a rate of 25°C/min. Both injection and interface temperatures were set at 280°C. 
One microliter sample was injected in splitless mode and analysed in MS full scan mode 
(m/z 40-650). The electron ionization was fixed at 70eV. Acquisition of data was 
performed using Chemsation software. Identification of phytochemical constituents 
was accomplished based on the similarity of more than 80 % between mass spectral 
































3.3.1 Yield of Pereskia bleo leaves extracts 
Table 3.1 presented the percentage of extract yield from P. bleo leaves with 
different methods of extraction and solvents. In the maceration method, methanol 
produced the highest extraction yield (21.00 %), followed by ethyl acetate (12.00 %) 
and hexane (10.50 %). The same trend was also observed in Soxhlet extraction where 
methanol demonstrated the highest extract yield (28.00 %) followed by ethyl acetate 
(15.50 %) and hexane (12.50 %). The aqueous extract was obtained by using the 
decoction method which resulted in 25.30 % of extraction yield.  
  
Table 3.1    Percentage of yield from P. bleo leaves extracts obtained via maceration, 














Maceration Hexane     10.00          1.05        10.50 
 Ethyl acetate     10.00          1.20        12.00 
 Methanol      10.00          2.10        21.00 
Soxhlet  Hexane      20.00          2.50        12.50 
 Ethyl acetate     20.00          3.10        15.50 
 Methanol      20.00          5.60        28.00 
Decoction  Aqueous      10.00          2.53        25.30 
 
3.3.2 Identification of phytocompounds from the maceration of P. bleo leaves 
In the present study, the leaves of P. bleo were extracted via maceration method 
using solvents of different polarity (hexane < ethyl acetate < methanol). The chemical 
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composition of each extract was analyzed using GC-MS. The identified compounds, 
their retention time (RT), percentage of composition (peak area), molecular weight and 
compound nature were detailed in Table 3.2, 3.3 and 3.4.  
3.3.2(a) Hexane  
Twenty-four compounds from sterols, terpenoids, fatty acids, phenolic 
compounds and others have been identified in the hexane extract of P. bleo leaves 
obtained via maceration as presented in Table 3.2. Sterols makes up the highest 
composition in the total compounds (23.35 %) in this extract where -sitosterol (17.53 
%) was the prominent compound followed by campesterol (4.39 %), stigmasterol (1.13 
%) and stigmast-7-en-3-ol, (3.beta.,5.alpha.)- (0.20 %). Terpenoids represent 12.53 % 
from the total compounds consisting of neophytadiene (5.84 %), phytol (5.22 %), 
squalene (1.05 %) and (-)-Loliolide  (0.42 %). Phenolic compounds represent 9.32 % 
of the total compounds consisting of -tocopherol (6.13 %), 2H-1-Benzopyran-6-ol,3,4-
dihydro-2,8-dimethyl-2-(4,8,12-trimethyltridecyl)- (2.15 %) and -tocopherol (1.04 
%).  Other than that, vitamin E (13.31 %) and fatty acids such as 1-Heptacosanol (2.72 
%), 9,12,15-Octadecatrienoic acid, methyl ester, (Z,Z,Z)- (2.69 %) as well as 9,12-














Table 3.2   Phytochemical compounds identified in the hexane extract of P. bleo 
                       leaves 
 












10.195 0.22 180 Others  
Cyclopentaneacetic acid,3-
oxo-2-pentyl-, methyl ester 
10.657 0.13 226 Fatty acid 
(-)-Loliolide 11.280 0.42 196 Terpenoids  
3-Eicosyne 11.610 0.37 279 Others  
Hexadecanoic acid, methyl 
ester 
11.855 1.90 270 Fatty acid  
9,12-Octadecadienoic acid, 
methyl ester 
12.513 2.55 294 Fatty acid  
9,12,15-Octadecatrienoic 
acid, methyl ester, (Z,Z,Z)-  
12.541 2.69 292 Fatty acid 
Phytol 12.583 5.22 297 Terpenoids  
Octadecanoic acid, methyl 
ester 








13.535 0.19 262 Others 
Tetracosanoic acid, methyl 
ester 
14.578 0.46 383 Others  




15.244 2.15 403 Phenol 
-tocopherol 15.538 1.04 417 Phenol  
-tocopherol 15.594 6.13 417 Phenol 
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1-Heptacosanol 15.706 2.72 397 Fatty acid 
Vitamin E 15.902 13.31 431 Vitamin E 
Campesterol 16.364 4.39 401 Sterols 
Stigmasterol 16.511 1.13 413 Sterols 
n-Tetracosanol-1 16.560 1.20 355 Fatty acid 
-sitosterol 16.819 17.53 415 Sterols 
Stigmast-7-en-3-ol, 
(3.beta.,5.alpha.)- 
17.106 0.20 415 Sterols  
































3.3.2(b) Ethyl acetate  
The GC-MS analysis of ethyl acetate extract from the leaves of P. bleo obtained 
via maceration has identified 23 individual compounds including sterols, terpenoids, 
fatty acids, phenolic compounds and others as listed in Table 3.3. Majority of the 
compounds were represented by terpenoids (23.94 %) consisting of phytol (16.09 %), 
neophytadiene (5.12 %) and (-)-Loliolide (2.73 %). In addition, sterols recorded 7.78 % 
from the total compounds in this extract ha  as made p of -sitosterol (9.63 %), 
campesterol (3.23 %), stigmastan-3,5-diene (1.31 %) and stigmasterol (0.82 %). 
Phenolic compounds represented 4.34 % of the total compounds composition with the 
presence of -tocopherol (2.42 %), 2H-1-Benzopyran-6-ol,3,4-dihydro-2,8-dimethyl-2-
(4,8,12-trimethyltridecyl)- (1.82 %) and 4-vinyl-2-methoxy-phenol (0.10 %). Vitamin 
E was presented at 3.49 % of the compounds presented in the ethyl acetate extract of P. 
bleo leaves while fatty acids such as nonanoic acid,9-(3-
hexenylidenecyclopropylidene)-2-hydroxy-1-(hydroxymethyl) (6.04 %), 9,12,15-
octadecatrienoic acid, methyl ester, (Z,Z,Z)- (5.90 %) and hexadecanoic acid,2-

















Table 3.3   Phytochemical compounds identified in the ethyl acetate extract of P. bleo 
                   leaves 
 














9.467 0.08 206 
Others 
(-)Loliolide 11.287 2.73 196 Terpenoids 
Neophytadiene 11.504 5.12 279 Terpenoids 
Hexadecanoic acid, ethyl ester 12.121 0.16 284 Fatty acid 
9,12,15-Octadecatrienoic acid, 
methyl ester, (Z,Z,Z)- 
12.541 5.90 292 
Fatty acid 
Phytol 12.590 16.09 297 Terpenoids 
9,12,15-Octadecatrienoic acid, 
ethyl ester, (Z,Z,Z)- 
12.786 1.18 306 
Fatty acid 
9-Octadecenamide, (Z)- 12.849 0.55 281 Fatty acid 
3,4-Dimethyl-3-cyclohexene-1-
carbaldehyde 




13.444 0.51 323 Alkene 
hydrocarbon 
Hexadecanoic acid,2-hydroxy-
1-(hydroxymethyl) ethyl ester 














15.243 1.82 403 
Phenol 
-tocopherol 15.594 2.42 417 Phenol 
1-Heptacosanol 15.706 2.39 397 Fatty acid 
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Stigmastan-3,5-diene 15.818 1.31 397 Sterols 
Vitamin E 15.895 3.49 431 Vitamin E 
Campesterol 16.364 3.23 401 Sterols 
Stigmasterol 16.511 0.82 413 Sterols 
Octacosyl acetate 16.56 1.13 453 Fatty acid 







































3.3.2(c) Methanol  
The methanol extract of P. bleo from the maceration method has identified 
thirty-six phytocompounds via GC-MS.  Table 3.4 showed the list of compounds 
consisting of sterols, terpenoids, fatty acids, phenolic compounds, alkaloids among 
others. Terpenoids recorded the highest composition (5.61 %) of the total compounds 
which contained (-)-Loliolide (2.39 %), phytol (1.75 %), neophytadiene (1.22 %) and 
4,8,12,16-Tetramethylheptadecan-4-olide (0.25 %). Phenolic compounds represented 
4.25 % of the total compounds composition that was made up of 4-vinyl-phenol (2.18 
%) and 2-Methoxy-4-vinylphenol (2.07 %). Meanwhile sterols exhibited 1.16 % with 
he presence of -sitosterol (0.93 %), campesterol (0.13 %) and stigmasterol (0.10 %). 
Interestingly, indole (0.18 %) from the alkaloids group was discovered for the first tim 
in the leaves extract of this plant. Fatty acids such as hexadecanoic acid, 2,3-
dihydroxypropyl ester (3.52 %) and 9,12,15-Octadecatrienoic acid, methyl ester, 





















Table 3.4    Phytochemical compounds identified in the methanol extract of P. bleo 
                      leaves 
 









Butyrolactone 4.096 0.18 86 Others 
Pyridine,2,4,6-trimethyl- 6.085 0.06 121 Others 
2-Pyrrolidinone 7.268 0.69 85 Others 
Methyl salicylate 8.186 5.66 152 Others 
4-vinyl-phenol 8.403 2.18 120 Phenol 
1H-Pyrrole-2,5-dione,3-ethyl-
4-methyl- 
8.473 1.16 139 Others 
Indole 8.865 0.18 117 Alkaloids 
2-Methoxy-4-vinylphenol 8.977 2.07 150 Phenol 
Cyclopropane, octyl- 9.292 0.25 154 Others 
1-Hexadecanol 9.831 0.56 242 Fatty acid 
2-Naphtalenamine 10.251 0.54 143 Aromatic 
amine 
3-Methyl-4-phenylpyrrole 10.405 0.45 157 Others 
4-(1E)-3-Hydroxy-1-
propenyl)-2-methoxyphenol 
11.189 0.92 180 Others 
(-)-Loliolide 11.308 2.39 196 Terpenoids 
Neophytadiene 11.512 1.22 279 Terpenoids 
2-Pentadecanone,6,10,14-
trimethyl- 
11.533 0.64 268 
Others 
Hexadecanoic acid, methyl 
ester 
11.855 1.70 270 
Fatty acid 
Cyclotetradecane 12.415 0.87 196 Others 
9,12,15-Octadecatrienoic acid, 
methyl ester, (Z,Z,Z)-  
12.541 2.13 292 Fatty acid 
Phytol 12.583 1.75 297 Terpenoids 
Methyl 16-methyl-
heptadecanoate 
12.625 0.34 299 
Others 
Cyclohexyl-15-crown-5 12.695 0.24 302 Others 
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Bis(2-ethylhexyl) maleate 12.723 0.27 341 Others 
Decyltetraglycol 12.786 0.84 335 Others 
2-Butanedioic acid (E)-, bis(2-
ethylhexyl) ester 




13.437 0.25 325 Terpenoids 
Hexagol 13.724 0.91 282 Others 
Hexadecanoic acid, 2,3-
dihydroxypropyl ester 
13.941 3.52 331 Fatty acid 
13-tetradecenal 14.501 1.44 210 Others 
hexaethylene glycol 
monododecyl ether 
15.062 0.89 451 Others 
1-Octacosanol 15.699 0.38 411 Fatty acid 
Vitamin E 15.895 0.23 431 Vitamin E 
Campesterol 16.357 0.13 401 Sterols 
Stigmasterol 16.504 0.10 413 Sterols 
n-tetracosanol-1 16.553 0.28 355 Fatty acid 

















3.3.3 Identification of phytocompounds from Soxhlet extraction of P. bleo leaves 
Besides the maceration method, the current study also has successively 
extracted compounds from the leaves of P. bleo using Soxhlet extractor with solvents 
of different polarity (hexane < ethyl acetate < methanol). The extracts obtained were 
subjected to GC-MS analysis for identification of the presence phytoconstituents in each 
extract. The results were shown in Table 3.5, 3.6 and 3.7 which detailed the list of 
compounds, their retention time (RT), percentage of composition (peak area), molecular 
weight and compound nature. 
3.3.3(a) Hexane  
A totoal of 19 compounds have been identified from the hexane extract of P. 
bleo from the Soxhlet method as listed in Table 3.5. This extract consisted of terpenoids, 
sterols and others compounds. The most abundant compound was sterols representing 
10.05 % of the total compound composition, indica ing he presence of -sitosterol (8.68 
%) and campesterol (1.37 %). Terpenoids represented 9.75 % of the total compounds 
in this extract and were made up of neophytadiene (5.15 %), (Z)-1,3-Phytadiene (2.55 
%), (-)-Loliolide (1.04 %) and squalene (1.01 %). Other compounds were also found in 
this extract such as vitamin E (4.16 %) and fatty acids contained predominantly by 












Table 3.5    Phytochemical compounds identified in the hexane extract of P. bleo 
                        leaves 
 









Benzoic acid, methyl ester 8.202 1.67 136 Others 
Octanoic acid, methyl ester 8.426 0.37 158 Fatty acid 
Decanoic acid, methyl ester  9.749 0.24 186 Fatty acid 
Dodecanoic acid, methyl 
ester  





10.981 0.54 180 Others 
Methyl tetradecanoate  11.752 0.84 242 Fatty acid 
(-)-Loliolide 12.06 1.04 196 Terpenoids 
Neophytadiene 12.256 5.15 279 Terpenoids 
(Z)-1,3-Phytadiene 12.431 2.55 279 Terpenoids 
Hexadecanoic acid, methyl 
ester 
12.599 6.29 271 Fatty acid 
n-Hexadecanoic acid 12.739 11.03 256 Fatty acid 
Heptadecanoic acid, methyl 
ester 
12.991 0.56 285 Fatty acid 
9,12,15-Octadecatrienoic 
acid, methyl ester, (Z,Z,Z)- 
13.299 9.29 293 Fatty acid 
 9,12,15-Octadecatrien-1-ol, 
(Z,Z,Z)- 
13.446 35.12 265 Others 
Hexadecanoic acid, 2,3-
dihydroxypropyl ester- 
14.692 0.68 331 Fatty acid 
Squalene 15.743 1.01 411 Terpenoids 
Vitamin E  17.262 4.16 431 Vitamin E 
Campesterol 18.032 1.37 401 Sterols 
-sitosterol  18.719 8.68 415 Sterols 
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3.3.3(b) Ethyl acetate 
The GC-MS analysis of the ethyl acetate extract from P. bleo leaves showed the 
presence of twenty-two phytochemical compounds as presented in Table 3.6. 
Flavanoids were the highest compounds (20.81 %) identified in this extract with the 
predominate compound of 4H-Pyran-4-one,2,3-dihydro-3,5-dihydroxy-6-methyl. 
Terpenoids were also identified at 9.38 % of the total compound composition 
comprising of neophytadiene (4.29 %), phytol (3.59 %) and (-)-Loliolide (1.50 %). 
Meanwhile, phenolic compounds represented 1.93 % of the total compound containing 
4-vinyl-syringol (1.32 %), 4-vinylphenol (0.53 %) and -tocopherol (0.08 %). Sterols 
made up 1.76 % of the total extract composi ions consis ing of -sitosterol (1.56 %) and 
campesterol (0.20 %). Other compounds that were identified include vitamin E (0.36 

























Table 3.6    Phytochemical compounds identified in the ethyl acetate extract of 
                          P.bleo leaves 
 









Protoanemonine 5.429 0.08 96 Others 
Decane 7.186 0.28 142 Hydrocarbon 
1,2,3-Propanetriol, 
monoacetate 
8.257 11.03 134 Others 
4H-Pyran-4-one,2,3-dihydro-
3,5-dihydroxy-6-methyl 
8.608 20.81 144 Flavonoids 
4-vinylphenol 9.105 0.53 120 Phenol 
Dodecanoic acid, methyl 
ester 
10.813 1.03 214 Fatty acid 
Dodecanoic acid 10.981 1.26 200 Fatty acid 
4-vinyl-syringol 11.065 1.32 180 Phenol 
4-((1E)-3-Hydroxy-1-
propenyl)-2-methoxyphenol 
11.891 1.31 180 Others 
(-)-Loliolide 12.074 1.50 196 Terpenoids 
Neophytadiene  12.256 4.29 279 Terpenoids 
Hexadecanoic acid, methyl 
ester 
12.599 1.12 271 Fatty acid 
Hexadecanoic acid 12.746 5.25 256 Fatty acid 
Trans - sinapyl alcohol 12.928 0.78 210 Others 
Phytol 13.341 3.59 297 Terpenoids 




14.699 3.42 331 Others 
Ethyl linoleolate 15.995 0.86 306 Others 
-tocopherol 16.793 0.08 417 Phenol 
Vitamin E 17.262 0.36 431 Vitamin E 
Campesterol 18.032 0.20 410 Sterols 
-sitosterol 18.725 1.56 415 Sterols 
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3.3.3(c) Methanol  
Twenty-eight compounds were identified in P. bleo methanol extract by GC-
MS analysis as shown in Table 3.7.  The prevailing compounds were from phenolic 
group (34.93 %) consisted of phenol, 2,6-dimethoxy- (11.64 %), 2-Methoxy-4-
vinylphenol (8.30 %), 4-vinylphenol (5.78 %), phenol, 2-methoxy-4-(1-propenyl)- 
(3.90 %), 4-vinyl -syringol (3.72 %) and -tocopherol (1.59 %). On the other hand, 
11.12 % of this extract was represented by terpenoids which consisted of neophytadiene 
(8.44 %), (Z)-1,3-Phytadiene (1.84 %), squalene (0.61 %) and olean-12-en-28-oic acid, 
3-oxo-,methyl ester (0.23 %). Sterols comprising of -sitosterol (0.47 %), stigmasta-
3,5-dien-7-one (0.21 %) and campesterol- (0.21 %) representing 0.89 % of the total 
compound composition of this extract. Meanwhile, vitamin E was found at 1.28 % of 
total compounds content as well as fatty acids such as 9,12,15-Octadecatrienoic acid, 























Table 3.7    Phytochemical compounds identified in the methanol extract of 
                            P. bleo leaves 
 









2(3H)-Furanone, dihydro- 4.765 0.57 86 Others 
Pyrazine, trimethyl- 6.364 0.31 122 Others 
Pyrazine, 3-ethyl-2,5-dimethyl- 6.971 0.45 136 Others 
Benzoic acid, methyl ester 7.374 1.06 136 Others 
2-Isobutylthiazolidine 8.073 0.57 145 Others 
4-vinylphenol 8.562 5.78 120 Phenol 
2-Methoxy-4-vinylphenol 9.002 8.30 150 Phenol 
Phenol, 2,6-dimethoxy- 9.236 11.64 154 Phenol 
Phenol, 2-methoxy-4-(1-
propenyl)- 
9.735 3.90 164 Phenol 
DL-Proline, 5-oxo-, methyl 
ester 
9.9 3.75 143 Others 
4-vinyl -syringol 10.327 3.72 180 Phenol 
Neophytadiene 11.455 8.44 279 Terpenoids 
(Z)-1,3-Phytadiene 11.632 1.84 279 Terpenoids 
Methyl palmitate 11.811 3.32 271 Fatty acid 
n-Hexadecanoic acid 12.381 2.49 256 Fatty acid 
9,12,15-Octadecatrienoic acid, 
methyl ester 
12.496 3.38 292 Fatty acid 
Hexadecanamide 12.84 2.28 255 Fatty acid 
Behenic alcohol 13.805 0.63 327 Others 
Hexadecanoic acid, 2-hydroxy-
1(hydroxymethyl)ethyl ester 
13.923 2.78 331 Others 
9,17-Octadecadienal, (Z)- 14.491 3.57 264 Others 
13-Docosenamide 14.713 0.94 338 Others 
Squalene 14.819 0.61 411 Terpenoids 
-tocopherol 15.515 1.59 417 Phenol 
Vitamin E 15.81 1.28 431 Vitamin E 
Campesterol 16.264 0.21 410 Sterols 
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-sitosterol 16.688 0.47 415 Sterols 
Stigmasta-3,5-dien-7-one 17.073 0.21 411 Sterols 
Olean-12-en-28-oic acid, 3-
oxo-,methyl ester 







































3.3.4 Identification of phytocompounds from decoction of P. bleo leaves aqueous 
extract 
In this study, the aqueous extract of P. bleo leaves was also obtained via 
decoction method. Identification of the phytocompounds was performed using GC-MS 
analysis. From the results, sixteen compounds have been found as listed in Table 3.8. 
The most abundant compound as from phenols (4.34 %) consis ing -tocopherol (2.38 
%) and 2-Methoxy-4-vinylphenol (1.96 %). Alkaloids represented 2.64 % from the total 
compound composition containing 1,2,3,4-Tetrahydro-cyclopenta(b)indole (1.80 %) 
and Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)- (0.84 %). 
Phytol, a predominant compound (1.31 %) from the terpenoid group was also identified 
in the aqueous extract of this plant. Sterols represented 0.91 % of the total compound 
composition comprising mainly of -sitosterol. Vitamin E was recorded at 0.52 % while 























Table 3.8    Phytochemical compounds identified in the aqueous extract of 
                             P. bleo leaves 
 









Pyrazine, trimethyl- 6.218 0.34 122 Others 
Thiazolidine,2-isobutyl- 8.067 1.90 145 Others 
Benzofuran,2,3-dihydro- 8.389 0.82 120 Others 
2-Methoxy-4-vinylphenol 8.977 1.96 150 Phenol 
4-methyl-2,5-
dimethoxybenzaldehyde 
10.314 0.76 198 Others 
1,2,3,4-Tetrahydro-
cyclopenta(b)indole 
10.405 1.80 157 Alkaloids 
Methyl dihydrojasmonate 10.65 2.30 226 Fatty acid 




11.932 0.84 210 Alkaloids 
9,12,15-Octadecatrienoic acid, 
methyl ester, (Z,Z,Z)- 
12.534 0.38 292 Fatty acid 
Phytol 12.583 1.31 296 Terpenoids 
-tocopherol 15.587 2.38 416 Phenol 
n-Tetracosanol-1 15.699 1.56 354 Fatty acid 
Vitamin E 15.888 0.52 430 Vitamin E 
1-Heptacosanol 16.553 0.91 396 Fatty acid 












3.4 Discussion  
Nowadays, medicinal plants have attracted the focus of researchers due to their 
health benefits and also a source of therapeutic compounds that lead to the discovery 
and development of new drugs. Medicinal plants possess extensive of secondary 
metabolites and phytochemicals which work synergistically contributing to its efficacy 
in the treatment of various health problems. In this regard, extraction and analysis of 
plant material are important in the development, upgrading, and quality control of 
herbal formulations (Sasidharan et al., 2011).  
Numerous studies have been done on this plant, nonetheless, its phytochemical 
studies remained unexplored. Most phytochemical studies involving this plant leaves 
usually use fractions instead of crude extracts. However, in traditional practice, the 
leaves are commonly prepared as crude. Thus, the present study was conducted to 
investigate the phytochemicals presented in the crude extracts of P. bleo. The leaves 
samples were extracted using solvents of different polarities through maceration, 
Soxhlet and decoction extraction methods. The crude extracts obtained were then 
subjected to GC-MS analysis for phytochemical compounds identification.   
In the medicinal plant analysis, extraction is an important step to obtain 
phytochemical compounds of interest from the plant materials (Sasidharan et al., 2011). 
The target compounds comprise of different structures that determine their solubility in 
the different polarity solvents that are used for extraction (Z o ek et al., 2016). 
Therefore, the efficacy of extraction largely depends on the type of solvent that 
significantly influence the recovery of extraction yield from the plant materials. 
According to the results, high extraction yield was produced by methanol solvent 
followed by ethyl acetate and hexane in both successive maceration and Soxhlet 
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extraction method. The aqueous solvent from decoction method also found producing 
high extraction yield. This was probably due to the presence of high level of polar 
compounds with high molecular weight in the plant materials that is soluble in high 
polarity solvents like methanol and aqueous. According to Truong et al. (2019), highly 
polar solvents enhanced the efficacy of the extraction process where they found that 
methanol extract of Severinia buxifolia produced the highest extraction yield compared 
to other tested solvents. In other study by Tambunan et al. (2017) demonstrated that the 
highest extract yield of Ageratum conyoides Linn. Leaves was obtained by aqueous 
extract (30.20 %) followed by ethanol extract (15.00 %). The current results indicated 
that the polarity of solvents influences the extraction yield. 
As the target compounds may be non-polar to polar and thermally labile, the 
suitability of the methods of extraction must be considered. The current study used 
maceration, Soxhlet and decoction techniques to extract P. bleo leaves because they are 
commonly used in the extraction process of medicinal plants. In successive extraction 
method, the Soxhlet method outperformed the maceration method recording the best 
percentage of extract yield. The order of solvent effectiveness is as follows: methanol 
> ethyl acetate > hexane. Similar findings have been reported by Muthukumarasamy et 
al. (2018) where the Soxhlet extraction of Osbeckia parvifolia plant demonstrated 
excellent recovery over other extraction methods with the highest percentage of yield 
obtained in methanol followed by ethyl acetate, ethanol and hexane. There are several 
factors that can enhance the efficacy of extraction including a longer extraction period. 
However, this will not work once the equilibrium between solute and solid material has 
been achieved (Zhang et al., 2018). In the current study, Soxhlet extraction recorded the 
best recovery percentage in the shortest time compared to maceration even though 
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maceration method required a longer extraction period about 30 days which may be 
caused by the equilibrium between the solvent and the plant materials.   
The GC-MS analysis was conducted to identify the presence of 
phytocompounds in the leaves of P. bleo leaves extracts obtained by successive 
extraction with different solvents via maceration, Soxhlet and decoction extraction 
method. GC-MS is an ideal method for analysis of volatile components, terpenoids, 
lipids, fatty acids, phenolics, alkaloids and glycosides in the medicinal plants (McGhie 
and Rowan, 2012; Sixto et al., 2019; Stashenko and Martínez, 2012). Our findings 
highlighted that all extracts from the leaves of P. bleo contain compounds like sterols, 
terpenoids, phenolic, flavonoids and alkaloids.  
The crude hexane extract of P. bleo leaves showed the presence of terpenoids, 
sterols and phenolic compounds from maceration while a mixture of sterols and 
terpenoids were recorded from the Soxhlet extraction. Sterols were the highest 
phytocompound isolated in this extract obtained from both extraction methods which 
consis  predominan l  of -sitosterol. Terpenoids were the second-highest 
phytocompound isolated in this extract from both extractions with neophytadiene as the 
main compound. Hexane is effective for the extraction of non-polar compounds such as 
lipid, lignin, terpenoids and sterols (Cowan, 1999; Houghton and Raman, 2012). 
Phytochemical study of hexane extract from Pluchea indicia Less leaves reported 
similar findings where sterols were the highest compound found in this extract beside 
flavonoids, phenolic and alkaloid (Widyawati et al., 2014). In addition, the current study 
identified low levels of phenolic compounds in the crude hexane extract from the 
maceration while there were no phenolic compounds detected from Soxhlet method. A 
study has reported the presence of phenolic content at a low level in Terminalia 
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ferdinandiana leaves together with flavonoids and tannins after being soaked in the 
hexane solvent at 4°C for 24 h (Courtney et al., 2015). Solvents such as hexane, 
chloroform, propanol, ethyl acetate, ethanol, methanol and water are commonly used to 
extract phenolic compounds and the capacity of the compounds is affected by the 
polarity of the solvent (Aires, 2017). However, temperature also plays an important role 
in the recovery of phenolic compounds because some thermolabile phenolic compounds 
are vulnerable to high temperatures close to their boiling points (Seidel, 2012). Thus, 
this finding suggested that phenolic compounds might be degraded when extracted 
using Soxhlet method probably due to excess temperature during extraction that exceeds 
the boiling point of the hexane.  
Terpenoids were found in abundance in the ethyl extract of P. bleo leaves from 
maceration followed by sterols and phenolic compounds. Phytol was the major content 
of terpenoids in this extract. Terpenoids and phenolic compounds were reported as the 
major compounds present in ethyl acetate extract of Durio zibethinus L. leaves prepared 
through maceration for 48 h at room temperature (Aruan et al., 2019). While in the 
Soxhlet method, flavonoids were dominated by the compound 4H-Pyran-4-one,2,3-
dihydro-3,5-dihydroxy-6-methyl in the ethyl extract of this plant followed by 
terpenoids, phenols and sterols. The most common solvents for flavonoids extraction 
are methanol and ethanol using extraction methods such as percolation, dipping, 
continuous reflux, reflux and decoction (Chun, 1998; Feng et al., 2017). For instance, 
in a report by Hossain and Rahman (2015) showed that high flavonoids were found in 
the methanolic extract of Orthosiphon stamineus leaves obtained using the Soxhlet 
method. However, in the current study, flavonoids in the leaves of P. bleo were best 
extracted using ethyl acetate obtained with the Soxhlet method. This finding suggested 
that ethyl acetate can be one of the best solvents for flavonoids extraction.  Apart from 
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that, the current findings, showed that the presence of terpenoids was higher in 
maceration extraction compared to Soxhlet. Several studies have reported low recovery 
of terpenoids at high temperatures due to degradation and instability of the compounds 
with increasing temperature during extraction (McGraw et al., 1999; Yang et al., 2007). 
Thus, the recovery of terpenoids was excellent through maceration compared with 
Soxhlet extraction as these compounds are less stable and easily degraded with the 
presence of heat.  
Methanol and aqueous are the polar solvents that are commonly used in 
extraction of medicinal plants. Methanol is effective for the extraction of polar 
compounds such as sugar, amino acid, glycoside compounds, phenols, tannin, saponin 
and terpenoids (Cowan, 1999; Houghton and Raman, 2012). The methanol extract of P. 
bleo leaves obtained through maceration showed the highest amount of terpenoids 
predominated by (-)-Loliolide followed by phenolic compounds, sterols and alkaloids. 
Meanwhile in Soxhlet extraction, phenolic compounds were detected the highest 
amount (predominant compounds namely 2-Methoxy-4-vinylphenol) followed by 
terpenoids and sterols. The aqueous solvent is effective to extract compounds including 
amino acid, sugar, glycoside and aglycon compounds (Houghton and Raman, 2012; Liu 
et al., 2011). Phenolic compounds were the highest compounds present in the aqueous 
extract of P. bleo leaves obtained through decoction followed by alkaloids and sterols. 
These findings showed that phenols and sterols are thermolabile compounds as well as 
heat-stable as they have better recovery from Soxhlet and decoction which were carried 
out in the presence of heat. Meanwhile terpenoids are not heat stable compounds and 
can be isolated at low temperature.  
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In phytochemical research, it is important to choose proper methods of 
extraction for the isolation of target compounds as heat can degrade thermolabile 
compounds. In this study, various phytochemical compounds have been isolated from 
the leaves of P. bleo extracts. Table 3.9 summarizes similar and different compounds 
that have been isolated from the leaves of this plant between two methods of extraction 
maceration and Soxhlet. Previous studies on the phytochemical investigation involving 
this plant revealed the presence of dihydroactinidiolide, a mixture of sterols 
(campes erol, s igmas erol, -sitosterol), 2,4,-di-tert-butylphenol, -tocopherol, phytol, 
vitexin and vitamin E in the ethyl extract fraction of P. bleo leaves (Abdul-Wahab et 
al., 2012; Malek et al., 2009; Rahman, 2008). Meanwhile, -carotene, -tocopherol and 
a mixture of flavonoids (catechin, quercetin, epicatechin, myricetin) were found in dried 
leaves of P. bleo (Abdul-Wahab et al., 2012). In addition, -sitosterol was present in 
the hexane and ethyl acetate fraction of this plant while dichloromethane extract 
con ained -sitosterol glucoside (Abdul-Wahab et al., 2012; Rahman, 2008).  
As for the maceration method, the current findings showed the presence of 
several new compounds from the leaves of P. bleo such as -tocopherol, 1-
Heptacosanol, n-Tetracosanol-1 and indole together with previously reported 
compounds namel  s igmas erol and -sitosterol. Stigmasterol is one of the plant sterols 
that demonstrated anti-tumor activity and a popular antioxidant effect. Stigmasterol 
isolated from Bacopa monnieri Linn exerted anti-tumor effect on Ehrlich Ascites tumor 
in mice by reducing the proliferation and size of the tumor as well as improving other 
biochemical parameters (Ghosh et al., 2011). In another study, mice with skin tumors 
showed a reduction in the size of tumor, papillomas cell numbers, level of lipid 
peroxidase and DNA damage after 16 weeks of treatment with stigmasterol isolated 
from Azadirachta indica plant (Ali et al., 2015). Thus, the current findings suggested 
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that all the above mention compounds obtained via maceration method were heat-
sensitive compounds as they are stable at room temperature extraction.   
Meanwhile, in the Soxhlet method, the newly isolated compounds were 4H-
Pyran-4-one,2,3-dihydro-3,5-dihydroxy-6-methyl, 4-vinyl-syringol, Phenol, 2,6-
dimethoxy, phenol, 2-methoxy-4-(1-propenyl)-, Stigmasta-3,5-dien-7-one and 
hexadecanoic acid as shown in Table 3.9. 4H-Pyran-4-one,2,3-dihydro-3,5-dihydroxy-
6-methyl (DDMP) is a flavanoid that exhibits anti-proliferative, pro-apoptotic effects, 
protective effects and antioxidant activity. DDMP isolated from onions induced cell 
death in colon cancer cells (HCT116 and SW620) through suppression of anti-apoptotic 
proteins Bcl-2 and the expression of pro-apoptotic proteins Bax (Ban et al., 2007). 
DDMP isolated from Plukenetia conophora plant exhibited protective effects where it 
significantly reduced nitric acid and malondialdehyde levels in the reproductive toxicity 
of male rats induced by cadmium chloride (Olaniyan et al., 2018). DDMP also 
demonstrated strong antioxidant activity in glucose-histidine Maillard reaction products 
(Yu et al., 2013). Besides that, hexadecanoic acid, also known as n-hexadecanoic acid 
exhibited anticancer effects when it was isolated from the crude chloroform extract of 
Kigelia pinnata leaves showing the cytotoxic effects on human colorectal carcinoma 
(HCT-116) cells (Ravi and Krishnan, 2017). Other than that, it possesses antibacterial 
activity. This was evident in a study by Johannes and Litaay (2017) where n-
hexadecanoic acid that was isolated from hydroid Aglaophenia cupressina 
Lamaoureoux at a concentration of 30 ppm inhibited the growth of Salmonella typhi 
after 48 hours incubation. Furthermore, anti-inflammatory effects have also been 
reported as a characteristic of n-hexadecanoic acid (Aparna et al., 2012). Meanwhile, 
4-vinyl-syringol and phenol, 2,6-dimethoxy are well known for their antioxidant 
activity (Adelakun et al., 2012; Galano et al., 2011; Nyanhongo et al., 2013). Phenol, 
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2-methoxy-4-(1-propenyl) also known as isoeugenol has been reported to exhibit anti-
microbial and cytotoxic effects (Atsumi et al., 2000; Foo et al., 2015). Thus, it can be 
suggested that these compounds are heat stable because they were not degraded at high 
temperature during Soxhlet extraction.  
Apart from that, there were several similar new active compounds present in the 
leaves of P. bleo extract obtained with maceration and Soxhlet methods such as (-)-
Loliolide, neophytadiene, -tocopherol, squalene, -sitosterol, 4-vinylphenol, 2-
Methoxy-4-vinylphenol, 9,12,15-Octadecatrienoic acid, methyl ester, (Z,Z,Z) and 
together with previously reported compounds such as phytol, campesterol and vitamin 
E. -sitosterol has been previously reported to influence cholesterol synthesis in liver 
and intestinal cell lines (Ho and Pal, 2005). It also acts as a cytotoxic sensitizing agent 
(Carter et al., 2007). In addi ion, -sitosterol from Strobilanthes crispus leaves extract 
was found to be cytotoxic against colon and liver cancer cell lines (Endrini et al., 2014). 
Besides that,  neophytadiene is widely known for its antioxidant properties  (Yamuna 
et al., 2017). Meanwhile, -tocopherol is popular for its antioxidant properties and 
recent studies have also reviewed other benefits of these compounds such as anticancer, 
anti-inflammatory and cancer preventive effects (Cervinkova et al., 2016; Constantinou 
et al., 2019). Phytol is believed to have anticancer properties (Jeong, 2018). It has been 
reported to trigger apoptosis in liver and lung cancer cells activated via caspase 3 and 9 
pathway (Kim et al., 2015; Thakor et al., 2017). In addition, 4-vinyl-2-methoxy-phenol 
or 2-methoxy-4-vinylphenol (2M4VP) showed anti-cancer effects on Panc-1 and SNU-
213 pancreatic cell lines. Moreover, 2M4VP reduced the cells viability of Panc-1 cells 
by inhibiting the expression of the cells nuclear antigen (PCNA) proteins while 
supressing the migration of Panc-1 and SNU-213 cells (Kim et al., 2019). In addition, 
2M4VP possesses anti-inflammatory activity (Jeong et al., 2011; Sridevi et al., 2014). 
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It was observed in a study where 2M4VP extracted from pine needles was had strong 
anti-inflammatory effects in LPS-stimulated RAW264.7 cell line (Jeong et al., 2011). 
On top of that, chemopreventive effects of squalene were evident while the formation 
of a preneoplastic lesion in the colonic was inhibited  in rats after they were given a 
dietary containing 1% squalene, with no significant effect on serum cholesterol (Rao et 
al., 1998). Other than that, squalene is also a potential anticancer agent in combination 
with other commercial anti-cancer agents such as adriamycin, bleomycin or cis-
dichlorodiamminoplatinum which demonstrated cytotoxic effects against sarcoma cells 
(S180) (Nakagawa et al., 1985). Thus, the current findings suggest that all the 
compounds mentioned above were stable at both low and high temperature since they 
present in maceration (at room temperature) and Soxhlet (high temperature) extraction 
methods. 
There are limited studies on the chemical compounds from the aqueous extract 
of P. bleo leaves compared to other Pereskia species. Sim et al. (2010a) reported the 
presence of phenolic compounds in the aqueous extract of P. bleo leaves which are 
concomitant with the present finding except it only measured total phenolic content. 
Meanwhile, the present study has elucidated the compounds from the phenolic group 
namely 2-Methoxy-4-vinylphenol and -tocopherol. Sharif et al. (2015) reported that 
aqeous extract of P. bleo leaves contains fatty acids and high content of myo-inositol 
and sugars (galactose and phenanthrene). On the contrary, our GC-MS analysis revealed 
the presence of alkaloids, terpenoids, fatty acids and phenolic compounds. Phenolic 
compounds consisting of 2-Methoxy-4- in lphenol and -tocopherol were the major 
compounds identified in the aqueous extract of P. bleo leaves. These differences might 
be due to the difference in temperature used during extraction. Sharif et al. (2015) 
carried out the extraction at 30oC while the temperature used in this study was 50oC. 
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Extraction at a higher temperature releases higher phenolic compound compared to a 
lower temperature (Prenesti et al., 2007).   
The current findings showed that there were various phytochemical compounds 
presented in the leaves of P. bleo identified via GC-MS analysis and the potential active 
compounds together with their biological activities were listed in Table 3.10. Thus, 
solvents such as hexane, ethyl acetate, methanol and aqueous solution were successful 
and suitable for the isolation of wide range of non-polar and polar compounds in the 
leaves of P. bleo. Methanol and aqueous solvents recorded the highest extraction yield 
obtained from maceration, Soxhlet and decoction extraction methods due to abundant 
of polar compounds with high molecular weight. Maceration method was the best 
technique for the isolation of terpenoids and phenolic compounds. Soxhlet method 
























Table 3.9    Comparison and similar phytochemical compounds isolated from the 








1-Heptacosanol Hexadecanoic acid 
Stigmasterol Dodecanoic acid, methyl ester 
n-Tetracosanol-1 Pyrazine, trimethyl- 
-tocopherol Benzoic acid, methyl ester 
-sitosterol 4-vinyl-syringol 
Stigmast-7-en-3-ol, (3.beta.,5.alpha.)- Phenol, 2,6-dimethoxy- 
Stigmastan-3,5-diene Phenol, 2-methoxy-4-(1-propenyl)- 






Hexadecanoic acid, methyl ester 
9,12,15-Octadecatrienoic acid, methyl ester, (Z,Z,Z)-  





















Table 3.10    Ten potential active compounds presented in the leaves of P. bleo 












(Ban et al., 
2007) 
 Protective effects (Olaniyan et 
al., 2018) 
 Antioxidant (Yu et al., 
2013) 
   
Sterols  -sitosterol Cytotoxic agent (Carter et al., 
2007) 
 Campesterol  Anti-angiogenic 
effects 
(Choi et al., 
2007) 







Anzúrez et al., 
2017) 
   
Phenolic  -tocopherol Anti-
inflammatory  
(Himmelfarb 
et al., 2007; 
Wolf, 2006) 
 Anti-cancer agent (Wolf, 2006) 
 Antioxidant  (Singh et al., 
2008) 
 2-Methoxy-4-vinylphenol Anti-microbial, 
antioxidant, 
analgesic 




(Jeong et al., 
2011; Sridevi 
et al., 2014) 
 Anti-cancer 
effects 
(Kim et al., 
2019) 
   
Terpenoids  (-)-Loliolide Antioxidant  (Yang et al., 
2011) 
 Anti-cancer  (Machado et 
al., 2012) 
 Neophytadiene Antioxidant  (Yamuna et al., 
2017) 
 Phytol  Anti-cancer  (Jeong, 2018) 
 Antioxidant  (Santos et al., 
2013) 
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 Antinociceptive  (Santos et al., 
2013) 
 Anti-bacterial (Pejin et al., 
2014) 
   
Vitamin E Vitamin E Antioxidant  (Niki and 
Noguchi, 
2004) 
 Anticancer  (Yu et al., 
2009) 
   
Fatty acid Hexadecanoic acid Anti-cancer  (Ravi and 
Krishnan, 
2017) 




(Aparna et al., 
2012) 































3.5 Conclusion  
In conclusion, the recovery of extraction yield and compounds of interest from 
the plant materials are largely depend on the suitable extraction and solvent types. Our 
findings showed Soxhlet and decoction extractions were the ideal technique to extract 
phenolic and flavonoids compounds from the leaves of P. bleo. Maceration was best for 
extraction of terpenoids and phenolic compounds from this plant leaves. Terpenoids, 
sterols, alkaloids, fatty acids, flavonoids, vitamin E and phenolic compounds were 
identified from the crude extracts of P. bleo leaves. Furthermore, several new 
compounds identified from the leaves of P. bleo including (-)-Loliolide, neophytadiene, 
- ocopherol, -tocopherol, squalene, 4H-Pyran-4-one,2,3-dihydro-3,5-dihydroxy-6-
methyl, 4-vinyl-syringol, phenol,2-methoxy-4-(1-propenyl) and hexadecanoic acid 
which possess anti-cancer and antioxidant properties that contribute to the therapeutic 









CHAPTER 4  
 
CYTOTOXICITY, CELL CYCLE ARREST AND APOPTOSIS INDUCTION 
OF Pereskia bleo LEAVES EXTRACTS AGAINST SELECTED CANCER 
CELL  
4.1 Introduction 
To date, cancer remains the primary cause of death in humans worldwide in 
spite of the advancement in tools for its diagnosis, treatment and prevention (Razali et 
al., 2016). It remains a global public health issue as its mortality and morbidity rate are 
predicted to increase every year (Pumiputavon et al., 2017). Effective cancer treatment 
is important and urgently needed for future management of the disease. Conventional 
cancer treatments such as surgery, chemotherapy and radiotherapy, even though proven 
to be effective, remains unsatisfactory in some types of cancer due to their detrimental 
side effects, cancer prevalence and decline of general health in cancer patients (Schloss 
et al., 2017). Thus, the discovery of novel potent anti-cancer agents for cancer treatment 
will always be in demand.  
Elimination of cells from our body involves a number of mechanism including 
necrosis and apoptosis. Necrosis is a non-specific form of cell death indicated by 
disruption of cell membrane which prompt a localized inflammatory response and 
injury of the surrounding tissue as well as cells (Yang et al., 2015). On the contrary, 
apoptosis involves an instant engulfment and removal of apoptotic bodies by 
phagocytosis without damage the surrounding cells and tissue (Wong, 2011). Besides, 
it is a natural cell death consequence from activation of a tightly regulated events that 
are frequently modified in cancer cells (Elmore, 2007; Hanahan and Weinberg, 2016). 
The mechanism of apoptosis is divided into two categories which are extrinsic (death 
receptor) and the intrinsic (mitochondrial) pathways. Therefore, apoptosis activation 
76 
has been pointed out as the main strategy in inhibiting the proliferation of cancer cells 
and in searching for anti-cancer drugs (Chen et al., 2008).  
The typical morphology that defining the apoptotic cells include cell shrinkage, 
fragmented nucleus, membrane disruption and blebbing as well as apoptotic body 
formation (Kumar et al., 2017; Saraste and Pulkki, 2000).  Inverted or fluorescent 
microscopes are commonly used to detect the alterations in the cell structures due to 
apoptosis while Hoechst staining is the best method to identify condensed chromatins 
and fragmented nucleus of the apoptotic cells (Rahman et al., 2013). Besides that, 
various assays have been developed for apoptosis detection such as DNA 
fragmentation, cytotoxicity and cell proliferation, flow cytometry apoptosis Annexin 
V/PI staining and apoptotic proteins expression (Banfalvi, 2017; Martinez et al., 2010).   
The application of natural products including medicinal plants as an alternative 
treatment for cancer has caught the attention of oncologists. Both plants and their 
products including crude extracts and pure compounds are recognized as pro-apoptotic 
agents due to the variation in their mechanism of actions and as well as their minimal 
side effects (Rasul and Ma, 2012; Wu et al., 2002). Nevertheless, in traditional practice, 
plants are often consumed raw or in the form of crude extracts for medicinal purposes 
(Chai, 2011). In addition, studies have reported better efficacy of plant crude extracts 
compared to single compounds in cancer research (Aiyelaagbe et al., 2011; Rasoanaivo 
et al., 2011). Drugs that are derived from plants are often accessible, inexpensive and 
safe without significant detrimental effects towards consumers (Yadav and Agarwala, 
2011). Furthermore, synergistic actions from various phytochemicals in the crude 
extracts may be the reason behind the healing potential of the plants (Ma et al., 2009). 
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A number of popular medicinal plants have been studied for their apoptosis 
induction for example Clinacanthus nutans. Hexane extract of this plant was reported 
to induce apoptosis in HepG2 (liver), A549 (lung) and CNE1 (nasopharygeal) cancer 
cells modulated by oxidative stress and upregulation of caspases (-3, -8, -9) level (Ng 
et al., 2017). Another study by Wan-Ibrahim et al. (2019) found methanol extract of 
Abrus precatorius promotes apoptosis in MDA-MB-231 breast cancer cells via 
inhibition of cell progression at G0/G1 phase and upregulation of Bax level. Aqueous 
extract of Annona muricata leaf exerted cytotoxic effects and triggered apoptosis in 
MDA-MB-231 cells through intrinsic pathway by producing reactive oxygen species 
(ROS) and cell cycle arrest at G0/G1 phase (Kim et al., 2018). Ethanolic extract of 
Moringa oleifera leave induced cell death in liver HepG2, breast MCF7 and colon HCT 
116 and Caco-2 cancer cells indicated by high number of apoptotic cells after treatment 
with this extract (Abd-Rabou et al., 2017).            
In this study, medicinal plant in focus is Pereskia bleo (P. bleo). The locals 
believe it can be used for cancer prevention and treatment (Malek et al., 2009; Sri 
Nurestri et al., 2008; Yen et al., 2013). In addition, there are many biological activities 
of P. bleo that have been reported including anti-cancer and anti-tumor, (Sri Nurestri et 
al., 2008; Wahab et al., 2009). Several in-vitro studies have reported the cytotoxic 
effects of fractionated extracts (hexane, ethyl acetate and water) and pure compounds 
in ethyl acetate extract from the leaves of P. bleo against various cancer cell lines such 
as human hormone-dependent breast carcinoma cell line (MCF7), human lung 
carcinoma cell line (A549), human colon carcinoma cell line (HCT 116), human 
nasopharyngeal epidermoid carcinoma cell line (KB) and human cervical carcinoma 
cell line (CasKi) (Malek et al., 2009; Sri Nurestri et al., 2008). Meanwhile, the crude 
methanol extract from a mixture of the leaves and stems of P. bleo was found to be 
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cytotoxic towards human breast carcinoma cell line (T-47D) and caused apoptosis via 
the stimulation of caspase-3 and c-myc proteins (Tan et al., 2005). However, there is a 
lack of information regarding its effects on other common cancer cell lines. Therefore, 
the current study aims to explore the cytotoxic response of crude extracts from P. bleo 
leaves on HeLa, MDA-MB-231 and SW480 cell lines. In order to understand the 
mechanism of cell death, the most active cytotoxic extract with its corresponding cancer 














4.2 Materials and methods 
4.2.1 Sample collection 
Refer section 3.2.1 (page 39). 
4.2.2 Maceration, Soxhlet and decoction extraction of P. bleo leaves  
Refer section 3.2.2 for maceration (page 39), section 3.2.3 for Soxhlet (page 40) 
and section 3.2.4 for decoction (page 40).    
4.2.3 Cell lines and cell culture 
Cancer cell lines namely cervical (HeLa), breast (MDA-MB-231), colon 
(SW480) and normal mouse fibroblast cell line (NIH 3T3) were purchased from ATCC. 
A comple e medi m con aining D lbecco s Modified Eagle s Medi m (DMEM; 
Gibco), 10% fetal bovine serum (FBS; Gibco), 1% penicillin-streptomycin (Gibco) was 
used in the culture of the cell lines with 5% CO2 at 37oC.  
4.2.4 Anti-proliferative activity of P. bleo leaves extracts 
An assay using 3-[4,5-dimethyl thiazol-2-yl] 2,5-diphenyl tetra-zolium bromide 
(MTT; Merck) was carried out to measure the cytotoxicity activity of P. bleo extracts. 
The cells were seeded in 96-well flat bottomed plates (Eppendorf) at a density of 5×104 
cells per well in a final volume of 100µl/well. After 24 h incubation at 37oC with 5% 
CO2, the cells were treated with 2 µl of a serial dilution of hexane, ethyl acetate, 
methanol and aqueous extracts of P. bleo leaves at concentrations starting from 0.3 
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µg/ml to 99 µg/ml (concentration of extract in the well). The serial concentrations of P. 
bleo leaves extracts were added into the wells shown as in Table 4.1. In addition, the 
cells were treated with a positive control tamoxifen (concentration of 0.3 µg/ml to 99 
µg/ml) and a negative control DMSO (concentration < 1%). After 72 h of incubation 
period, 50µl MTT solution (2 mg/ml) were added to each well and further incubated for 
4 h at 37oC. Then, 200µl of DMSO was added to each well to dissolve the MTT crystals 
and their absorbance was recorded at 570 nm using an enzyme-linked immunosorbent 
assay (ELISA) plate reader. Each experiment was performed in triplicates. The 
percentage of cell viability was determined using the following formula:  
Absorbance of treated cells  
Percentage of cell viability (%) =           (extracts/tamoxifen)                      × 100% 
                                                               Absorbance of DMSO    
  
The IC50 values of the treated cancer and normal cells were determined by 
plo ing a graph of cell s iabili  ers s e rac  concentration. The extract with the 
















extract in the well 
(mg/ml) 
Concentration of 
extract in the well 
(µg/ml) 
10.000 0.0990 99.00 
5.000 0.0495 49.50 
2.500 0.0248 24.80 
1.250 0.0124 12.40 
0.625 0.0062 6.20 
0.313 0.0031 3.10 
0.156 0.00155 1.55 
0.078 0.00077 0.77 
0.039 0.00039 0.39 
 
4.2.5 Morphological assessment of apoptotic HeLa cells induced by PBEA  
4.2.5(a) Bright field inverted microscopy 
A total of 5 × 104 cells/ml of HeLa cells were seeded in a six-well plate and 
treated with IC50 value of ethyl acetate extract of P. bleo leaves (PBEA) and tamoxifen 
(positive control) at a concentration of 14.37 µg/ml and 2.71 µg/ml respectively and 
incubated for 24 h, 48 h and 72 h time points. The negative control used in this study 
was untreated cells. The cells were observed under an inverted microscope (OLYMPUS 
CK40) at 20× magnification to observe their morphological changes and evaluate the 
effect on HeLa cells after treatment with PBEA. The cells images were captured by 
using a camera (NIKON D5600). 
4.2.5(b) Fluorescence microscopy  
Hoechst 33258 staining was performed to determine the morphological changes 
in the nuclei of HeLa cells that were treated with PBEA.  The cells were grown on glass 
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slides that were placed in a tissue culture dish and treated with PBEA (IC50 value =14.37 
µg/ml) for 24 h, 48 h and 72 h. After each incubation time, the slides were washed twice 
with 1× PBS and fixed with 4% paraformaldehyde for 30 minutes at 4°C. Subsequently, 
the slides were incubated with 30 µg/ml of Hoechst 33258 solution for 30 minutes in 
the dark at room temperature. The slides were dried and mounted with DPX mounting 
medium and viewed under a fluorescence microscope (Imaging Source Europe GmBH, 
Bremen, Germany) at 40× magnification (excited at 350nm and emitted at 461nm). A 
brighter blue fluorescence nucleus is an indication of the apoptotic cells.  
4.2.6 Induction of cell death in HeLa cancer cells induced by PBEA  
4.2.6(a) Cell cycle assay  
Flow cytometry was used to evaluate the changes in cell cycle distribution of 
HeLa cells induced by PBEA. The cells were treated with PBEA at a concentration of 
IC50 and incubated with 5% CO2 at 37oC for several time intervals (24 h, 48 h and 72 
h). Untreated cells were used as the control group in this study. After that, the samples 
were processed using BD CycletestTM Plus DNA Kit (BD Bioscience) as per the 
man fac rer s pro ocol. The cells were resuspended in a buffer solution at 
concentration of 5 × 105 cells per sample. Then, the cells were incubated with trypsin 
buffer (10 min, room temperature), trypsin inhibitor and RNase buffer (10 min, room 
temperature) and lastly cold PI stain solution (10 min, 2oC  8oC) on ice in the dark. 
After incubation, the samples were analyzed using FACSCANTO II (BD Bioscience). 
A minimum of 10 000 events was acquired per sample and the data were analyzed by 
using ModFiT LT 5.0 software. 
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4.2.6(b) Annexin V-FITC assay 
Annexin V-FITC Detection Kit I (BD Bioscience) was used to identify the 
distribution of early or late apoptosis induced by PBEA towards HeLa cells. The assay 
was conducted according to the manufacturer s pro ocol. The cells were later incubated 
with the IC50 concentration of PBEA for 24 h, 48 h and 72 h with 5% CO2 at 37oC.  
Untreated cells were used as the control group. After that, the cells were washed twice 
with cold PBS and stained with 5µl FITC Annexin V and 5µl propium iodide (PI) for 
15 min at room temperature in the dark. Results for the stained cells were obtained (10 
000 events per sample) through FACSCANTO II (BD Bioscience). The data acquired 
were analyzed by using FlowJo_V10 software. The test was repeated thrice 
independently. 
4.2.6(c) Apoptotic proteins expression 
The expression of apoptosis proteins such as Bax, Bcl-2, p53 and caspase-3 in 
HeLa cells following treatment with PBEA were determined by the means of flow 
cytometry. Cells were incubated with the IC50 concentration of PBEA for 24 h, 48 h and 
72 h with 5% CO2 at 37oC. Untreated cells were used as the control group. The proteins 
ere s ained i h an ibod  conj ga e according o he man fac rer s pro ocol. The 
cells were later harvested and washed with PBS. After that, the cells (1 × 106 cells) were 
fixed with ice-cold 70% ethanol for 1 hour at 4oC. The cells were washed twice after 
fixation and blocked in 2% bovine serum albumin for 10 min at room temperature. After 
the blocking process, 100 µl of cells (1 × 105 cells) were transferred into flow tubes and 
stained with antibodies: Bax-PE (Santa Cruz), Bcl-2-Alexa Fluor 647 (Santa Cruz), 
p53-Alexa Fluor 480 (Santa Cruz) and caspase 3-Alexa Fluor 480 (Santa Cruz). Results 
for 10, 000 events per sample were recorded with FACSCANTO II (BD Bioscience). 
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The data were then analysed using FlowJo_V10 software. The experiment was carried 
out thrice independently. 
4.2.7 Statistical analysis 
Each data was presented as mean ± standard deviation (SD). The results were 
analyzed using repeated measure one-way ANOVA (P<0.05) and T ke s m l iple 
comparison test was done to determine the significance between groups. The normality 
was checked by Shapiro-Wilk test. All statistical analysis was performed with 













4.3.1 Anti-proliferative activity of P. bleo leaves extracts  
The anti-proliferative assay was done to evaluate the cytotoxic effects of P. bleo 
leaves extracts on the survival and growth of selected normal and cancer cells. The cell 
viability measured using MTT assay after 72 h treatment with each extract. The anti-
proliferative effects can be determined with the IC50 concentration of the extracts where 
at this concentration has caused the inhibition of 50 % of the cell proliferation. At their 
IC50 concentrations, the plant extracts are considered active and demonstrate cytotoxic 
activity (Boik, 2001).  
The cytotoxic activity of extract can be classified as the following: very active 
(IC50  20 g/mL), moderately active (IC50 > 20 - 100 g/mL), weakly active (IC50 > 
100 - 1000 g/mL and inactive (IC50  1000 g/mL) (Atjanasuppat et al., 2009; 
Baharum et al., 2014). In addition, the American National Cancer Institute (NCI) has 
established the cut off IC50 value less than 20 µg/ml for the most active extract or pure 






4.3.1(a) Anti-proliferative activity of P. bleo leaves extracts obtained via 
maceration extraction against selected cancer and normal cell lines 
 
The MTT assay was carried out to determine the effect of P. bleo leaves extracts 
obtained via maceration on HeLa, MDA-MB-231, SW480 and NIH/3T3 cell lines. The 
maximum concentration of the extracts used were 99 µg/ml as stated in Table 4.1. 
However, there was no IC50 recorded at this maximum concentration, thus the 
maximum concentration of the extracts was increased to 990 µg/ml.  
The results showed high percent of viability values (86  118%) in all cell types 
at the lowest concentration (4 µg/ml) of each P. bleo extract (hexane, ethyl acetate and 
methanol) after 72 h incubation period. The value of cell viability was low (5  19%) at 
the highest concentration (990 µg/ml) of P. bleo extracts in all cell types after 72 h of 
treatment except for methanol extract in SW480 cells which showed high percentage 
(56%). These results indicated that all extracts of P. bleo leaves have significantly 
reduced cell viability in HeLa (Figure 4.1), MDA-MB-231 (Figure 4.2), SW480 (Figure 
4.3) and NIH/3T3 (Figure 4.4) after 72 h treatment (P<0.05). Tamoxifen was used as 
the positive control in this study (Figure 4.5). 
Table 4.2 presented IC50 values of all extracts from maceration extraction 
towards all tested cell lines. Hexane and methanol extracts showed weak cytotoxic 
effect on normal cells and all cancer cells with IC50 values above 100 µg/ml. Ethyl 
acetate extract demonstrated very active cytotoxic effect on HeLa and MDA-MB-231 
with IC50 values of 17.51 ± 8.6 µg/ml and 19.39 ± 1.26 µg/ml respectively. Meanwhile, 
SW480 showed moderate cytotoxic effect (IC50 value = 31.80 ± 16.1 µg/ml) and low 
cytotoxic effects at IC50 value of 182.0 ± 23.0 µg/ml on NIH/3T3 cells. The current 
findings showed that ethyl acetate extract obtained via maceration method possessed 










Figure 4.1 Representative graphs of the percentage of cell viability for HeLa  after 
72 h treatment with hexane, ethyl acetate and methanol extracts of P. 
bleo leaves (maceration extraction) at various concentration. Data were 
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Figure 4.2 Representative graphs of the percentage of cell viability for MDA-MB-
231 after 72 h treatment with hexane, ethyl acetate and methanol extracts 
of P. bleo leaves (maceration extraction) at various concentration. Data 
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Figure 4.3 Representative graphs of the percentage of cell viability for SW480 after 
72 h treatment with hexane, ethyl acetate and methanol extracts of P. 
bleo leaves (maceration extraction) at various concentration. Data were 
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Figure 4.4 Representative graphs of the percentage of cell viability for NIH/3T3 
after 72 h treatment with hexane, ethyl acetate and methanol extracts of 
P. bleo leaves (maceration extraction) at various concentration. Data 
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Figure 4.5 Representative graphs of the percentage of cancer and normal cells 
viability treated with various concentration of tamoxifen (positive 
control) for 72 h. Data were represented as mean ± SD from three 
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4.3.1(b) Anti-proliferative activity of P. bleo leaves extracts obtained via Soxhlet 
extraction against selected cancer and normal cell lines 
Cell viability after 72 h treatment with all extracts obtained via Soxhlet method 
was measured using the MTT assay to explore the effect of the extracts on the selected 
normal and cancer cells. High percentage values in cell viability (92  129%) was 
observed in HeLa cells (Figure 4.6), MDA-MB-231 cells (Figure 4.7), SW480 (Figure 
4.8) and NIH/3T3 (Figure 4.9) after 72 h treatment at the lowest concentration (0.4 
µg/ml) of hexane, ethyl acetate and methanol extract. Treatment with hexane and ethyl 
acetate extracts at the highest concentration (99 µg/ml) showed low percent of viability 
(13  28 %) in HeLa and MDA-MB-231 cells (Figure 4.6 and 4.7). However, high 
percentage of cell viability (80  121%) was observed in SW480 and NIH/3T3 after 72 
h incubation with the highest concentration of these extracts. Treatment with methanol 
extract at the highest concentration showed high values of cell viability (67  111%) in 
all cell types.  
The results showed hexane and ethyl acetate extracts have significantly reduced 
the viability of HeLa and MDA-MB-231 cell after 72 h of treatment (P<0.05). 
Treatment with hexane and ethyl extract also showed reduction of cell viability in 
SW480 and NIH/3T3 cells (Figure 4.8 and 4.9) with no statistical differences. Methanol 
extract slightly reduced the viability in all cell types with no statistical differences. All 
cells were treated with tamoxifen as the positive control (Figure 4.10). 
The summary IC50 values of all extracts and tamoxifen were shown in Table 4.2.  
Ethyl acetate showed very active cytotoxic effect on HeLa cells (IC50 value = 
93 
14.37±8.40 µg/ml) while moderate cytotoxicity was observed in MDA-MB-231 cells 
(IC50 value = 41.60±35.68 µg/ml). Hexane extract demonstrated moderate cytotoxic 
effects on HeLa cells (IC50 value = 20.24±11.69 µg/ml) and MDA-MB-231 (IC50 value 
= 43.76±36.86 µg/ml). On the other hand, both extracts showed weak cytotoxic effects 
on SW480 cells. Methanol extract also showed weak cytotoxic effects on all cancer cell 
lines. In addition, all extracts exerted low cytotoxic effects on normal cells NIH/3T3. 
Thus, our findings suggested that ethyl acetate extract from Soxhlet extraction exhibited 































Figure 4.6 Representative graphs of the percentage of cell viability for HeLa after 
72 h treatment with hexane, ethyl acetate and methanol extracts of P. 
bleo leaves (Soxhlet extraction) at various concentration. Data were 
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Figure 4.7 Representative graphs of the percentage of cell viability for MDA-MB-
231 after 72 h treatment with hexane, ethyl acetate and methanol extracts 
of P. bleo leaves (Soxhlet extraction) at various concentration. Data were 
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Figure 4.8 Representative graphs of the percentage of cell viability for SW480 after 
72 h treatment with hexane, ethyl acetate and methanol extracts of P. 
bleo leaves (Soxhlet extraction) at various concentration. Data were 
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Figure 4.9 Representative graphs of the percentage of cell viability for NIH/3T3 
after 72 h treatment with hexane, ethyl acetate and methanol extracts of 
P. bleo leaves (Soxhlet extraction) at various concentration. Data were 
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Figure 4.10 Representative graphs of the percentage of cell viability for cancer and 
normal cells viability treated with various concentration of tamoxifen 
(positive control) for 72 h. Data were represented as mean ± SD from 
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4.3.1(c) Anti-proliferative activity of P. bleo leaves  aqueous extract obtained 
via decoction extraction against selected cancer and normal cell lines 
There was no IC50 value detected for the treatment with the aqueous extract of 
P. bleo leaves within the range of tested concentration, which was more than 99 µg/ml. 
Therefore, the concentration was increased to the maximum 990 µg/ml. Treatment at 
the lowest concentration of aqueous extract (4 µg/ml) showed high percent values of 
cell viability (94  118%) in all cell types meanwhile low percent of cell viability (8  
15%) observed in all cell types at the highest concentration of extract (990 µg/ml) after 
72 h incubation.  
The results showed the cell viability of cancer (HeLa, MDA-MB-231, SW480) 
and normal NIH/3T3 cells were significantly reduced after 72 h treatment with this 
extract as illustrated in Figure 4.11 (P<0.05). However, this extract exerted weak 
cytotoxic effects towards normal and all cancer cells with IC50 values of more than 100 



























Figure 4.11 Percentage of cancer (HeLa, MDA-MB-231 and SW480) and normal 
cells NIH/3T3 after treatment with aqueous extract of P. bleo leaves at 
various concentration. Data were represented as mean ± SD from three 
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Table 4.2    IC50 values of cytotoxic effects from P. bleo leaves crude extracts against 




IC50 values (µg/ml) 
HeLa MDA-MB-231 SW480 NIH/3T3 
Maceration      
     
Hexane  278.01 ± 12.8 95.75 ± 27.9 154.0 ± 2.0 275.0 ± 16.0 
Ethyl acetate 17.51 ± 8.6 19.39 ± 1.26 31.80 ± 16.1 182.0 ± 23.0 
Methanol  683.47 ± 15.7 213.23 ± 27.7 > 990 631.0 ± 22.0 
     
Soxhlet      
     
Hexane  20.24±11.69 43.76±36.86 >99 >99 
Ethyl acetate 14.37±8.40 41.60±35.68 >99 >99 
Methanol  >99 >99 >99 >99 
     
Decoction      
     
Aqueous  100.40 ± 2.3 224.31 ± 25.6 128.2 ± 7.5 359.5 ± 27.5 
     
     
Tamoxifen  2.71 ± 0.88 2.24 ± 0.95 2.66 ± 0.22 3.78 ± 1.46 

















4.3.2 Morphological assessment of apoptotic HeLa cells induced by PBEA 
4.3.2(a) Bright field inverted microscopy 
Apoptotic cells display characteristics such as membrane blebbing, cell 
shrinkage, condensation of chromatin and fragmented nuclei. The changes on cell 
morphology were visualized using a bright field microscope to determine the effect of 
PBEA on HeLa cells.  
In comparison to control cells (untreated), morphological alterations in HeLa 
cells were observed after 24 h, 48 h and 72 h treatment with PBEA as shown in Figure 
4.12, Figure 4.13 and Figure 4.14 respectively. Untreated cells maintained their 
morphology with rounded nuclei and attached to the surface of the tissue culture flask. 
In contrast, cells treated with PBEA showed typical apoptotic features such as nuclei 
fragmentation, condensed chromatin and shrinkage of cells. In addition, the viability of 
cells was significantly reduced after 72 h incubation with PBEA along with the 
appearance of rounding and losing contact with adjacent cells. Thus, our findings 























Figure 4.12 Morphology of HeLa cells. (i) untreated 24 h, for 24 h treatment with 
PBEA (ii) and tamoxifen (iii). Apoptotic HeLa cells were indicated by 
condensation of chromatin (yellow arrow) and fragmented nuclei (red 


























Figure 4.13 Morphology of HeLa cells. (i) untreated 48 h, for 48 h treatment with 
PBEA (ii) and tamoxifen (iii). Apoptotic HeLa cells were indicated by 
condensation of chromatin (yellow arrow) and fragmented nuclei (red 




























Figure 4.14 Morphology of HeLa cells. (i) untreated 72 h, for 72 h treatment with 
PBEA (ii) and tamoxifen (iii). Apoptotic HeLa cells were indicated by 
condensation of chromatin (yellow arrow) and fragmented nuclei (red 















4.3.2(b) Fluorescence microscopy 
Apart from the bright field microscopy, apoptotic features can be observed via 
fluorescence microscopic examination using Hoechst 33258 staining. Our findings 
showed that PBEA treated HeLa cells demonstrated typical features of apoptosis such 
as condensed chromatin and fragmented nuclei when compared to control cells as 
shown in Figure 4.15. Control cells that were untreated exhibited rounded and intact 
nuclei with lighter blue staining as presented in Figure 4.15(i). In addition, the cells 
were attached to the tissue culture flask and in contact with the adjacent cells. On the 
other hand, the nuclei of apoptotic cells after treatment with PBEA were highly 
condensed, fragmented and in the form of crescents indicated by brighter blue 
fluorescence staining (Figure 4.15ii).  After 48 h and 72 h incubation, PBEA treated 
HeLa cells started to lose their shape and lost in contact with the adjacent cells (Figure 
4.15iii and Figure 4.15iv). Observation of cell death using Hoechst staining showed that 
































Figure 4.15 Morphology of HeLa cells stained with Hoechst. (i) control cells (ii) 24 
h treatment with PBEA, (iii) 48 h treatment with PBEA and (iv) 72 h 
treatment with PBEA. Apoptotic HeLa cells were indicated by 
condensation of chromatin (yellow arrow) and fragmented nuclei (red 









4.3.3 Cell death in HeLa cells induced by PBEA 
4.3.3(a) Cell cycle assay 
The effects of PBEA on cell cycle distribution in HeLa cells were evaluated by 
the analysis of cell cycle arrest using flow cytometry method. Cell cycle arrest analysis 
is based on the measurement of DNA content in the cells following PI staining (Wang 
et al., 2011). The inhibition of cell proliferation (arrest of cells)  is indicated by the 
accumulation of cells stained with PI at certain phases in the cell cycle (Cecchini et al., 
2012). Cells treated with the IC50 value of PBEA for 24 h, 48 h and 72 h were analyzed 
for the distribution in G0/G1, S and G2/M phases of the cell cycle (Figure 4.16(i)).  
Figure 4.16(ii) shows the number of HeLa cells in G0/G1 phase were increased 
by 90 ± 0.38% after 72 h of treatment with PBEA, compared with control cells (P<0.05). 
The number of cells in S and G2/M phases after 72 h of treatment with PBEA decreased 
to 5 ± 0.85% and 5 ± 1.03%, respectively, compared with control cells (P<0.05). 
Accumulation of cells at G0/G1 phase indicated the cell proliferation was halted at this 
phase. This showed that PBEA induced changes in the cell cycle progression of HeLa 









Control 24 h 
48 h  72 h 
(i) 
Figure 4.16 The effects of PBEA on the cell cycle of HeLa cells. (i) The flow 
cytometry histogram shows the DNA content and the corresponding 
percentage of cell distribution in the control and treated HeLa cells after 
24 h, 48 h and 72 h. The distribution of cell cycle showed the 
accumulation of treated cells in the G0/G1 phase. (ii) The bar columns 
wer represented as mean±SD from three independent experiments. 














































Figure 4.16 Continue 
4.3.3(b) Annexin V-FITC assay 
In order to identify whether or not the cells underwent apoptosis, control and 
treated HeLa cells with PBEA were stained with Annexin V (FITC) and PI to measure 
the presence of apoptotic cells. A negative result for both Annexin V and PI negative 
indicates viable cells. Meanwhile, V positive and PI negative is a sign of cells in the 
early apoptotic stage while cells that Annexin V and PI positive are in the late stage of 
apoptosis. Annexin V negative and PI positive shows necrotic cells. Apoptosis occurred 
in HeLa cells within 72 h upon treatment with PBEA as per flow cytometric analysis 
result as shown in Figure 4.17. The percentage of apoptotic cells measured after 24 h 
treatment with PBEA was 27.39±1.62 % while 40.96±1.8 % and 44.82±4.44 % after 48 
h and 72 h of treatments respectively (Figure 4.17(ii)). The percentage of apoptotic 
HeLa cells increased after the treatment with PBEA. The apoptosis rate was 
111 
significantly different for every incubation period in treated groups compared to the 
control group (P<0.05).   
    









Figure 4.17  (i) Distribution of Annexin V-FITC staining dot plots in control and 
PBEA treated HeLa cells detected by flow cytometry after 24 h, 48 h and 
72 h incubation. The four quadrants represent viable cells (Q1), necrotic 
cells (Q2), early apoptotic cells (Q3) and late apoptotic cells (Q4). (ii) 
The bar column illustrated the percentage of HeLa cells undergoing 
apoptosis. The data represent the mean±SD of three independent 









4.3.3(c) Apoptotic proteins expression 
Apoptotic proteins (Bax, Bcl-2, p53 and caspase-3) expression levels in HeLa 
cells following treatment with 14.37±8.40 g/ml of PBEA were assessed by flow 
cytometry analysis (Figure 4.18). Figure 4.18(ii) shows the expression level of apoptotic 
protein Bax and p53 was upregulated to 65 % and 75 % respectively following the 72 
h treatment period.  Meanwhile, the level of anti-apoptotic protein Bcl-2 was 
downregulated (5 %) (Figure 4.18(ii)). There were significant differences observed for 
the expression levels of Bax, p53 and Bcl-2 treated and the control cells (P<0.05). Even 
though there was only a slight upregulation in the expression of caspase-3 (10 %), the 
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Figure 4.18  Flow cytometry analysis of apoptosis proteins expression in HeLa cells 
induced by PBEA. (i) Histograms of apoptosis protein Bax, Bcl-2, p53 
and caspase-3 (cas-3) expression level measured in HeLa cells for 
control and treated with PBEA after 24 h, 48 h and 72 h incubation. (ii) 
The bar columns showed the percentage of apoptosis proteins expression 
in control and HeLa cells treated with PBEA. PBEA significantly 
upregulated expression of Bax, p53 and caspase-3, whereas Bcl-2 was 
downregulated. The data was shown as mean ± SD which represent three 












The search for anticancer agents from botanical sources has been gaining 
popularity worldwide due to their potential in arresting cancer cell proliferation with 
minimal side effects and easily accessible. At present, a large number of active 
compounds from natural sources such as herbs and medicinal plants have been isolated 
and developed as new drugs for cancer treatment (Wang et al., 2013). P. bleo leaves is 
one of the important sources of medicine and traditionally used to treat various ailments 
such as haemorrhoid, hypertension, cancer, diabetes, infections, headaches, 
rheumatism, asthma as well as a health supplement (Er et al., 2007; Malek et al., 2009; 
Sim et al., 2010b; Sri Nurestri et al., 2008). Previous studies commonly used methanol 
crude extract and fractions for its anti-cancer study (Malek et al., 2009; Tan et al., 2005). 
In this study, a few solvents were utilized besides methanol which includes hexane, 
ethyl acetate and the aqueous solution obtained via conventional extraction methods to 
determine the cytotoxic effects of P. bleo leaves crude extracts on several common 
cancer cell lines such as HeLa, MDA-MB-231 and SW480 that have not been reported. 
Two conventional successive extraction methods known as Soxhlet and 
maceration were used in this study. The different between these two methods are the 
presence of heat and time. Soxhlet method utilizes the heating during extraction with a 
shorter extraction time while maceration involves prolong soaking of the plant materials 
in the solvents at room temperature.  
Pharmacology screening of plants is essential in the search for novel and 
effective drugs with minimal side effects (Kuete et al., 2013). National Cancer Institute 
(NCI), USA has established IC50 value below than 20 g/mL for in vitro cytotoxic 
activity of the crude extract which considered highly cytotoxic (Srisawat et al., 2013). 
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According to Fatemeh and Khosro (2013), the IC50 value of a good anti-cancer agents 
should be as low as possible to avoid undesirable effects to the patients.  
This study revealed that crude ethyl acetate extract (PBEA) obtained via Soxhlet 
method exhibited the strongest cytotoxic effects (IC50 value = 14.37± 8.40 g/ml) 
among all the extracts on its corresponding cancer cell: HeLa cervical cancer cells. In 
addition, no cytotoxicity was observed in the normal cells (NIH/3T3) treated with 
PBEA at concentration of 14.37 µg/ml. The ability of the extract to distinguish between 
the normal and malignant cells is a crucial aspect of the development of an anti-cancer 
agent (Badmus et al., 2015). This characteristic was evident for PBEA in this study 
hence making it a high potential option as an anti-cancer agent for the cervical cancer.  
Apart from that, the effectiveness of PBEA towards HeLa cells possibly due to 
presen  of ph ochemicals ha  can inhibi  he cell s prolifera ion. PBEA is known to 
contain several useful phytochemicals such as terpenoids, and phenolic compounds 
(Abdul-Wahab et al., 2012; Malek et al., 2009; Sri Nurestri et al., 2008). Various studies 
have reported that terpenoids and phenols exhibited cytotoxic activity against several 
cancer cells like colon and liver (Endrini et al., 2014; Sharma et al., 2017). In addition, 
the current study has identified new flavonoid compound namely 4H-Pyran-4-one,2,3-
dihydro-3,5-dihydroxy-6-methyl as described in Chapter 3. These compound were 
found predominantly in PBEA obtained via Soxhlet method and have been reported for 
its anti-proliferative activity and pro-apoptotic effects (Ban et al., 2007).   
Previous studies on the cytotoxic effects of P. bleo leaves also found ethyl 
ace a e (EA) frac ion and -tocopherol compound isolated from EA fraction exerted 
high cytotoxic effects against human nasopharyngeal cancer cells (KB) with IC50 values 
of 4.5 and 0.81 g/ml respec i el  (Malek et al., 2009; Sri Nurestri et al., 2008). In 
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contrast, the current study found the crude PBEA was highly cytotoxic towards HeLa 
cells. However, in the traditional setting, the plant extract in the crude form is preferred 
compared to the pure compounds due to the synergistic actions from all compounds in 
the crude extract which contribute to the effectiveness of the plants (Chai, 2011; Ma et 
al., 2009). Furthermore, studies have suggested that the crude extract usage offers better 
effectiveness compared to the pure compounds as all the compounds presented in the 
crude extract (Aiyelaagbe et al., 2011; Rasoanaivo et al., 2011). 
Apart from the high cytotoxic effects against HeLa cells, PBEA from Soxhlet 
method showed moderate cytotoxic activity on breast cancer cells (MDA-MB-231). 
HeLa is a hormone-dependent cervical tumor cells while MDA-MB-231 is a hormone-
independent breast tumor cells (Rampogu et al., 2018; Robinson et al., 1990). The 
variation in the effectiveness of PBEA towards these two types of cancer cells was 
possibly due to the presence of phytochemicals in this extract that enable it to inhibit 
the activity of the hormones involved. Al-Shehri and Moustafa (2019) reported a 
methanol extract of Aerva javanica (AJME) showed significant cytotoxic effects on 
hormone-dependent cancer cell lines namely prostate (PC3) and breast (MCF7) cells. 
They suggested that the activity of the implicated hormones might be suppressed by 
various effective phytochemicals in AJME. Thus, the presence of these phytochemicals 
including the new compound might contribute to the most potent cytotoxic effect of 
PBEA extracted via Soxhlet method on HeLa cancer cells. 
Even though the methanol extract of P. bleo leaves obtained via both successive 
extractions gave the highest extraction yield in this study (as described in Chapter 3), 
there were no cytotoxic effects exhibited by these extracts on all cancer cell lines. Our 
results was in agreement with the findings from Er et al. (2007) that the methanol extract 
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of this plant showed no anti-proliferative effects on a mouse mammary cancer cells 
(4T1) as well as to the normal cells NIH/3T3 (IC50 values more than 200 µg/ml). In 
contrast, Tan et al. (2005) reported high cytotoxic activity exhibited by the methanol 
extract of this plant on T47-D breast cancer cells. The variation in the results obtained 
from the aforementioned studies and the current study might be due to the different 
cancer cells used and lower amount of effective phytochemicals isolated that are 
responsible to the cytotoxic activity of this plant extracts. 
In this study, P. bleo leaves aqueous extract showed IC50 values above 100 
µg/ml which indicates weak cytotoxic effects on all cell lines. A study by Er et al. 
(2007) also reported similar findings with the current study where no anti-proliferative 
activity demonstrated by the aqueous extract of this plant against 4T1 and NIH/3T3 
cells. Another study found hot water extract of this plant possessed moderate cytotoxic 
effects towards a human colon cancer cells (HT29) which contrary to our findings (Lum 
et al., 2013). In this study, the aqueous extract was not able to show cytotoxic effects 
possibly due to low amount of the effective compounds such as phytol and sterols (in 
Chapter 3) which may be responsible to the cytotoxic activity of this extract.      
Since PBEA obtained via Soxhlet extraction was found to show the potent 
cytotoxic effects towards HeLa cells, only PBEA and HeLa cells were used for further 
analysis. In order to explore the cytotoxic effect of PBEA on HeLa cells, the changes in 
their structure were observed after 72 h treatment with PBEA. In this study, the 
microscopic examination of PBEA-treated HeLa cells found the presence of apoptotic 
cells indicated by fragmented nuclei and condensed chromatin. As the time of 
incubation period with PBEA increased to 72 h, HeLa cells underwent apoptosis when 
they appeared round, shrunken with condensed chromatin and lost their original 
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morphology as well as contact with the adjacent cells beside detaching from the tissue 
culture flask. The apoptotic cells were floated in the culture medium upon the loss of 
cellular adhesion to the substrate (Rahman et al., 2013). Once the apoptotic monolayer 
adherent cells experience early detachment from their basal membrane, they are known 
as anoikis (Thuret et al., 2003).  
In the present study, apoptosis also was assessed using Hoechst 33258 staining. 
This method makes use of a permeable blue fluorescent nucleic acid dye called a 
Hoechst stain to detect the condensation of chromatin and the fragmented nuclei of cells 
that had undergone apoptosis (Rahman et al., 2013). Our findings showed that HeLa 
cells that were treated with PBEA exhibited features of apoptosis such as cell shrinkage, 
highly condensed chromatin, nuclei fragmentation and decreased number of cells. In 
addition, crescent-shaped nuclei were also observed in PBEA treated HeLa cells. The 
appearance of crescent-shaped nucleus that picked up the brighter blue dye indicated 
the onset of early apoptosis event (Brady, 2004). Apart from that, cells in their later 
stage of apoptosis can be identified through their detachment from adjacent cells with 
convoluted outline as well as cell shrinkage (Saraste and Pulkki, 2000). Thus, our 
findings suggested that PBEA is effective in inhibiting the growth of HeLa cells and 
exerted cytotoxic effect on this cancer cells.      
Cell cycle arrest and induction of apoptosis were tested to determine the 
mechanism involved in the inhibition of cell growth by PBEA leading to the 
cytotoxicity in HeLa cells. The ability of cells to sustain proliferation is a key factor in 
tumor progression and development. This is evident through the dysregulation of the 
cell cycle when the expression or activity of the related proteins are altered (Feitelson 
et al., 2015). The current findings showed that PBEA significantly inhibits the 
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proliferation of HeLa cells. A defining characteristic of an anti-cancer agent is their 
ability to interfere with the cell cycle progression thus suppressing cancer cells growth 
(Bailon-Moscoso et al., 2017). The cell cycle analysis demonstrated that PBEA arrested 
HeLa cells at G0/G1 phase in a time-dependent manner as the accumulation of the cells 
were noticeable at this stage after 72 h. This finding indicates that PBEA may inhibit 
the progression of proliferation in HeLa cells at the G0/G1 phase. Cell proliferation is 
controlled by the cyclin-dependent kinases (CDKs) such as CDK4 and CDK6 at each 
checkpoints and upon DNA damage, it can be inhibited by activation of the checkpoints 
(Otto and Sicinski, 2017). During cell division, the checkpoints that exist at each phase 
of the cell cycle will identify the potential DNA impairment which allows for cell repair 
to take place (Wiman and Zhivotovsky, 2017). Arresting DNA replication at the G0/G1 
phase can direct the cells either to be repaired or to undergo apoptosis (Chen, 2016; 
Mantena et al., 2006; Visconti et al., 2016). In addition, numerous studies reported the 
ability of natural compounds from various plants in modulating the cell cycle arrest in 
the tumor cells. For instance, ethyl acetate extract of Opuntia humifusa was found to 
significantly inhibited the proliferation of HeLa cells by arresting the cell progression 
at G1 phase associated cyclin D1, cyclin-dependent kinase 4 (CDK4) and 
phosphorylated retinoblastoma proteins (Hahm et al., 2015). In another study, ethyl 
acetate extract of Glycosmis parva leaf reduced the viability of colorectal cancer cells 
HT-29 by inhibiting the cell proliferation through arresting the cell cycle at G0/G1 phase 
related with the suppression of cyclin A, cyclin B, COX-2 and BCL-2 expression which 
subsequently leads to apoptosis (Buranabunwong et al., 2015). Thus, our findings 
suggested that PBEA was able to suppress the proliferation of HeLa cells by blocking 
the cell cycle progression at the G0/G1 phase. This should be looked into in future 
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studies where the blocking activity may be associated with the CDK mechanism or other 
pathways. 
 In order to confirm the onset of apoptosis following cell cycle arrest, HeLa cells 
treated with PBEA were stained with Annexin V-FITC and analyzed using flow 
cytometry. Apoptosis begins with the alteration of the plasma membrane which 
exposing  phosphotidylserine (Segawa and Nagata, 2015). Annexin V is conjugated to 
the phosphotidylserine along with PI which binds to cells at different stages and 
distinguishes apoptosis from necrotic cells (Hingorani et al., 2011). In the current study, 
apoptosis activation in a time-dependent manner was observed due to the accumulation 
of apoptotic cells in both early and late stage of apoptosis after 72 h of treatment with 
PBEA. These findings were in consistent with the morphological changes observed on 
PBEA-treated HeLa cells such as nuclei fragmentation, condensed chromatin, cells 
shrinkage and finally detachment of the apoptotic cells from the tissue culture flask. 
Thus, our results confirmed that HeLa cells had undergone apoptosis as a result of the 
cytotoxic effects induced by PBEA.  
Exploitation of the apoptotic signaling pathways to induce the cancer cell death 
is the main strategy of most chemotherapeutic drugs currently used in the clinical 
oncology (Pistritto et al., 2016). Apoptosis can occur either through the extrinsic 
pathway (death receptor) or the intrinsic pathway (mitochondrial). Upon stimulation by 
DNA damage for example triggering the activation of p53 (a tumor suppressor gene) 
which cause cell cycle arrest or apoptosis in the cells (Chen, 2016). Activated p53 
causes alteration in the ratio of Bax/Bcl-2 apoptotic proteins which results in 
permeability of the mitochondrial outer layer (MOMP) subsequently activates caspases 
cascade leading to apoptosis (Aubrey et al., 2018; Marchenko and Moll, 2014). 
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p53 plays a vital role in the tumor suppression. p53 loss its functions when in 
mutation form which associated with the majority of cancer and high level of mutant 
p53 proteins detected in the tumors promotes the tumorigenesis (Yue et al., 2017). Our 
findings showed the increment of p53 level in HeLa cells after treatment with PBEA in 
a time-dependent manner. Increase in the expression level of p53 suggesting that the 
arrestment of DNA in the HeLa cells occurred. This is indicated by the inhibition of cell 
cycle progression at the G0/G1 phase leading to apoptosis as evidenced by the detection 
of apoptotic HeLa cells after 72 h of treatment with PBEA. A study by Saio et al. (2017)  
demonstrated similar findings where the aqueous-methanol extract of Rhododendron 
arboretum promoted apoptosis and cell cycle arrest in HeLa cells via upregulation of 
p53. Another study reported that p53 mediated apoptosis and cell cycle arrest in HeLa 
cells induced by the methanol extract of Polyalthia longifolia leaf (Vijayarathna et al., 
2017). 
In healthy cells, the tumor suppressor p53 remained at low concentration. p53 
protein level will elevate due to various stimuli and regulate the apoptotic gene 
expression besides arresting the cell cycle (Giono and Manfredi, 2007). It induces 
apoptosis by suppressing anti-apoptotic proteins such as survivin and Bcl-2. At the same 
time, pro-apoptotic protein such as Bax is activated thus initiating the caspase cascade 
(Amaral et al., 2010; Wu et al., 2013). Activation of pro-apoptotic proteins promoted 
mitochondrial outer membrane permeabilization (MOMP) and triggering the release of 
cytochrome c that will bind with Apaf-1 producing apoptosome which stimulates the 
occurrence of apoptotic (Kavitha et al., 2017). The current results suggested that PBEA 
acted as an apoptosis inducer, suppressing Bcl-2 expression through the increment of 
p53 as well as Bax expression level in the HeLa cells. This observation is in line with a 
study by Wang et al. (2016) who reported that barberin hydrochloride acted as an 
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efficient apoptotic inducer in HeLa cells via upregulation of p53 and downregulation of 
Bcl-2 as well as cox-2 expression level. Other than that, a study by Cheng et al. (2017) 
recorded ampelopsin (AMP) identified from ethyl acetate extract of Ampelopsis 
megalophylla induces apoptosis in HeLa cells validated through downregulation of Bcl-
2 expression and upregulation of Bax, cytochrome c, caspase 3 and caspase 9 suggesting 
apoptosis mediated via mitochondrial pathway.  
Activation of caspases can be triggered through the extrinsic or intrinsic 
pathways and are crucial mediators in apoptosis with the activation of caspase 3 
(downstream effector caspase).  Our results showed that caspase-3 expression level was 
slightly increased in the HeLa cells upon treatment with PBEA. The current findings 
seem to support the previous study by Tan et al. (2005) where they discovered the 
methanol extract of P. bleo leaves induced apoptosis in the breast carcinoma cell line 
(T47-D) via activation of caspase-3 and c-myc. Thus, PBEA treatment induced the 
activation of caspase-3 through extrinsic or intrinsic pathway in HeLa cells that initiated 
the action of other proteins which leads to apoptosis. 
According to the rise of cancer incidence globally associated to its morbidity, 
mortality and high cost of treatment, the important strategy to control this incidence is 
an early prevention of the disease. In regards to cancer, chemoprevention is one the 
potential approach which involves the usage of a natural, synthetic or biological agent 
to reduce the risk or delay the occurrence of malignancy (Steward and Brown, 2013). 
Understanding on how carcinogenesis works biologically and identification of potential 
molecular targets to disturb this process are important elements in chemoprevention 
(Steward and Brown, 2013). The success of chemoprevention has been demonstrated in 
cancer including prostate, colon and breast (Wu et al., 2011). Meanwhile, when the 
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patient is diagnosed with cancer, treatment is an important opt to consider. The main 
goal of cancer treatment is to achieve a cure (Khan et al., 2005). However, when cure 
is not possible due to advanced state of disease, treatment of cancer will focus on 
palliation aim for prolongation of patient s life span and reduce the sufferings (Khan et 
al., 2005). 
In addition, standardization of the plant and crude extract is very much essential 
to establish the correct identity and maintain their quality for future purposes. The 
process of standardization usually involves pharmacognostic techniques 
(morphological, anatomical and biochemical characteristics) and phytochemical studies 
(Calixto, 2000; Organization, 1998). As for standardization of P. bleo plant for future 
purposes, macro and microscopical examinations by botanist should be done for 
accurate identity of the plant. Environmental factor such as climate, altitude and place 
of origin can affect the content of active ingredients in a plant (Kunle et al., 2012). 
Hence, it is important to ensure the same location as well as right plant part are taken to 
maintain the content of active ingredients for optimum activity of the plant used for 
instance in the future research. Phytochemical studies involving extraction with suitable 
solvents, purification and characterization of the active phytoconstituents in this plant 
should be done to assess the purity of the plant for future research or purposes. It is also 
important to perform toxicological studies to standardize this plant for future use as an 
herbal formulation (Kunle et al., 2012).   
The current findings showed the morphological alterations in HeLa cells treated 
PBEA with the presence of apoptotic features such as cell shrinkage, condensation of 
chromatin, fragmentation of nuclei and a significant reduction in the HeLa cell number. 
The morphological changes observed were in line with the detection of apoptotic event 
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from Annexin V staining. Thus, the results of this study clearly demonstrated that PBEA 
induced apoptosis in cervical cancer (HeLa cells) through Bax/Bcl-2 signalling pathway 
with the involvement of caspase-3, while inducing G0/G1 phase cycle arrest via the p53-
mediated mechanism. 
4.5 Conclusion 
In conclusion, our findings demonstrated that PBEA at concentration of 14.37 
µg/ml induced cell death in the cervical cancer HeLa cells indicated by the presence of 
apoptotic cells observed microscopically. This is confirmed by the evaluation of 
Bax/Bcl-2, caspase-3 and p53 expression level. PBEA also induced the G0/G1 phase 
cycle arrest via p53-mediated mechanism. Therefore, it can be concluded that P. bleo 
has the potential to become a chemopreventive agent. Further research, particularly in 
vivo study, should be carried out to provide further evidence of the anti-cancer 






CHAPTER 5  
 
ACTIVATION AND CYTOTOXIC ACTIVITY OF NATURAL KILLER 
CELLS TOWARDS CERVICAL CANCER CELLS HeLa INDUCED BY 
Pereskia bleo LEAVES EXTRACT 
5.1 Introduction 
Immune system plays a role in protection, contributing to the homeostasis by 
removal of detrimental stimuli, invading pathogens as well as tumour cells from the 
body (Comi and Tondo, 2017). Immunosuppression increases susceptible to infections 
and malignancies (Tinguely, 2013). Immunomodulation is a process of modification 
of the immune response to increase the efficiency against infectious agents and tumors 
(Saroj et al., 2012). Thus, immunostimulant is an immunomodulatory substance that 
is used to increase the immune response (Avorn, 2011). In recent years, 
immunostimulants have emerged as a new approach for the treatment of ailments such 
as cancer, immunodeficiency diseases and infectious diseases (Fraser and Poole, 2019; 
García-Martínez et al., 2018; Pranchevicius and Vieira, 2013).  
NK cells mediate cytotoxicity against tumor cells without prior sensitization 
upon activation (Marcus et al., 2014). Due to that special ability, modulation of NK 
cells has been widely studied to develop an alternative method for the treatment of 
cancer besides the conventional chemotherapy (Kwon et al., 2017). 
Several studies have reported of substances that can stimulate NK cells activity 
for instance IFN-  and IL-2 which are used as adoptive immunotherapy for cancer 
treatment (Garris et al., 2018; Jiang et al., 2016). However, cancer immunotherapy has 
its limitations, for instance, the administration of IL-2 can cause detrimental side effect 
and toxicity to the patients (Sharma et al., 2017; Suck and Koh, 2010; Surayot and 
You, 2017).  
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Medicinal plants are well known for their benefits in the prevention and 
treatment of many diseases with minimal side effects. Medicinal plants used in 
traditional therapy are able to enhance immune response of patients with malignant 
disease especially when the host defence mechanism is suppressed due to 
chemotherapy (Singh et al., 2016). Several medicinal plants as well as its isolated 
compounds from the natural products have been reported for their immunomodulatory 
effects on the activation of NK cells particularly. For instance, the extract of Nigella 
sativum was reported to promote activation and increase the cytotoxic activity of NK 
cells against human leukaemia cells (K562) by the production of IFN-  and TNF-  
and granzyme A release (Shabsoug et al., 2008). A study revealed the increase in NK 
cells cytotoxic activity against a lymphoma (YAC-1) and K562 after treatment with 
an acetone extract from Kumquat pericarp (Nagahama et al., 2015). In other study, a 
fermented extract of Triticum aestivum was found able to stimulate the NK cells 
activation and enhanced their killing activity in immunocompetent BALB/c mice 
through increased degranulation and high production of IFN-  (Barisone et al., 2018). 
In addition, a phenolic compound namely resveratrol was reported in promoting the 
cytotoxic effects of NK cells towards human A549 (lung), HepG2 (liver) and K562 
(leukaemia) cancer cells by increased perforin release, suppression of NKG2D 
expression as well as increased kinase activity of JNK and ERK1/2 MAP (Lu and 
Chen, 2010).  
As for Pereskia bleo (P. bleo), this edible medicinal plant is well known for its 
anti-cancer properties. Various reports regarding this plant indicated their anti-
proliferative effect, anti-cancer effect and cytotoxic activity towards numerous cancer 
cell lines (Er et al., 2007; Malek et al., 2009; Tan et al., 2005; Yen et al., 2013). 
However, there is no report available on its immunomodulatory activity on NK cells. 
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In this study, we demonstrated that ethyl acetate extract of Pereskia bleo leaves 
(PBEA), significantly induces apoptosis in cervical cancer cells HeLa (Chapter 4).  
This have led us to evaluate the activation and cytotoxic activity of this plant extract 
on freshly isolated human NK cells from healthy and cervical cancer patients against 





























5.2 Materials and methods 
5.2.1 Preparation of extract 
20 g of the powdered leaves was successively extracted with ethyl acetate 
solvent using the Soxhlet system as described in Chapter 3 (section 3.2.3, page 40). 
Then the extract was concentrated with rotary evaporator and kept at -20°C until use.  
5.2.2 Human subjects 
Human primary NK cells used in this study were obtained from blood samples 
collected from three healthy donors and three cervical cancer patients. All healthy 
donors were female aged between 18 to 45 years old with no acute or chronic disease, 
not consuming any immunosuppressive drugs, non-smokers and not pregnant. For 
cancer patients, the donors were female diagnosed with cervical cancer, aged between 
45 to 60 years old, have not received any treatment, free of acute or chronic diseases, 
non-smokers and not pregnant. All donors have been informed and consented at the 
beginning of this study. This study protocol was reviewed and approved by the Human 
Research Ethics Committee of Universiti Sains Malaysia (JEPeM-USM) (JEPeM 
USM Code: USM/JEPeM/17100566).    
5.2.3 Isolation of human NK cells 
A total of 5 ml of fresh whole blood from each donor was collected in EDTA 
blood collection tubes (BD Vacutainer®). The blood was diluted at a ratio of 1:2 with 
1x PBS. The diluted blood was layered on an equal volume of lymphocyte separation 
medium (LSM, Cornell) and separated by density gravity centrifugation at 400 x g 
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without brake for 30 minutes at room temperature. The layers formed after 
centrifugation were plasma, buffy coat containing peripheral blood mononuclear cells 
(PBMCs), LSM and erythrocytes as illustrated in Figure 5.1. 
Buffy coat was instantly aspirated with caution and collected in 15 mL conical 
tube. The buffy coat was washed twice with sterile PBS and centrifuge at 300 x g for 
10 minute at room temperature. The pellet (PBMCs) was resuspended in a complete 
RPMI medium (Gibco) which consisted of 10% FBS (Gibco) and 1% penicillin 
streptomycin (Gibco). The PBMCs were incubated for 24 h at 37 °C with 5% CO2.  
After 24 h incubation, monocytes become attached to the bottom of the T75 
tissue culture flask (Eppendorf) while lymphocytes were suspended in the culture 
medium. The lymphocytes were collected in 15 mL conical tube. They were washed 
twice with 1x PBS centrifuged at 300 x g for 10 minutes at 4 °C and ready for the NK 
cells isolation process. 
The isolation of NK cells from healthy donors and cervical cancer patients was 
performed using human NK Cell Isolation Kit (Miltenyi Biotec) by negative selection 
with LS column as per kit s ins r c ions. Then cells (lymphocytes) were counted using 
automated cell counter (Invitrogen). After that, the cell pellet was resuspended in 40 
µl of NK buffer (up to 107 of total cells). A total of 10 µl of NK Cell Biotin-Antibody 
Cocktail was added, mixed and incubated at 2  8 °C for 5 minutes. Another 30 µl of 
NK buffer was added followed by 20 µl of NK Cell MicroBead Cocktail. The mixture 
was mixed thoroughly and incubated at 2  8 °C. After 10 minutes, 500 µl of NK buffer 
was added to the cell suspension. Then, the cells suspension was placed in the LS 
column. Earlier the LS column was rinsed with 3 mL of NK buffer and placed in the 
magnetic field of MACS Separator. The flow-through cells (unlabeled cells) were 
131 
collected in 15 mL tube. The obtained unlabeled cells contained the enriched NK cells. 
Another 3 mL of NK buffer were applied onto the LS column and the pass-through 
cells were collected and combined with the previous unlabeled cells.  
  
 








5.2.4 Identification of human NK cells 
To access the purity of the isolated NK cells, the unlabelled cells (enriched NK 
cells) were resuspended in PBS with a final concentration of 107 cells/ml. A total of 
500 µl of blocking reagent bovine serum albumin (BSA, Miltenyi) was added to the 
cell suspension and incubated for 10 minutes at 4 °C. After that, 100 µl of the cell 
suspension was transferred into new labelled tubes and stained with 5 µl of anti-CD3-
FITC (Santa Cruz) and 5 µl of anti-CD56-PE (Santa Cruz) for 30 minutes on ice under 
dark condition. 2 ml of PBS was added to the tubes and centrifuged for 5 minutes at 
400 x g. Then, the supernatant was carefully aspirated and the pellet was resuspended 
in 500 µl of 1x PBS. The purity of the NK cells was assessed by flow cytometry 
through FACSCANTO (BD Bioscience) for minimum of 10,000 events per sample. 
The data was analysed using FCS Express De Novo software. 
5.2.5 Proliferation assay of human NK cells 
The cells from healthy individuals were subjected to a proliferation assay at 
several different incubation time (24 h, 48 h and 72 h) to determine the optimum period 
for NK cells proliferation. A volume of 100 µl of NK cells (5 x 103 cell/ml) were 
seeded from the complete medium DMEM into each well of flat bottom 96-well plates 
(Eppendorf) and incubated for 4 hours with 5% CO2 at 37 °C. PBEA containing IC50 
(14.37 ± 8.40 µg/ml) that has been subjected to serial dilution from 1 µg/ml until 200 
µg/ml were used to treat the seeded NK cells at several incubation periods: 24 h, 48 h 
and 72 h in a humidified atmosphere (5% CO2, 37 °C). The negative control of this 
experiment is DMSO at a concentration of less than 1%. After each incubation time, 
20 µl of MTT reagent (5 mg/ml) was added into each well and further incubated for 
133 
4h at 37 °C. A volume of 100 µl of DMSO was added into each well and their optical 
density (OD) was measured using ELISA microplate reader at 570 nm. The experiment 
was done in triplicates and repeated 3 times using different donors. The percentage of 
NK cells proliferation was determined as following formula: 
 
NK proliferation (%) = (Absorbance of treatment/absorbance of control) × 100 % 
5.2.6 Co- culture of human NK cells with cervical cancer cells HeLa 
Based on the results of the potent cytotoxic activity of PBEA obtained via 
Soxhlet method on HeLa cells (Chapter 4) as well as the NK cells proliferation, the 
co-culture experiments for NK cells stimulatory and cytotoxic activity on HeLa cells 
induced by PBEA was carried out at 24 h incubation. The overview of this experiment 
is illustrated in Figure 5.2. 
5.2.6(a) Natural Killer cells 
NK cells were isolated from 5 ml of fresh whole blood from donors and 
purified as described in section 5.2.3. 
5.2.6(b) Target cells 
Human cervical cancer cell line (HeLa) was purchased from ATCC (US). HeLa 
cells were grown in a complete media DMEM supplemented with 10% FBS (Gibco) 
and 1% penicillin streptomycin (Gibco).  
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5.2.6(c) Killing assay of human NK cells against HeLa cells induced by PBEA 
Killing assays of human NK cells were performed by determining the 
percentage of target cell death after 24 h of PBEA treatment. Effector cells (NK cells 
of healthy or cervical cancer donors) were incubated with the target cells (HeLa) at 
specified ratio of effector to target (E: T = 25:1). Prior to the incubation with HeLa 
cells, NK cells were treated with PBEA (14.37 ± 8.40 µg/ml) for 4 hours with 5% CO2 
atmosphere at 37 °C. After activation, NK cells were transferred into a plate containing 
HeLa cells and incubated for additional 20 hours. NK cells without treatment with 
PBEA were used as a control in this study. After 24 h incubation, HeLa cells were 
collected and centrifuged at 300×g for 5 minutes. The supernatants were aspirated and 
kept to evaluate their level of cytokines as well as degranulation produced while the 
pellet was washed with PBS prior the staining process. Next, the cells were stained 
with Annexin V-FITC and PI for 15 minutes (in the dark). The target cell death was 
quantified using FACSCANTO (BD Bioscience) at 10,000 events per sample. The 
data analysis was performed using FCS Express 7 De Novo software. The experiment 
was conducted in independent triplicate.  
5.2.6(d) ELISA for degranulation (Perforin, Granzyme B) and cytokines (IFN-
, IL-2) production  
The expression of perforin, granzyme B, interferon gamma (IFN- ) and 
interleukin 2 (IL-2) were determined using human PRF1 (Perforin 1), human GzmB 
(Granzyme B), human IFN-  (In erferon gamma) and h man IL-2 (Interleukin 2) kits 
from Elabscience as per man fac rer s pro ocol. A total of 100 µl of each sample 
[supernatant obtained from the NK cells co-culture experiment in section 5.2.6(c)] 
were added into each wells and incubated for 90 min at 37°C. Then, 100 µl of 
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biotinylated detection Ab working solution were added into each well after the removal 
of liquid and further incubated for 60 min at 37°C. Then, the plate was washed three 
times followed by addition of 100 µl of HRP conjugate working solution and incubated 
for 30 min at 37°C. After that, the plate was washed five times and 90 µl of substrate 
reagent were added into the wells followed by incubation for 15 min at 37°C (in the 
dark). The OD values of each well were measured with microplate ELISA reader at 
450 nm. The results were expressed in pg/ml. Each experimental and control sample 
was assayed in triplicates.  
 
 
Figure 5.2 The overview of co-culture experiment of NK cells with target HeLa 
cells induced by PBEA 
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5.2.6(e) Statistical analysis 
The data obtained were presented as mean ± SD. The results were analysed 
using independent t-test for the number of NK cells (healthy individuals and cervical 
cancer patients). One-way ANOVA test was conducted for the co-culture experiments 
of NK cells and T ke s m l iple comparison es  as done o de ermine he 
significance between the groups. The significant value of the data was set at P<0.05. 
In addition, Shapiro-Wick es  as performed for he da a s normali . All statistical 















5.3.1 Purification of human NK cells 
In order to evaluate the performance of Human NK cells Isolation kit (Miltenyi 
Biotech) with the condition of the present study, purification testing was carried out 
using three healthy donors. After the isolation, the expression of NK cells stained with 
anti-CD3-FITC and anti-CD56-PE were evaluated by flow cytometry analysis to 
confirm the presence of NK cells. Fig re 5.3 sho ed he res l s of NK cells  purity 
from one of the healthy donors as a representative of the overall findings. The results 
were similar for all the three individual samples tested in this study. Our findings 
showed that about 85% of purified human NK cells (CD3-CD56+) was obtained 
through this kit. The purification testing was not carried out for the cervical cancer 





(i)          (ii) 
 
Figure 5.3 Purification of human NK cells. (i) Representative dots plot for gating 
of NK cells population. (ii) Dots plot of purified NK cells indicated 













5.3.2 The number of NK cells from healthy individuals compared to cervical 
cancer patients 
The isolation of human NK cells was performed using magnetic separation by 
negative selection. NK cells were obtained from three healthy and three cervical cancer 
donors. NK cells counts were determined using trypan blue exclusion method. In this 
study, NK cells from healthy individuals exhibited higher number of cells (7.8 × 105 
cells/ml) compared to cervical cancer patients (3.15 × 105 cells/ml) as shown in Figure 





















Figure 5.4 Number of human NK cells isolated from healthy and cervical cancer 
donors. Data are represented as mean ± SD from three independent 
experiments (n=3) with triplicates each. *P<0.05 when compared to 












5.3.3 PBEA enhanced the proliferation of human NK cells 
In the current study, the freshly isolated human NK cells from healthy donors 
were incubated with PBEA at the various concentration (1  200 µg/mL) to determine 
their effect on the proliferation of NK cells after 24 h, 48 h, and 72 h. The IC50 value 
of PBEA (14.37± 8.40 µg/ml) from section 4.3.1(b) was also included in order to 
evaluate its proliferation effect on NK cells.  
Figure 5.5(i) shows the increased of NK cells proliferation to 45 % with the 
increase in PBEA concentration after 24 h of treatment. Besides, the proliferation rate 
of PBEA treated-NK cells at concentration of 14.37 µg/ml (IC50 of PBEA) was 
significantly different in comparison to 48 h and 72 h treatment groups (P<0.05). The 
proliferation was not amplified after 48 h of treatment when the concentration of 
PBEA was less than 14.37 µg/ml (Figure 5.5 ii). However, when the concentration of 
PBEA was more than 14.37 µg/ml, the rate of NK proliferation was substantially 
increased to 35 % (Figure 5.5 ii).  
At 72 h of treatment, the level of NK proliferation was observed to rise 25 % 
when treated with PBEA at concentration below 14.37 µg/ml (Figure 5.5 iii). The 
proliferation of NK cells was slightly decreased (10 %) at a concentration of 14.37 
µg/ml and gradually increased to 35 % for concentrations of more than 50 µg/ml after 
72 h of treatment (Figure 5.5 iii). This observation suggested that PBEA did not exert 
toxicity on human NK cells due to increase in their proliferation even at high 



















































Figure 5.5 Proliferation of NK cells after treatment with different concentration of 
PBEA (1  200 µg/mL) for (i) 24 h, (ii) 48 h and (iii) 72 h. *PBEA at 
concentration of 14.4 µg/ml is significant different when compare to 48 
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5.3.4 NK cells treated with PBEA enhanced the killing of target cells 
Target cells killing assay of human NK cells activated by PBEA was assessed 
through flow cytometry. NK cells from healthy donors and the cervical cancer patients 
were treated with 14.37 µg/ml of PBEA prior to incubation with HeLa cells (target 
cells). As shown in Figure 5.6, the co-culture of HeLa cells with NK cells of healthy 
donors showed a substantial increase in the percentage of apoptotic target HeLa cells 
(88.65 ± 5.3 %) after treatment with PBEA (PBEA+NK+HeLa). A total of 53.73 ± 
11.97 % of apoptotic cells were recorded in the treatment group without NK cells 
(PBEA+HeLa), 49.18 ± 16.01 % after treatment with DMSO (DMSO+NK+HeLa) and 
64.62 ± 10.12 % without treatment with PBEA (NK+HeLa). The results demonstrated 
that the percentage of apoptotic cells in PBEA-treated group was significant different 
from the DMSO treated group and in the absence of NK cells (P<0.05).  
Meanwhile in Figure 5.7, co-culture of HeLa cells with NK cells from cervical 
cancer patients showed high percentage of apoptotic target HeLa cells which was 
74.62 ± 4.62 % after treatment with PBEA (PBEA+NK+HeLa). Other groups 
exhibited lower number of apoptotic cells which were 55.44 ± 3.55 % without NK 
cells (PBEA+HeLa), 60.00 ± 4.33 % with DMSO treatment (DMSO+NK+HeLa) and 
57.81 ± 3.73 % without PBEA treatment (NK+HeLa). There were significant 
differences of apoptotic rate of HeLa cells in PBEA-treated NK cells from the groups 
that were not treated with PBEA as well as the groups that received DMSO treatment 
without NK cells (P<0.05). 
 Although the percentage of apoptotic HeLa cells was high in co-culture with 
NK cells from healthy donor compared to NK cells from cervical cancer donors, the 
results showed that PBEA has the ability to enhance the cytotoxic effects of NK cells 
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from cervical cancer donors to kill the target cells as indicated by high percentage of 
















































           
  
 














Figure 5.6 Effect of NK cells from healthy donors on the target cells  death after 
stimulated with PBEA for 24 h . (i) The representative of dot plots 
distribution of HeLa cells co-culture with treated and untreated PBEA 
NK cells. The quadrants show the cells that are viable (Q1), necrotic 
(Q2), in early apoptosis (Q3) and late apoptosis (Q4). (ii) The bar 
graphs representing percentage of apoptotic HeLa cells after incubation 
with treated and untreated PBEA NK cells. Data are represented as 
mean ± SD from three independent experiments (n=3) with triplicates. 
















           
  
 


















Figure 5.7  Effect of NK cells from cervical cancer patients on the target cells 
death after stimulated with PBEA for 24 h. (i) The representative dot 
plots the distribution of HeLa cells co-culture with treated and untreated 
PBEA NK cells. The quadrants show the cells that are viable (Q1), 
necrotic (Q2), in early apoptosis (Q3) and late apoptosis (Q4). (ii) The 
bar graphs represent percentage of apoptotic HeLa cells after incubation 
with treated and untreated PBEA NK cells. Data are represented as 
mean ± SD from three independent experiments (n=3) with triplicates. 
















5.3.5 NK cells treated with PBEA enhanced cytokines (IFN-  and IL-2) 
production 
The production of NK cells granules (perforin and granzyme B) was measured 
to investigate the activation and cytotoxic activity of NK cells towards HeLa cells 
stimulated by PBEA. Based the results obtained, the expression of granzyme B was 
detected (9.39 ± 3.97 pg/ml) in PBEA-treated NK cells from cervical cancer patients. 
However, no expression of granzyme B measured in PBEA-treated NK cells from 
healthy donors. Perforin was also absent in all experiment conditions. In addition, the 
expression of IFN-  as detectable in PBEA-treated NK cells from cervical cancer 
patients (19.82 ± 4.57 pg/ml) as well as in cells without PBEA treatment (19.60 ± 5.05 
pg/ml), without statistical differences. On the other hand, the level of IL-2 expression 
was detectable in all treatment experiment conditions, without statistical differences. 
Table 5.1 summarized the results of perforin, granzyme B, IFN-  and IL-2 released by 
PBEA-activated NK cells from healthy and cervical cancer donors that were incubated 
with HeLa cells. 
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Table 5.1    ELISA results of perforin, granzyme B, IFN-  and IL-2 detection of human NK cells from healthy and cervical cancer 
                               donors stimulated by PBEA in co-culture with target HeLa cells. 
 
 Concentration (pg/mL) 
 Perforin Granzyme B IFN-  IL-2 
Healthy donors 
 
    
PBEA treated NK cells co-culture with HeLa cells ND ND ND 9.86±0.94 
NK cells co-culture with HeLa cells ND ND ND 10.43±1.45 
NK cells treated DMSO co-culture with HeLa ND ND ND 9.34±1.75 
Untreated NK cells ND ND ND 8.76±0.22 
     
Cervical cancer donors 
 
    
PBEA treated NK cells co-culture with HeLa cells ND 9.39±3.97 19.82±4.57 10.60±1.81 
NK cells co-culture with HeLa cells ND ND 19.60±5.05 13.20±3.78 
NK cells treated DMSO co-culture with HeLa ND ND ND 13.75±3.88 
Untreated NK cells ND ND ND 9.68±0.31 
                 Values (n=3, 3 independent experiments with thrice replicates each) represent the means ± SD. ND indicates not detected. 
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5.4 Discussion  
Innate immune response represents the first line defense mechanism in the 
body that provides a protective shield against infections and malignancies. Nowadays, 
the modulation of immune responses to improve health status especially in cancer has 
been extensively studied. Natural killer (NK) cells are one of the most important cells 
in the innate immune system and endowed with cytotoxic function (Habif et al., 2019). 
NK cells are able to identify and kill tumor cells without prior activation and for this 
reason the cells have emerged as a therapeutic alternative for treatment of multiple 
malignancies (Nayyar et al., 2019). Interestingly, numerous traditional medicinal 
plants have been reported which modulate immune responses against tumor cells.  
Several pure active compounds which have been isolated from plants such as 
resveratrol and lectins have been tested for its modulation effects on NK cells 
(Braedel-Ruoff, 2010; Lu and Chen, 2010; Rauf et al., 2018). After demonstration of 
the potent cytotoxic activity of PBEA against HeLa cells (Chapter 4), we decided to 
evaluate if PBEA has additional immunomodulatory effects on NK cells that would 
potentiate its anti-tumor effects. In this regard, PBEA and HeLa cells were used to 
further the study and co-culture with NK cells. In this study, the immunomodulatory 
effect of PBEA was evaluated in a system composed of HeLa cells (target) and NK 
cells (effectors). 
In the present study, NK cells were isolated from fresh whole blood samples 
of healthy and cervical cancer donors. The isolation of NK cells from both groups was 
performed using negative selection (Human NK Cell Isolation Kit) together with LS 
column. The isolation obtained CD3-CD56+ NK cells with purity of more than 85%. 
By using the same method and kit, Sugita et al. (2018) reported the similar purity of 
isolated NK cells from PBMCs (purity about 86%). In order to increase the purity of 
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NK cells, further purification with CD56 micromagnetic beads was suggested by Deng 
et al. (2014). The principle of CD56 micromagnetic beads purification was based on 
positive selection labelling of CD56 cells from PBMCs. Yi et al. (2018) demonstrated 
70 % of initially enriched NK cells isolated using the same kit with slightly 
modifications. Then they further purified the NK cells using positive selection CD56 
magnetic beads with more than 99 % of purity. Thus, according to the previous reports, 
a high degree of purity could be obtained with the inclusion of an additional final 
purification using CD56 micro magnetic beads.         
In the present study, the results showed that the number of NK cells from 
healthy donors was higher compared to cervical cancer patients. About 10% of 
peripheral blood lymphocytes of healthy individuals contains NK cells, whereas, in 
cancer patients, the cells were recorded in low amounts (He et al., 2016; Klingemann 
et al., 2016; Levy et al., 2011). Similarly, Levy et al. (2011) agreed that NK cells are 
not naturally present in the malignant tissue of advanced stage human neoplasm hence 
the low amount that was recorded. Studies have also reported the decrease number of 
NK cells observed in cervical cancer patients where these cells are often dysfunctional 
leading to defective NK cells cytotoxic activity against tumor cells (Arreygue-Garcia 
et al., 2008; Garcia-Iglesias et al., 2009). Other than that, Saito et al. (2013) reported 
a higher percentage of apoptotic cells (21.3 ± 11.6%) in gastric cancer patients 
compared to healthy individuals (11.2 ± 5.2%) which associated with the development 
of the cancer as well as low number of NK cells.  Reduction of CD56+ NK cells was 
also observed in advanced stage of colorectal and gastric cancer patients with liver 
metastasis (Gulubova et al., 2009). The minimal presence of NK cells has been coined 
as the reason for metastasis due to the tumor cells escape from the liver immune control 
mechanism (Gulubova et al., 2009). Furthermore, several studies also reported that 
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cancer patients with high progression of the disease exhibited a decrease in number of 
peripheral or tumor infiltrated NK cells which often have associated with low survival 
rate (Ishigami et al., 2000; Li et al., 2016; Peng et al., 2017).    
In pharmacological drug screening, a potential anti-cancer agent should exert 
greatest cytotoxic effect with almost negligible side effects. Based on the National 
Cancer Institute (NCI) guidelines, plant extracts with IC50 value less than 20 µg/mL 
are considered to have a potent cytotoxic effect (Srisawat et al., 2013), which is in 
correspondence with the results of the cytotoxic effects of PBEA (Chapter 4). In the 
current study, the results showed the augmentation of NK cells proliferation as the 
concentration of PBEA increased to 200 µg/ml. This indicated that high concentration 
of PBEA was not toxic to the NK cells. This finding also was in agreement with the 
finding from the cytotoxic study of PBEA in Chapter 4 where concentration of PBEA 
more than 99 µg/ml was not toxic towards the normal cells. However, to avoid the 
direct killing of the target cells (HeLa), PBEA with concentration of 14.37 µg/ml was 
chosen to carry out the cytotoxic study of NK cells. The greatest proliferation was 
observed after 24 h of incubation with PBEA. The NK proliferation was not significant 
after 48 h and 72 h which could be influenced by the small sample size of the study 
(Angelo et al., 2015). According to the results of the proliferation study, the evaluation 
of the effect of PBEA on the cytotoxic activity of NK cells was carried out using 24 h 
of PBEA treatment.  
After activation, the cytotoxic activity of NK cells on target tumor cells can be 
determined based on the number of killed target cells (Li, 2010; Nishimura et al., 
2017). In the current study, target cells death was evaluated using Annexin V-FITC 
apoptosis assay. The results demonstrated that percentage of apoptotic HeLa cells was 
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markedly increased in the co-culture experiment of PBEA induced NK cells from 
cervical cancer patients when compared with the respective untreated control groups. 
According to this, it can be suggested that PBEA was able to promote the activation 
of NK cells to kill HeLa cells. A study by Surayot and You (2017) also demonstrate 
the usefulness of our experimental model, where they found that sulfated 
polysaccharides isolated from the seaweed Codium fragile enhanced NK cells 
cytolytic activity against HeLa cells. Yeap et al. (2013) reported the potential of a 
methanol extract from a traditional herb, Rhaphidophora korthalsii which increased 
the cytotoxic effect of NK cells against the leukemia cell line K562. 
The killing pathway is used to evaluate the cytotoxic activity of NK cells by 
monitoring their response upon activation (Rudnicka et al., 2015). The killing 
mechanism of NK cells is mediated through three pathways which are Perforin and 
Granzyme B-mediated pathway, Fas Ligand pathway and antibody-dependent cellular 
cytotoxicity (ADCC) pathway (Yoon et al., 2015). Several parameters are used to 
measure activated NK cells response such as the number of apoptotic target cells, 
quantifying the expression of target markers expression (Fas Ligand, death receptors 
and caspases), degranulation release (granzyme A/B and perforin) or assessing 
cytokines secretion (IFN- , IL-12, IL-2) (Nishimura et al., 2017; Rudnicka et al., 2015; 
Yoon et al., 2015).  
The mechanism of action of NK cells begins by coming in tight contact with 
the target cells through the immune synapse then polarizing lytic granules as well as 
other organelles to the contact site (de Saint Basile et al., 2010; Stinchcombe et al., 
2006). Perforin, a pore-forming protein that is contained within lytic granules will 
generates holes in the target cells membrane upon release followed by delivery of 
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granzyme to the cytosol of the target cells which initiates apoptosis (Backes et al., 
2018; Voskoboinik et al., 2006). The current study showed perforin was not detected 
in all treatment groups (both from healthy and cancer donors). In contrast, the secretion 
of granzyme B was detected in the co-culture of NK cells from cancer patients treated 
with PBEA. This may be due to stimulation from PBEA which enhanced the activation 
of the NK cells  cytotoxicity towards the HeLa cells. This finding is in agreement with 
a previous report by Surayot and You (2017) which found that sulphated 
polysaccharides (SP) from Codium fragile enhances NK cells activation indicated by 
the release of granzyme B. In addition, absence of perforin and relatively low 
expression of granzyme B that were found in NK cells incubated with Hela cells in all 
treatment groups suggested that HeLa cells lack other activating signals for PBEA-
activated NK cells from healthy and cancer patients. A study by Zhang et al. (2007) 
also reported no cytotoxic activity of NK cells against HeLa cells that was stimulated 
by recombinant membrane fractalkine (mhFKN) due to the absence of other activating 
signals for  mhFKN-activated NK-92 cells on HeLa cells. The activation of NK cells 
is the result of the influence of the multitude of activating receptors such as the 
activating form of killer cell immunoglobulin-like receptor (KAR), NKG2D, NKp46, 
NKp44 and NKp30 which trigger the cytotoxic effects and cytokines release (Long et 
al., 2013; Yoon et al., 2015). 
In addition to degranulation detection, cytokines expression such as IFN-  as 
measured to evaluate NK cells cytotoxic activity upon stimulation with PBEA. IFN-  
is produced by NK cells after activation for the direct killing of the target tumor cells 
(Martín-Fontecha et al., 2004; Schoenborn and Wilson, 2007). It was found that after 
24 h incubation, the level of IFN-  prod c ion as detected in co-culture of HeLa cells 
and NK cells from cancer patients in the groups of presence and absence of PBEA 
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treatment. According to these results, the expression of IFN-  ma  be con rib ed by 
the stimulation effect from PBEA on NK cells. In addition, the increased production 
of IFN-  also might be due to the influence by cytokines produced by other 
contaminating immune cells. A previous study showed that Rhaphidophora khorthasii 
modulated NK cells to produce IFN-  due to IL-2 produced by the neighboring 
lymphocytes along with the stimulation by the extract (Yeap et al., 2013).  
In addition, the results obtained could be associated to the memory-like activity 
of NK cells from the patients, which could be pre-activated by stimulatory signals and 
tumor antigens (Pahl et al., 2018). In this regard, the presence in HeLa cells of shared 
tumor antigens with the tumoral cells of the patients could induce the NK cells 
activation mediated by a recall response, evidenced by the production of granzyme B 
and IFN- , hich as more po en ia ed in he presence of PBEA. This po en ial 
explanation is supported by the fact that these results were not observed in the healthy 
donors. Several studies indicated that NK cell activation by cytokines can induce the 
generation of NK cells with memory-like properties. The adoptive transfer of murine 
splenic NK cells pre-treated with IL-12, IL-15 and IL-18 into tumor-bearing mice 
effectively reduced tumor growth when compared to naïve nor IL-15- or IL-2-
pretreated NK cells in combination with radiation therapy (Ni et al., 2012). Similar to 
murine memory-like NK cells, human NK cells that were pre-activated with IL-12, IL-
15 and IL-18 and subsequently rest for several days display increased IFN-  
production upon re-stimulation with cytokines or target cells compared with control 
NK cells (Ni et al., 2012; Romee et al., 2012). In addition, the memory-like NK cells 
demonstrated increase expression of activating receptors CD94, NKG2A, NKG2C and 
CD69 with lack of inhibiting receptors CD57 and KIR (Ni et al., 2012; Romee et al., 
2012). Memory-like activation of NK cells also could be induced in response to 
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antigens. A study showed that NK cells of the mouse produced high level of IL-12, 
IFN-  and IFN-  in response to re-exposure with the same hapten called 
dinitrofluorobenzene (DNFB) (Majewska-Szczepanik et al., 2013). 
According to the current findings, PBEA was found to be non-toxic to human 
NK cells, indicating that this extract can possibly represent a safe alternative to the 
existing therapies such as IFN- . A study conducted on the KHYG-1 NK cells line 
showed IFN-  production and NK cell cytotoxic activity against K562 and YAC-2 
cells, which were significantly higher after treatment with a Fortunella crassifolia 
fraction (Nagahama et al., 2015). A similar mechanism could be operative with the 
use of PBEA, which should be explored in further studies. 
Some studies have reported that activated NK cells produce IL-2, thus we 
decided to examine the presence of IL-2 in exploring the ability of PBEA in 
stimulating NK cells to produce IL-2. In this regard, the expression of IL-2 was 
detected in all treatment groups of NK cells from healthy and cancer patients. The 
detection of IL-2 expression may be explained by the synergistic effect from the 
contaminating cells and endogenous IL-2 production where activated NK cells 
particularly in cancer patients can produce IL-2 (Rangel-Corona et al., 1998; Rimoldi 
et al., 1993). IL-2 is well-known for its ability in stimulating proliferation of NK cells 
as well as enhances their cytotoxic activity against tumor cells (Floros and Tarhini, 
2015; Srivastava et al., 2013). Nowadays, IL-2 is used as immunotherapy to induce 
NK proliferation in cancer patients. However, the side effects of IL-2 such as nausea, 
flu-like symptoms and dizziness among others limit the wide application of IL-2 
(Surayot and You, 2017). High dose consumption of IL-2 can also cause toxicity in 
patients (Suck and Koh, 2010).  
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Naturally, ADCC is one of the target cell death modes mediated by NK cells. 
It involves a process where antibodies such as Immunoglobulin G (IgG) become 
coated with the target cells and recruit effector cells (NK cells) to trigger target cell 
death via a lytic mechanism (Zahavi et al., 2018). IgG facilitates the access of effector 
cells to the target cells with the Fab region of the IgG that binds to the target cells while 
he Fc por ion associa ing i h Fc R on NK cells ha  e press CD16 (Fc RIII) (Fanger 
et al., 1989; Prager et al., 2019). Upon Fc R ac i a ion, NK cells release lytic granules 
to destroy antibody-sensitized target cells (de Saint Basile et al., 2010). However, in 
our study, the target cells death observed in PBEA-induced NK cells from cancer 
patients probably was not related to ADCC killing mechanism of the target cells as the 
NK cells obtained with the exclusion of the plasma fraction of blood. 
Besides ADCC pathway and the release of perforin and granzyme, NK cells 
can induce apoptosis in the target cells through death receptors such as Fas Ligand 
(FasL) or TNF-related apoptosis-inducing ligand (TRAIL). The activation of death 
receptors facilitates the formation of death-inducing signal complex that prompts the 
activation of caspase cascade (caspase 8 and 10) and ultimately result in apoptosis of 
the target cells (Strasser et al., 2009; Wilson et al., 2009). Although the exact 
mechanism of PBEA in activating immune cell cytotoxicity towards target HeLa cells 
is yet to be fully understood, it is predicted that FasL pathway is responsible for the 
activation of NK cells. HeLa cells are classified as Fas positive target cells in which 
the cells are highly sensitive to the apoptosis-inducing effects of Fas receptor 
stimulation (Cullen et al., 2013). NK cells killing via Fas ligand-mediated pathway is 
induced through the formation of a death-inducing signaling complex which leads to 
the activation of caspases cascade and subsequently promotes apoptosis to the CD95-
expressing target cells (Yoon et al., 2015). In addition, NK cells serial killing 
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mechanism can switch from granzyme B-mediated cytotoxicity to death receptor 
pathway in a time dependent manner (Prager et al., 2019).  A study by Prager et al. 
(2019) demonstrated that the response of NK cells serial killing on target cells HeLa 
showed predominance of granzyme B activity at early time of incubation period (31 ± 
16 min) and later at 45 ± 20 min, the cells develop a higher caspase 8 activity. In our 
study, PBEA-induced NK cells were incubated with the target cells for 24 hours with 
no perforin expression and low expression levels of granzyme B. These findings could 
be related to the shift of killing mode of NK cells from perforin granzyme pathway to 
death receptor pathway over time.   
In addition, our findings showed that PBEA was capable of stimulating the 
activation NK cells of cancer patients by promoting cell death in the target cells. 
Despite the significant target cells death observed in PBEA-treated NK cells of cancer 
donors with no expression of perforin and slightly upregulated granzyme B and IFN-
, it is possible that NK cells killing mechanism towards HeLa cells is also mediated 
by other pathways such as FasL. However, further investigations are required to 
elucidate NK cells killing mechanism enhanced by PBEA to provide scientific 

















5.5 Conclusion  
As a conclusion, our findings demonstrated that PBEA induced proliferation 
of NK cells in healthy donors and promoted cytotoxic activity of NK cells of cervical 
cancer patients by inducing cell death in HeLa cells. These results demonstrated the 
immunomodulatory effects of PBEA and support the future evaluation of this extract 






























CHAPTER 6  
 
GENERAL DISCUSSION, CONCLUSION AND FUTURE 
RECOMMENDATIONS 
6.1 General discussion 
Over the last few decades, the search for the medicinal plants with anti-cancer 
properties and non-toxic to healthy cells remains relevant and desirable due to lack of 
tumor specificity and multidrug resistance of chemotherapy drugs (Greenwell and 
Rahman, 2015). P. bleo, an edible medicinal plant has been claimed by the locals for 
its effectiveness in curing cancer (Yen et al., 2013). In order to explore its potential as 
a source for cancer treatment, it is important to study this plant for its anti-cancer 
properties to gather more information and understanding on its mechanism of action. 
  In cancer drug discovery, it is important to find cytotoxic agents that induce 
cell death with low or no toxicity toward normal cells. According to the NCI, anti-
cancer agents with IC50 value below than 20 µg/ml is considered highly cytotoxic  
(Srisawat et al., 2013). In this study, PBEA demonstrated high cytotoxic effects against 
cervical cancer cells (HeLa cells) while no cytotoxic effects were found on normal cell 
lines. These findings showed that PBEA has a potential as an anti-cancer agent that is 
non-toxic to the normal cells. Besides, an acute oral toxicity study found no toxicity in 
mice following administration of P. bleo crude extracts at the highest dose of 2500 
mg/kg (Sim et al., 2010b).  As toxicity is a major concern with the use of medicinal 
plants in cancer treatment, hence, the findings of this study can provide a significant 
information in toxicity awareness for future in vivo study of P. bleo.  
Apoptosis is a programmed cell death to remove damaged or aged cells from 
the body. One of the hallmarks of cancer is resistance of cancer cells to apoptosis that 
favor their survival which contribute to tumorigenesis (Hanahan and Weinberg, 2016). 
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Most of anti-cancer drugs are designed by targeting apoptosis induction to destroy the 
cancer cells (Hassan et al., 2014). The current findings showed that P. bleo has an 
ability to trigger cell death in HeLa cells through stimulation of pro-apoptotic proteins 
that work in similar manner as chemotherapeutic drugs. This information provides on 
high value of P. bleo in the development of cancer treatment. However, this study is 
not intended to isolate the compounds from this plant but with the significant findings 
from this study, we want people to know about the goodness of this plant especially 
for health maintenance. In addition, the research on its compounds and therapeutic 
activities serve as a good platform to strengthen the proof of its anti-cancer properties 
claimed by people (Yen et al., 2013).  
Studies have shown that the formation and progression of tumor are closely 
rela ed o an indi id al s imm ne s s em (Wang et al., 2020). Malignant cells can 
transform themselves to escape from immune surveillance leading to tumor 
progression and survival (Lussier and Schreiber, 2016). Anti-tumor immune response 
can be triggered through both innate and adaptive immunity with the involvement of 
dendritic cells, macrophages, NK cells, Tregs cells, B cells and CD4+/CD8+ T 
lymphocytes (Gun et al., 2019; Sarvaria et al., 2017). At present, cancer 
immunotherapy has gained more attention due to its efficacy in treating various cancer 
and safe (Wang et al., 2020). The current study found that PBEA possess the ability to 
boost immune response to destroy the cancer cells by stimulating the activation of NK 
cells from cervical cancer patients towards the killing of HeLa cells. Furthermore, 
PBEA has promoted the proliferation of NK cells from healthy donors and this 
indicates that PBEA was safe and non-toxic to NK cells. Thus, this study has shown 
that PBEA could potentiate as immunotherapy for cervical cancer treatment in regard 
to its anti-cancer effects and safety.  
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On top of that, maintaining a healthy life by consuming plant-based foods is 
important to enhance he bod s immunity against diseases especially cancer. High 
consumption of plant-based foods rich in antioxidant such as fruits, vegetables and 
legumes may prevent cancer or improve treatment has been supported by some studies. 
Results of these studies indicate that vitamins and some antioxidant compounds 
including carotenoids and flavonoids, are effective to inhibit growth of breast, stomach 
and human colorectal cancer cells (Martínez-Pérez et al., 2016; Oliveira et al., 2017; 
Wei et al., 2019). A 6-months clinical trial involving consumption of plant-based diet 
consist of whole grain and vegetables showed a reduction in prostate-specific antigen 
(PSA) level among recurrent prostate cancer patients (Nguyen et al., 2006).  P. bleo 
contains high level of antioxidant as well other compounds that responsible for its anti-
cancer properties which point out its benefit in prevention and cancer treatment. 
According to this, consumption of P. bleo is recommended as it may enhance the 
immune responses against cancer additionally the current findings supported the 
people s claim on he sef lness of his plan  for cancer pre en ion and rea men . 
 This study showed that P. bleo has the potential to be an anti-cancer agent.  
Thus it is suggested to explore more on its anti-cancer immune response involving 
other types of cancer cells and other immune cells such as CD4+ and CD8+ T cells. 
Furthermore, a clinical trial as a plant-based diet among healthy people and cancer 
patients should be carried out to gather more information regarding its effectiveness in 
cancer prevention and treatment. This information is crucial to create as well as 
increase the awareness on usage of P. bleo.      
Thus, our findings showed that PBEA promoted cell death in cervical cancer 
HeLa cells and possessed stimulatory effects on the activation of NK cells from 
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cervical cancer patients towards elimination of cancer cells reflecting its anti-cancer 
properties. Figure 6.1 illustrates the mechanism of action involved in the cytotoxic and 

































6.2 Conclusion  
The phytochemicals screening on the leaves of P. bleo showed the presence of 
beneficial compounds that contribute to therapeutic activity of this plant. Ethyl acetate 
extract of P. bleo leaves (PBEA) demonstrated a potent cytotoxic effects against 
cervical cancer cell line (HeLa) associated with the synergistic effects of all 
compounds presented in the extract which need to further study in future. The results 
indicated that PBEA promoted cell death in HeLa via apoptosis and inhibition of cell 
cycle at Go/G1 phase mediated through p53 and caspase-3 activation. In addition, 
PBEA was found to enhance the activation of NK cells in cervical cancer patients by 
killing HeLa cells through the detection of granzyme B and IFN-  as ell as increased 
the percentage of apoptotic cells. Thus, it can be concluded that PBEA exerted 
cytotoxic effects and can potentially regulate NK cells in cervical cancer patients 
against cervical cells. These findings provided a better understanding of P. bleo as 
anti-cancer agents and potential as immunotherapy in cervical cancer treatment.   
6.3 Recommendations for Future Research 
The present study has many limitations due to the budget and time constraint. 
Thus, it is recommended for future studies to find a better approach in order to provide 
a better understanding on the anti-cancer activity of this plant. Suggestions for the 
future study on this plant anti-cancer activity are as following: 
1. Measurement the effects of direct oral intake of P. bleo leaves among 
healthy individuals and cancer patients for its potential in chemoprevention 
and nutrition therapy. 
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2. Investigate the mechanism of cell death in cancer cells using other extracts 
of P. bleo leaves. 
3. Study the mechanism of cell death using additional apoptosis markers such 
as Fas Ligand (FasL) receptor cell death, tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), cytochrome-c and caspase-9. 
4. Study on chemopreventive and anti-cancer effects of P. bleo leaves in 
animal models.  
5. Increase the sample size of healthy individuals and cancer patients in NK 
cells activation study in order to provide better results and conclusion. 
6. Study on the NK cells activation in promoting cancer cell death using other 
extracts of P. bleo leaves. 
7. Additional of positive selection CD56 microbeads during purification to 
obtain maximum purity of NK cells. 
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Kelayakan Penyertaan I Participants Criteria 
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bleo, Abrus precatorius and liposom. 
Nama Penyelidik dan penyelidik bersama [sila sertakan no. Pendaftaran badan profesional (contoh 
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Principal investigator: 
Dr. Norzila Ismail (Pharmacology) 
Co-Researchers : 
1 . Prof Dr Armando Acosta (INFORMM) 
2 . Dr Ramlah Kadir (Immunology) 
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PENGENALAN 
Kajian ini adalah berkaitan dengan ujikaji kesan ekstrak Daun Saga (Abrus precatorius) dan ekstrak daun 
duri tujuh (Pereskia bleo) dan partikel nano semulajadi yang dikenali sebagai liposom, ke alas sel darah 
putih manusia iaitu sel NK (natural killer atau sel pembunuh semulajadi). Kedua-dua jenis tumbuhan 
tersebut digunakan secara tradisional untuk merawat kanser oleh masyarakat tempatan . Kajian di 
peringkat sel dan molekul dalam makmal juga telah menunjukkan bahawa ia boleh membunuh sel 
kanser. Walaubagaimanapun. masih banyak peringkat kajian yang perlu dilakukan untuk memastikan 
ia benar-benar berkesan untuk membunuh kanser di dalam tubuh manusia. Manakala liposom pula 
adalah sejenis partikel nano-halus yang bersaiz 100 nanometer diameter yang diperolehi darpada 
bakteria yang tidak berbahaya. Kajian ke atas liposom adalah untuk menjadikannya sebagai molekul 
"pembawa" ubat terus ke lokasi kanser di dalam tubuh manusia bagi mengurangkan kesan 
sampingan ubat ke atas sel-sel yang sihat. 
Dalam kajian ini. kami akan melakukan ujian untuk mengetahui sama ada sel NK akan membunuh sel 
kanser dengan lebih baik atau tidak apabila dikulturkan bersama dengan ekstrak daun dua herba tersebut 
dan liposom . Sel NK manusia boleh diperolehi daripada darah manusia sebanyak 0.08-0.43%. 
Adalah penting bagi anda membaca dan memahami maklumat kajian sebelum anda bersetuju untuk 
menyertai kajian penyelidikan ini dengan menderma sebanyak 10ml darah sahaja. Walaupun sumbangan 
darah anda hari ini tidak memberi impak kepada tahap kanser anda. tetapi sumbangan anda hari ini 
mungkin akan memberi manfaat dalam penyelidikan kanser, yang seterusnya akan membuka kepada 
peluang kesembuhan kepada pesakit kanser pad a masa akan datang. 
Penyertaan anda di dalam kajian ini dijangka mengambil masa satu hingga dua jam yang mana anda perlu 
menjawab beberapa soalan bagi memastikan anda memenuhi kriteria untuk pengambilan darah ; dan juga 
proses pengambilan darah. Seramai 18 orang dijangka akan menyertai kajian ini. 
TUJUAN KAJIAN 
Kajian ini bertujuan untuk memahami mekansima ketoksikan sel NK ke atas sel kanser oleh ekstrak aktif 
daripada Pereskia bleo (duri tujuh) dan daun Abrus precatorius (saga) serta partikel nano liposom. 
KELAYAKAN PENYERTAAN 
Salah seorang kakitangan kajian akan membincangkan kelayakan untuk menyertai kajian ini. Adalah penting 
anda berterus terang kepada kakitangan tersebut termasuk sejarah kesihatan anda. 










Kajian ini akan melibatkan individu yang mempunyai ciri-ciri berikut: 
Bagi Peserta sihat: 
Tiada penvakit berat 
Tidak menqambil dadah lmmunosupresif 
Umur 18-45 tahun 
Tidak merokok 
Tidak hamil 
Kajian ini tidak akan melibatkan individu yang : 
Bagi peserta sihat: 
res if 
Bagi peserta pesakit kanser: 
Disahkan mengidap kanser oleh doktor 
Masih belum mendapat apa-apa 
rawatan 
Umur 18-45 tahun 
Tidak merokok 
Tidak hamil 
Bagi peserta pesakit kanser: 
Tidak didiagnos mempunya i kanser 
Menqambil dadah lmmunosupresif 
consent Mempunya i kanser dengan ko-morbidi ti 
*Tidak mengambil dadah immunosupressif 
sekurang-kurangnya 3 bulan yang lepas. 
lain 
Enggan memberi kebenaran (consent) 
• ko-morbiditi adalah kewujudan penvakit lain pada pesakit kanser, sepertl tekanan 
darah tlnggi, penyakit buah plnggang dan lain-lain . 
PROSEDUR-PROSEDUR KAJIAN 
Peserta (yang boleh berbahasa melayu) hanya perlu mengisi borang maklumat yang diperlukan untuk 
mengetahui sama ada peserta termasuk dalam kriteria yang diperlukan. Jika peserta memenuhi kriteria, 
darah peserta akan diambil oleh individu terlatih sebanyak 10 mi. Setelah selesai, peserta akan diberi 
honorarium. Sisa buangan saripada sampel kajian (sisa klinikal biohazard) akan dllupuskan dengan 
cara yang sistematik. 
RISIKO 
Secara umumnya, pesakit tidak akan mengalami sebarang masalah atau risiko dalam proses 
pengambllan darah sebanyak 10 mi. Sila ikut arahan kakitangan yang mengambil darah dan hanya 
meninggalkan makmal selepas darah kering. Sila maklumkan kepada kakitangan kajian sekiranya 
anda menghadapl sebarang masalah atau mempunyai sebarang maklumat penting yang mungkin 
mengubah persetujuan anda untuk terus menyertai kajian ini. 
MELAPORKAN PENGALAMAN KESIHATAN (Jika Kajian Melibatkan Kesihatan SAHAJA) 
Sila hubungi kakitangan berikut pada bila-bila masa sekiranya anda mengalami sebarang masalah kesihatan, 
samada berkaitan atau tidak berkaitan dengan kajian ini. 
Dr Wan Zainira Wan Zain [No. Pendaftaran Penuh Maj lis Perubatan Malaysia: 38667 1 di talian 019-
9216789 atau Dr Rahimah Rahim [No. Pendaftaran Penuh Majlis Perubatan Malaysia: 38338 I di talian 
012-8330274 secepat mungkin. 
PENYERTAAN DALAM KAJIAN 
Penyertaan anda dalam kajian ini adalah secara sukarela. Anda berhak menolak untuk menyertai kajian ini 
atau menamatkan penyertaan anda pada bila-bila masa, tanpa sebarang kehilangan manfaat yang 
sepatutnya anda perolehi. Hasil kajian ini tidak akan dimaklumkan kepada peserta kerana ia merupakan hasil 
dari kombinasi sel darah putih dari beberapa peserta dan bukan berorientasikan individu. 










Penyertaan anda juga mungkin boleh diberhentikan oleh kakitangan kajian ini tanpa persetujuan anda 
sekiranya anda didapati tidak sesuai untuk meneruskan kajian ini berdasarkan protokol kajian. Kakitangan 
kajian akan memaklumkan anda sekiranya anda perlu diberhentikan dari menyertai kajian ini. 
MANFAAT YANG MUNGKIN [Manfaat terhadap lndividu, Masyarakat, Unlverslti] 
Walaupun tiada manfaat secara langsung, walaubagaimanapun, secara tidak langsung hasil kajian ini akan 
dapat memberi manfaat kepada masyarakat umum untuk mendapat kesedaran (awareness) bahawa 
terdapat tumbuhan-tumbuhan yang bermanfaat untuk melawan kanser. 
PERSOALAN 
Sekiranya anda mempunyai sebarang soalan mengenai prosedur kajian ini atau hak-hak anda, sila hubungi; 
Dr. Norzlla Ismail 
Jabatan Farmakologi 
Pusat Pengajlan Sains Perubatan 
USM Kampus Keslhatan 
09-7676135/010-2251980 
Sekiranya anda mempunyai sebarang soalan berkaitan kelulusan Etika atau sebarang pertanyaan dan 
masalah berkaitan kajian ini, sila hubungi; 
KERAHSIAAN 
En. Mohd Bazlan Hafidz Mukrim 
Setiausaha Jawatankuasa Etika Penyelidikan (Man usia) USM 
Sahagian Penyelidikan dan lnovasl (P&I) 
USM Kampus Kesihatan. 
No. Tel: 09-767 2354/ 09-767 2362 
Email : bazlan@usm.my or jepem@usm.my 
Maklumat privasi seperti nama dan alamat serta identiti yang lain tidak akan diambil dalam kajian ini, 
melainkan status kesihatan serta soal selidik bagi memastikan pesakit memenuhi kriteria yang diperlukan 
dalam kajian. Oleh sebab itu, kerahsiaan peserta adalah selamat. 
Data yang diperolehi dari kajian ini tidak akan mengenalpasti anda secara perseorangan. Hasil kajian tidak 
berkaitan dengan identiti individu yang terlibat dalam pendermaan darah dan mereka yang menderma tidak 
akan dihubungi semula. Walaubagaimanapun hasil kajian mung kin akan diterbitkan untuk tujuan perkongsian 
ilmu. Pane l penilai J EPeM-USM dan ahli jawatankuasa terlibat boleh meneli ti data kajian 
apabila diperlukan. 
Bagi pesakit kanser, semua data dalam rekod perubatan anda mungkin akan disemak dan diuruskan oleh 
pakar kl inikal yang terlibat dalam kajian ini, bagi tujuan memastikan anda memenuhi kriteria yang diperlukan 
dalam kajian. Kerahsiaan akan dijaga mengikut etika kerahsiaan pesakit. Darah yang diambil juga akan 
melalui proses kajian di dalam makmal tanpa mengenalpasti pemilik darah. Setelah selesai kajian. sam pel 
darah akan dilupuskan sebagaimana pelupusan sisa klinikal biohazard. 
Dengan menandatangani borang persetujuan ini, anda membenarkan penelitian rekod, penyimpanan 
maklumat dan pemprosesan data seperti yang dihuraikan di alas. 
TANDATANGAN 
Untuk dimasukkan ke dalam kajian ini, anda atau wakil sah anda mesti menandatangani serta mencatatkan 
tarikh halaman tandatangan (Lihat contoh Borang Keizinan Peserta di LAMPIRAN S atau LAMPIRAN G 
(untuk sam pel genetik) atau LAMPl RAN P). 










Borang Keizinan Peserta 
(Halaman Tandatangan) 
LAMPIRAN S 
Tajuk Kajian: Memahami kesan sitotoksik sel Pembunuh Semulajadi (Natural killer cell) ke alas sel 
kanser payudara dan serviks yang dimodulasi oleh ekstrak Pereskia bleo, Abrus precatorius and liposom 
Nama Penyelidlk: Dr. Norzila Ismail , Dr. Ramlah Kadir , Dr. Rohlmah Mohamud, Prof 
Armando Acosta, Dr Wan Zainira Wan Zain (Surgery, No MMC 38667), Dr Rahimah 
Rahim (O&G, No MMC 38338),Puan Mazni Yusoff (Unit Perubatan lntegratif) 
Untuk menyertai kajian ini, anda atau wakil sah anda mesti menandatangani mukasurat ini. Dengan 
menandatangani mukasurat ini, saya mengesahkan yang berikut: 
Saya telah membaca semua maklumat dalam Borang Maklumat dan Keizinan 
Pesakit i n i termasuk apa-apa maklumat berkaitan ri siko yang ada dalam 
kajian dan saya Ieiah pun diberi masa yang mencukupi untuk 
memperti mbangkan maklumat te r sebut . 
Semua soalan-soaian saya Ieiah dijawab dengan memuaskan. 
Saya , secara sukarela , bersetuju menyertai kajian penyelidikan in i, 
mematuhi segala prosedur kajian dan memberi maklumat yang diperlukan 
kepada doktor , para jururawat dan juga kakitangan lain yang berkaitan 
apabila d iminta . 
Saya boleh menamatkan penyertaan saya dalam kajian i ni pada bila-bila 
masa . 
Saya Ieiah pun menerima satu salinan Borang Maklumat dan Keiz inan 
Peserta untuk simpanan per ibadi saya . 
Nama Peserta 
No. Kad Pengenalan Peserta 
Tandatangan Peserta atau Wakil Sah 
Nama & Tandatangan lndividu yang Mengendalikan 
Perbincangan Keizinan 
Nama Saksi dan Tandatangan 
Tarikh {dd/MM/yy) 
(Masa jika perlu) 
Tarikh {dd/MM/yy) 
Tarikh (dd/MM/yy) 
Nota: I) Semua pesorta yang mongambil bahagian dalam projek ponyelidlkan lnl lidak dilindunai insuran. 











Borang Keizinan Peserta untuk Pengambilan Sampel Genetik 
(Halaman Tandatangan) 
Tajuk Kajian: Memahami kesan sitotoksik sel Pembunuh Semulajadi (Natural killer cell) ke atas sel 
kanser payudara dan serviks yang dimodulasi oleh ekstrak Pereskia bleo, Abrus precatorius and liposom 
Nama Penyel/dl k : Dr. Norzila Ismail , Dr. Ramlah Kad ir, Dr. Rohimah Mohamud, Prof 
Armando Acosta , Dr Wan Zainira Wan Zain (Surgery, No MMC 38667) , Dr Rahimah 
Rah im (O&G , No MMC 38338) ,Puan Mazni Yusoff (Unit Perubatan lntegratif) 
Untuk menyertai kajian ini, anda atau wakil sah anda mesti menandatangani mukasurat ini. Dengan 
menandatangani mukasurat ini, saya mengesahkan yang berikut: 
Saya te lah membaca sem ua maklumat dalam Borang Maklumat dan Keizinan 
Pesakit ini te rmasuk apa-apa mak lumat b erkaltan r i siko yang ada dalam 
kajian dan saya telah pun diberi masa yang mencu kupi untuk 
mempert imbangkan maklumat tersebut. 
Semua soalan-soalan saya telah d ijawab dengan memuaskan . 
Saya, secara sukarela , bersetuju menyerta i kajian penyelidikan 1n1 , 
mematuhi segala prosedur kajian dan memberi maklu m at yang diperl ukan 
kepada doktor, para jururawat dan juga kakitangan l ain yang berkai tan 
apabila diminta . 
Saya boleh menamatkan penyertaan saya dalam kajian ini pada bila-bila 
masa. 
Saya telah pun menerima satu salinan Borang Maklum at dan Keizinan 
Peserta untuk simpanan peribadi saya . 
Nama Peserta 
No. Kad Pengenalan Peserta 
Tandatangan Peserta atau Wakil Sah 
Nama & Tandatangan lndividu yang Mengendalikan 
Perbincangan Keizinan 
Nama Saksi dan Tandatangan 
Tarikh (dd/MM/yy) 
Masa (jika perlu) 
Tarikh (dd/MM/yy) 
Tarikh (dd/MM/yy) 
~ i) Lebihan sampel kajian ini akan dilupuskan dan tidak akan digunakan untuk tujuan lain kecuali setelah mendapat 
kebenaran daripada Jawatankuasa Etika Penyelidikan (Manusia), USM. 
ii) Semua peserta yang mengambil bahagian dalam projek penyelidikan ini tidak dilindungl insuran. 











Borang Keizinan bagi Penerbitan Bahan yang berkaitan dengan Peserta Kajian 
(Halaman Tandatangan) 
Tajuk Kajlan: Memahami kesan sitotoksik sel Pembunuh Semulajadi (Natural killer cell) ke atas sel 
kanser payudara dan serviks yang dimodulasi oleh ekstrak Pereskia bleo, Abrus precatorius and liposom 
Nama Penyelidik: Dr . Norzll a Is mail , Dr . Ramlah K ad i r , Dr. Ro h ima h Mo hamud, Prof 
A rmand o A co s ta, Or Wa n Zain i ra Wan Zain (Surger y, No MMC 38667) , Dr Rahimah 
Ra h i m (O&G, No MMC 38338) ,Puan Mazn i Yusoff (Uni t Perubat an lntegratif) 
Untuk menyertai kajian ini, anda atau wakil sah anda mesti menandatangani mukasurat ini. 
Dengan menandatangani mukasurat ini, saya memahami yang berikut: 
Ba han yang akan diterb i tkan tanpa dilampirkan denga n na ma saya dan setia p 
percubaan yang akan dibua t untuk me mast i kan ke tanpana m aan saya . Saya 
memahami , walaubagaimanapun , ketanpanamaan yang se m pu rna tidak 
dapat dijamin . Kemungkinan sesiapa yang menjaga saya d i hos p i t a l a tau 
saudar a dapat m engenali saya . 
Bahan yang akan diter b i tkan dalam penerbitan 
mingguan /bu l anan /dwibulanan/suku tah u na n/dwi tah unan meru pakan satu 
penyebaran yang luas dan te r seba r ke se l ur uh dun ia . Ke banyakan 
penerbitan ini akan tersebar kepada doktor-doktor dan j uga b ukan dokto r 
t ermasuk ahl i sa ins da n ah l i j urna l . 
Ba han te rse but j uga akan d i lampirka n pada Iaman web ju rna l d i seluruh 
dunia . Sesetengah Iaman web ini bebas dikunjung i oleh sem ua o ra ng . 
Ba han te rsebu t juga akan d igunakan sebagai pener b itan te mpatan da n 
d isampaikan oleh ramai doktor dan ahli sa ins d i selu ruh du n ia. 
Bah an te r sebu t juga akan digunakan sebagai pen erb i ta n buku oleh pene rb i t 
jurnal. 
Bahan tersebut t idak akan d igunakan u nt uk pengiklanan ataupu n bah an 
un tuk membungkus . 
Saya j uga memberi keizi nan bahawa bahan terse bu t boleh d igu nakan seb agai 
penerb itan lain yang diminta o l eh pe ne r bi t dengan kriter ia berikut : 
Bahan ter sebut tidak akan digunakan un tuk pengi klanan atau baha n untu k 
membungkus . 
Bahan tersebu t tidak aka n d igunakan d i luar konteks- con tohn ya : Gam bar 
t ida k akan d igunakan u ntu k mengga m barka n sesuatu art ike l yang tidak 
berka itan dengan subje k dalam fo to ter sebu t. 
Nama Peserta 
No. Kad Pengenalan Peserta T /tangan Peserta 
Nama & Tandatangan lndividu yang Mengendalikan 
Perbincangan Keizinan 
JEPd1 USM Ttm pl~te fo r PIS and CF upd ated 10/05/2017 
Tarikh (dd/MM/yy) 
Tarikh (dd/MM/yy) 
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